Pharmaceuticals in industrial wastewater and their removal using photo-Fenton’s oxidation by Deegan, Ann-Marie
Pharmaceuticals in industrial wastewater and 
their removal using photo-Fenton‘s oxidation 
 
 
 
Ph.D. Research Thesis by 
Ann-Marie Deegan B.Sc. 
 
 
Supervisors 
Dr. Anne Morrissey 
Dr. Kieran Nolan 
Dr. John Tobin 
 
 
 
 
 
Collaborator 
Dr. Michael Oelgemöller 
 
School of Biotechnology 
Dublin City University 
Dublin 9 
Ireland 
 
 
July 2011 
2 
 
Declaration 
 
I hereby certify that this material, which I now submit for assessment on the 
programme of study leading to the award of Ph.D. is entirely my own work, 
that I have exercised reasonable care to ensure that the work is original, and 
does not to the best of my knowledge breach any law of copyright, and has 
not been taken from the work of others save and to the extent that such work 
has been cited and acknowledged within the text of my work.  
Signed: ____________  
ID No.: 53020118  
Date: _____  
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
ACKNOWLEDGEMENTS ............................................................. 7 
ABSTRACT .................................................................................. 8 
LIST OF FIGURES ........................................................................ 9 
LIST OF TABLES ....................................................................... 11 
ABBREVIATIONS ....................................................................... 12 
PUBLICATIONS, POSTERS AND ORAL PRESENTATIONS .... 14 
1. INTRODUCTION ................................................................... 15 
1.1 Project overview ........................................................................................16 
1.2 Limitations of project ................................................................................18 
1.3 The analytes under investigation .............................................................19 
1.3.1 Famotidine (CAS No. 76824-35-6) .............................................................19 
1.3.2 Tamsulosin hydrochloride (CAS No. 106133-20-4) ....................................19 
1.3.3 Solifenacin succinate (CAS No. 242478-38-2) ...........................................20 
1.3 Thesis layout .............................................................................................20 
2. LITERATURE REVIEW......................................................... 22 
2.1 Introduction .....................................................................................................23 
2.2 Review outline .................................................................................................23 
2.3 Overview of pharmaceutical industry wastewater ........................................24 
2.4 Biological treatments ................................................................................25 
2.4.1 Activated sludge treatment ......................................................................26 
2.4.2 Advances in aerobic treatment for pharmaceutical wastewater ...............31 
2.4.3 Anaerobic treatment ................................................................................34 
2.5 Physio-chemical treatment options .........................................................36 
2.5.1 Membrane filtration ..................................................................................36 
2.5.2 Reverse osmosis .....................................................................................37 
2.5.3 Activated carbon......................................................................................40 
2.5.4 Chlorination .............................................................................................41 
2.6 Oxidation reactions ...................................................................................41 
2.6.1 Ozonation ................................................................................................43 
2.6.2 Perozonation ...........................................................................................46 
2.6.3 Direct photolysis ......................................................................................48 
2.6.4 TiO2 photocatalysis..................................................................................49 
2.6.5 Fenton‘s reaction .....................................................................................52 
4 
 
2.6.6 Photocatalytic reactors for water treatment ..............................................54 
2.7 Electrochemical treatment options ..........................................................57 
2.8 Summary ....................................................................................................58 
3. MATERIALS AND METHODS .............................................. 63 
3.1 Analytical method development and validation for the detection of three 
APIs in industrial wastewater ..............................................................................64 
3.1.1 Chemicals and materials ............................................................................64 
3.1.2 Glassware preparation ...............................................................................64 
3.1.3 Sample preparation ....................................................................................64 
3.1.4 Sample collection .......................................................................................65 
3.1.5 Method development ..................................................................................65 
3.1.5.1 SPE method development ...................................................................66 
3.1.5.1.1 SPE cartridge selection ................................................................66 
3.1.5.1.2 Validated SPE method .................................................................66 
3.1.5.2 HPLC method development ................................................................67 
3.1.5.2.1 Wavelength optimisation...............................................................67 
3.1.5.2.2 Stationary phase optimisation .......................................................68 
3.1.5.2.3 Mobile phase optimisation ............................................................68 
3.1.5.3 Mass spectrometry method development ............................................69 
3.1.6 Method validation .......................................................................................70 
3.1.6.1 SPE-HPLC validation ..........................................................................70 
3.1.6.2 SPE-LC-MS/MS validation ..................................................................70 
3.1.7 Validated method conditions ......................................................................71 
3.1.7.1 Validated SPE-HPLC conditions..........................................................71 
3.1.7.2 Validated SPE-LC-MS/MS conditions ..................................................71 
3.1.8 COD analysis .............................................................................................72 
3.2 Photo-Fenton’s optimisation for the removal of APIs from water ...............73 
3.2.1 Chemicals and materials ............................................................................73 
3.2.2 Reactor configuration .................................................................................73 
3.2.3 Experimental procedures ...........................................................................74 
3.2.4 Optimisation of famotidine removal by photo-Fenton‘s oxidation ................74 
3.2.5 Optimisation of tamsulosin hydrochloride and solifenacin succinate removal 
by photo-Fenton‘s oxidation ................................................................................75 
3.2.6 Determination of intermediates by LC-MS ..................................................75 
4. RESULTS AND DISCUSSION .............................................. 76 
4.1 Analytical method development ....................................................................77 
4.1.1 Method requirements, considerations and applications ..............................78 
4.1.2 Plant description ........................................................................................80 
4.1.2 Sample pre-treatment ................................................................................81 
4.1.3 HPLC method development .......................................................................85 
4.1.3.1 Wavelength optimisation .....................................................................85 
4.1.3.2 Stationary phase optimisation .............................................................87 
4.1.3.3 Mobile phase optimisation ...................................................................88 
4.1.4 Mass spectrometry optimisation .................................................................91 
4.1.5 Detection of APIs in real wastewater ..........................................................95 
4.1.6 Validation of SPE-HPLC method ................................................................96 
4.1.7 Validation of SPE-LC-MS/MS method ...................................................... 102 
5 
 
4.2 Results of the sampling programme ........................................................... 105 
4.2.1 Occurrence of the APIs in wastewater...................................................... 105 
4.2.2 Trends in API concentration over sampling period ................................... 107 
4.2.3 Treatment efficiency of onsite treatment plant .......................................... 113 
4.2.3.1 Efficiency of plant for removal of famotidine ...................................... 113 
4.2.3.2 Efficiency of plant for removal of tamsulosin hydrochloride ................ 114 
4.2.3.3 Efficiency of plant for removal of solifenacin succinate ...................... 114 
4.2.4 Pharmaceutical wastewater regulations ................................................... 114 
4.2.5 Treatment options for the reduction of API concentration in wastewater .. 115 
4.3 Fenton’s oxidation ........................................................................................ 116 
4.3.1 Introduction to Fenton‘s oxidation ............................................................. 116 
4.3.2 Kinetic evaluation ..................................................................................... 118 
4.3.3 Choosing a quenching agent .................................................................... 119 
4.3.3.1 Demonstrating the requirement for a quenching agent ...................... 119 
4.3.3.2 Sodium sulphite as a quenching agent .............................................. 120 
4.3.3.3 Methanol as a quenching agent......................................................... 120 
4.3.3.4 Time-controlled experiment ............................................................... 121 
4.3.4. Optimisation of Fenton‘s oxidation for famotidine removal....................... 122 
4.3.4.1 The effect of different reactants on famotidine degradation ............... 122 
4.3.4.2 Famotidine light-Fenton‘s reactions ................................................... 124 
4.3.4.3 Kinetic evaluation of results ............................................................... 125 
4.3.5 Optimisation of Fenton‘s oxidation for removal tamsulosin hydrochloride . 129 
4.3.5.1 Light-Fenton‘s degradation of tamsulosin hydrochloride .................... 129 
4.3.5.2 The effect of different reactants on tamsulosin hydrochloride 
degradation ................................................................................................... 130 
4.3.5.3 Kinetic evaluation of results ............................................................... 131 
4.3.6 Optimisation of Fenton‘s oxidation for removal solifenacin succinate ....... 133 
4.3.6.1 Light-Fenton‘s degradation of solifenacin succinate .......................... 133 
4.3.6.2 The effect of different reactants on solifenacin succinate degradation
 ..................................................................................................................... 134 
4.3.6.3 Kinetic evaluation of results ............................................................... 135 
 ......................................................................................................................... 136 
4.3.7 Summary of photo-Fenton‘s optimisation experiments ............................. 137 
4.3.8 Intermediate study ................................................................................... 142 
4.3.8.1 Intermediates produced by photo-Fenton‘s oxidation of famotidine ... 142 
4.3.8.2 Intermediates produced by photo-Fenton‘s oxidation of tamsulosin 
hydrochloride ................................................................................................ 147 
4.3.8.3 Intermediates produced by photo-Fenton‘s oxidation of solifenacin 
succinate ....................................................................................................... 151 
4.3.8.4 Summary of the intermediate study ............................................... 156 
5. CONCLUSIONS AND FURTHER RESEARCH .................. 157 
5.1 Main findings and conclusions .................................................................... 158 
5.2 Main implications of study ........................................................................... 162 
5.3 Further research ........................................................................................... 162 
REFERENCES .......................................................................... 166 
APPENDICES ........................................................................... 192 
6 
 
Appendix A: Monthly summaries of results ..................................................... 193 
Appendix B: Fenton oxidation literature examples .......................................... 195 
Appendix C: Famotidine impurities ................................................................... 197 
Appendix D: Main tamsulosin metabolites ....................................................... 198 
Appendix E: Main solifenacin metabolites ........................................................ 199 
 
 
 
 
  
7 
 
Acknowledgements 
 
I would like to thank my lab colleagues Clair, Mark, Sharon, David, Nora, 
Ross, Basha, Cecilia and Zahra for their help, support and kindness. We 
shared lots of fun times and supported each other when things got a bit more 
difficult. Thanks for all the cups of tea and coffee and for listening to all my 
rants.  
 
I would like to thank all the technical staff in the School of Biotechnology and 
the NCSR. A special thanks to David Cunningham who is responsible for the 
HPLC and also to Stephen Fuller and Maurice Burke the technicians in 
charge of the LC-MS. 
 
Thanks to the staff in Astellas Ireland Pharmaceutical Limited especially 
Clodagh, Joe and Ray.  
 
I would like to thank the Questor Centre  for their financial support. 
 
I would like to acknowledge the hard work and dedication of my supervisors, 
Anne, John, Kieran and before leaving for Australia, Michael. Thank you for 
your guidance and support. 
 
Thanks to my family, my brothers and sisters, niece and nephews for their 
constant encouragement, to my friends especially those in the Caving Club in 
DCU who have provided welcome distraction and stress relief. 
 
To my Dad, who instilled in us the importance of education, the value of hard 
work and perseverance, to my Mam who taught me to be practical, grounded 
and solve problems pragmatically. My parents have been a wonderful 
support. 
 
Finally, a very special thank you to my fiancé, William, for everything. 
8 
 
Abstract 
 
Active pharmaceutical ingredients are known contaminants of surface and 
ground water. In some cases these are persistent organic chemicals which 
are only partially eliminated during conventional wastewater treatment. They 
have been detected in the effluent of various European wastewater treatment 
plants. However, there is a growing body of evidence to suggest that 
discharges from pharmaceutical plants themselves can contribute to the 
levels of pharmaceuticals in the environment. This project is based on both 
the detection and removal of pharmaceuticals from industrial sources. A 
SPE-LC-MS/MS method for the detection of famotidine, tamsulosin 
hydrochloride and solifenacin succinate in wastewater at a pharmaceutical 
production facility was developed and validated. The results of a six month 
sampling programme showed substantial concentrations of the analytes in 
both influent and effluent. Famotidine was detected at an average 
concentration of 1.6 mg/L and 2.6mg/L, tamsulosin hydrochloride at 5 μg/L 
and 4 μg/L and solifenacin succinate at 39 μg/L and 28 μg/L in influent and 
effluent respectively. Photo-Fenton‘s oxidation conditions were optimised for 
the removal of each of the three APIs from aqueous solutions. Intermediates 
and final products of the degradation have been identified via LC-MS. 
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1.1 Project overview  
 
Pharmaceuticals enter the aquatic environment at trace concentrations 
through their continuous release from numerous sources including run-off 
from land, hospital and municipal wastewater (Figure 1.1). The effects of 
individual APIs as well as synergistic effects of combinations of APIs in 
drinking water raise concern over possible human health effects (Fatta et al., 
2007; Webb et al., 2003). APIs have been detected in surface and 
wastewaters (Suarez et al., 2009; Tabak and Bunch, 1970; Watkinson et al., 
2007). This has been associated with damage to aquatic biota as well as 
bioaccumulation in terrestrial biota (Larsson et al., 1999; Oaks et al., 2004). 
The contribution of pharmaceutical production wastewaters to the 
environmental loading of APIs represents a significant knowledge gap. 
 
Pharmaceutical 
Production 
Plant
Human 
Waste
Release to 
environment or 
municipal sewer
Hospital 
Waste
Improperly 
disposed 
Drugs
Wastewater 
Treatment 
Plant
Environment
Agricultural 
Runoff
Aquaculture
Human and veterinary 
drugs
 
Figure 1.1: Routes of pharmaceutical entry into the environment. 
 
This project involves both the detection and removal of pharmaceutical 
residues from production wastewater at a chemical synthesis manufacturing 
17 
 
facility based in Mullhudart, Co. Dublin. The project was divided into three 
work packages as outlined below.  
 
Work package 1: To develop an SPE-LC-MS/MS method for the 
monitoring of three pharmaceuticals, namely famotidine, tamsulosin 
hydrochloride and solifenacin succinate in industrial wastewater. 
 
Step 1.1: Development and optimisation of HPLC method. 
Step 1.2: Development and optimisation of SPE method. 
Step 1.3: Development and optimisation of MS method.  
Step 1.4: Integrate developed methods into a single method suitable 
for the analysis of the drugs in chemical synthesis wastewater. 
 
Work package 2: A six month sampling programme for the monitoring of 
the three APIs. 
  
Step 2.1: Monitor influent and effluent concentrations of the APIs at the 
wastewater treatment plant for 6 months. 
Step 2.2: Examine the data obtained to establish the concentrations of 
pharmaceuticals lost to the municipal sewers as well as determining 
the efficiency of the wastewater treatment facility.  
 
Work package 3: Develop and optimise a method for the removal of the 
three pharmaceuticals from the production facility wastewater using 
photo-Fenton’s oxidation.  
 
Step 3.1: Optimisation of Fe(II) and H2O2 concentrations. 
Step 3.2: Monitor removal rates and kinetic evaluation using HPLC.  
Step 3.3: Carry out an intermediate study to identify the degradation 
pathways using LC-MS. 
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1.2 Limitations of project 
 
Monitoring of the discharge and effects of pharmaceuticals on the 
environment represents a small but important portion of the topic of micro-
pollutants in the environment. This project is limited to the monitoring and 
removal using photo-Fenton‘s oxidation of three pharmaceuticals in 
wastewater with regards to the actual concentrations of pharmaceuticals 
released from pharmaceutical production facilities. The scope for further 
investigation in this area is large and for example other analytes of various 
environmental significance including EDCs should be investigated. Other 
types of production facilities such as fermentation, R&D facilities and facilities 
that recover active ingredients from natural resources may contribute to a 
significantly different environmental loading than a chemical synthesis facility. 
Even between similar facilities the environmental loading may vary.   
 
Investigation of the biotoxicity of the analytes under investigation in this 
project and of the degradation products are beyond the scope of this project. 
However, the importance of this information in regards the photo-Fenton‘s 
oxidation should not be under-estimated. It is possible that products formed 
during photo-oxidation/catalysis may be more toxic than the parent 
compound.  
 
As discussed in the literature review there is a large number of treatment 
methods available for the removal of pharmaceuticals and for the treatment of 
pharmaceutical wastewater generally. This project is limited to photo-Fenton‘s 
oxidation.  
 
Further possible avenues of investigation beyond the scope of this project 
include legislative investigations and risk assessments of pharmaceuticals to 
the environment. 
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1.3 The analytes under investigation 
 
There were three pharmaceuticals in production at the Astellas 
Manufacturing facility in west Dublin during this project namely famotidine, 
tamsulosin hydrochloride and solifenacin succinate.  
1.3.1 Famotidine (CAS No. 76824-35-6) 
 
Famotidine is a H2-Receptor antagonist commonly used in the reduction of 
stomach acid production (Figure 1.2). A number of studies have investigated 
the presence of the API in municipal wastewater and surface waters (Gros et 
al., 2006; Gros et al., 2010; Muñoz et al., 2009). Famotidine was not detected 
in river water samples but was detected in municipal wastewater samples. . 
 
 
 
 
 
 
1.3.2 Tamsulosin hydrochloride (CAS No. 106133-20-4) 
 
Tamsulosin hydrochloride is a Α1a-selective alpha blocker used in the 
treatment of benign prostatic hyperplasia (Figure 1.3). To the best of the 
authors knowledge no studies have taken place monitoring the 
concentrations of tamsulosin in effluents or environmental waters. 
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Figure 1.2: Famotidine structure 
Figure 1.3: Tamsulosin hydrochloride structure 
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1.3.3 Solifenacin succinate (CAS No. 242478-38-2) 
 
Solifenacin Succinate is a urinary antispasmodic used in the treatment of 
overactive bladder (Figure 1.4). To the best of the authors knowledge no 
studies have taken place monitoring the concentrations of tamsulosin in 
effluents or environmental waters. 
N O
O
N
 
Figure 1.4: Solifenacin succinate structure 
 
 
 
1.3 Thesis layout  
 
This thesis is divided into a literature review, materials and methods, results 
and discussion, conclusions and opportunities for further investigation.   
 
Chapter 2: Literature review 
The literature review discusses the options for the treatment of 
pharmaceutical production facility wastewater focusing on the removal of 
APIs. The review includes a comprehensive list of tables showing removal of 
APIs using various treatment methods. 
 
Chapter 3: Materials and methods 
The materials and methods section focuses on the methods used for the 
detection of the APIs. Separate validated SPE-HPLC and SPE-HPLC-MS/MS 
methods are outlined for the detection of the three APIs. The methods used in 
the optimisation of the photo-Fenton‘s oxidation of the three APIs and 
methods for the monitoring of intermediates are also included.  
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Chapter 4: Results and discussion 
The concentrations of the three APIs in influent and effluent from the 
wastewater treatment facility from November 2009 to April 2010 are 
presented in the results and discussion. The method validation for both the 
SPE-HPLC method in distilled water and SPE-LC-MS/MS method in influent 
and effluent samples is included. Optimised photo-Fenton‘s oxidation 
conditions, kinetic results and degradation pathways for the three APIs are 
discussed. 
 
Chapter 5: Conclusions and further research opportunities  
Conclusions are drawn on the developed methods, results of the six month 
sampling programme and effectiveness of photo-Fenton‘s oxidation for the 
removal of the three APIs. Further research directions to broaden our 
understanding on the contribution of industrial facilities to the environmental 
loading of pharmaceuticals and treatment at source are discussed. 
 
Appendices 
Appendix A: monthly summaries of results from the monitoring programme. 
Appendix B: literature showing degradation of APIs via Fenton‘s oxidation.  
Appendix C, D and E show the structures of the famotidine impurities, 
tamsulosin and solifenacin metabolites used to interpret photo-Fenton‘s 
intermediates. 
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2. Literature review 
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2.1 Introduction 
 
The presence of pharmaceuticals and personal care products was first 
identified in surface and wastewaters in the United States and Europe in the 
1960‘s and 1970‘s (Stumm-Zollinger and Fair, 1965; Tabak and Bunch, 1970). 
The issue attracted substantial interest after the occurrence of 
pharmaceuticals in river water was linked to feminisation of fish living 
downstream of WWTP outfalls (Larsson et al., 1999). Subsequently damage 
to aquatic and terrestrial biota has been confirmed. For example, the non-
steroidal anti-inflammatory drug diclofenac has been directly correlated with 
the renal failure of vultures contributing to the >95% decline in their population 
in the Indian subcontinent since the 1990‘s (Oaks et al., 2004).  
 
Sources of pharmaceutical contamination of the aquatic environment included 
pharmaceutical production plants, WWTPs, hospitals, agriculture, 
aquaculture, landfills and even graveyards (Khetan and Collins, 2007). The 
most investigated route of entry of pharmaceuticals into the environment was 
through municipal wastewater treatment plants. Herberer (2002) found that 
human excretion of unchanged or slightly transformed APIs conjugated to 
polar molecules such as glucoronides, entered the WWTP which may then be 
cleaved, releasing the original API into the environment. Consequently 
numerous studies have investigated the removal efficiencies of 
pharmaceuticals at municipal WWTPs. Activated sludge WWTPs have 
received particular attention (Jones et al., 2007; Watkinson et al., 2007). A 
limited number of studies also found pharmaceuticals in drinking water (Webb 
et al., 2003) and hospital wastewater (Suarez et al., 2009). Monitoring of the 
levels of APIs released from pharmaceutical production facilities was largely 
neglected and the importance of such releases has not been established 
(Larsson and Fick, 2009).  
 
2.2 Review outline  
 
This review begins with an overview of pharmaceutical industry wastewater. It 
examines the options for the treatment of pharmaceutical production facility 
wastewater. The review focuses not only on the ability of various treatment 
24 
 
methods to reduce the oxygen demand of the wastewater but the removal of 
various constituents, in particular APIs. Conventional and advanced treatment 
methods are examined including aerobic and anaerobic biological processes, 
activated carbon, ozonation and chlorination. Emerging technologies for 
micro-pollutant removal including advanced oxidation processes are outlined 
in the latter part of this review. The review also contains an extensive list of 
tables showing API levels using different treatment methods.  
 
2.3 Overview of pharmaceutical industry wastewater 
 
Pharmaceutical production facility wastewater was known to contain solvents, 
catalysts, additives, reactants, intermediates, raw materials and APIs 
(Sreekanth et al., 2009). The wastewater was typically high strength, with high 
COD, high BOD and high COD:BOD ratio. It could be toxic or odorous when 
released into the environment (Suman Raj and Anjaneyulu, 2005). The 
wastewater could also contain priority pollutants including cyanide (Suman 
Raj and Anjaneyulu, 2005). It was estimated that up to half the 
pharmaceutical wastewater produced worldwide was released without any 
treatment (Enick and Moore, 2007).   
  
Pharmaceutical manufacturing processes included fermentation, chemical 
synthesis, isolation or recovery from natural resources or a combination of all 
three (EPA, 1997). Fermentation and chemical synthesis generated large 
volumes of wastewater, with a high organic load. The presence of toxic or 
recalcitrant substances in such wastewaters resulted in lower COD removal 
efficiencies (Chellipan et al., 2006). Recovery systems for the removal of 
solvents were applied. However solvents were still present in the wastewater. 
Wastewaters include wash water from cleaning equipment and floors, cooling 
waters, process water, municipal and storm water (EPA, 1997). Biological 
treatment of this water was common and economical (Kulik et al., 2008).  
However biological methods have shown to be insufficient for the removal of 
all potentially hazardous constituents of the wastewater (Clara et al., 2005; 
Joss et al., 2004; Joss et al., 2005; New et al., 2000; Suman Raj and 
Anjaneyulu, 2005). More advanced mechanisms for the treatment of the 
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wastewater was required. Recently MBR technology, ozonation and advanced 
oxidation processes have shown varying degrees of efficiency for the 
treatment of pharmaceutical wastewaters (Addamo et al., 2005; Alum et al., 
2004; Andreozzi et al., 2005; Andreozzi et al., 2006; Doll and Frimmel, 2005 
a, b and c; Helmig et al., 2007; Perez-Estrada et al., 2005 a; Ravina at al., 
2002). Integrating various biological and more advanced treatment methods 
may provide the solution to the treatment of the wide variety of potentially 
hazardous substances present in pharmaceutical wastewater (Arana et al., 
2002; Arslan-Alaton and Dogruel 2004; Helmig et al., 2007; Iketata et al., 
2006). 
 
Licensing agreements in the country in which the production facility was 
based governed the quality of the wastewater that was allowed to be 
released. In the US and Europe the majority of licences focused on BOD, 
COD, suspended solids and pH without any control on the release of specific 
APIs, intermediates, raw materials or other recalcitrant substances (Larsson 
and Fick, 2009). ‗Ireland seems to be the only jurisdiction where specific 
regulatory licence limits have been established for APIs‘ (Helmig et al., 2007). 
While some attention has been focused on endocrine disrupting chemicals the 
presence of other APIs largely remain unmonitored.  
 
2.4 Biological treatments  
 
Biological treatment methods have traditionally been used for the 
management of pharmaceutical wastewater (Suman Raj and Anjaneyulu, 
2005). Aerobic applications include activated sludge, membrane batch 
reactors and sequence batch reactors (Chang et al., 2008; Chen et al., 2008; 
Ileri et al., 2003; La Para et al., 2002; New et al., 2000; Noble, 2006; Suman 
Raj and Anjaneyulu, 2005). Anaerobic methods include anaerobic sludge 
reactors, anaerobic film reactors and anaerobic filters (Chellipan et al., 2006; 
Enright et al., 2005; Gangagai Rao et al., 2005; Nandy and Kaul, 2001; Oktem 
et al., 2007; Sreekanth et al., 2009).  
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Wastewater characteristics may suggest suitability or unsuitability of biological 
treatments for pharmaceutical industry wastewater. Solvents, APIs, 
intermediates and raw materials represent biologically recalcitrant substances 
which affect the efficiency of biological treatment systems (Helmig et. al., 
2007; Oz et al., 2004).  For example activated sludge treatment is unsuitable 
for wastewater with COD levels in excess of 4000 mg/L (Suman Raj and 
Anjaneyulu, 2005).  
 
The biological processes presented in this review are well established for the 
treatment of municipal wastewater. However for the treatment of 
pharmaceutical wastewater the processes require modification due to its 
complex and toxic nature. It has been reported to contain solvents which may 
include methylene chloride, toluene, isopropyl alcohol, chloroform, 
chlorobenzene, chloromethane cyanide, phenol and benzene. These solvents 
have been mostly removed by solvent recovery systems but the wastewater 
may still have relatively high concentrations of these solvents (EPA, 1997). A 
fraction of solvents may be difficult to biodegrade and may adversely affect 
the performance of biological treatment systems (Akarsubasi et al., 2005). 
       
In addition to high strength wastewater, solvents and recalcitrant substances 
there are approximately 3000 different APIs known to be manufactured 
worldwide (Helmig et al., 2007). These comprise a wide variety of structures, 
complexity and physiochemical properties. By design APIs are persistent with 
low biodegradability. APIs are often hydrophobic in nature which may cause 
them to concentrate in sludge and cause adverse effects on the anaerobic 
digestion process applied to sludges (Fountoulakis et al., 2008).  
 
2.4.1 Activated sludge treatment 
 
Activated sludge treatment is the agitation or aeration of wastewater in order 
to promote the growth of bacteria and microorganisms which digestion the 
organic components of the wastewater. Conventional activated sludge with a 
long hydraulic retention time (HRT) has historically been the method of choice 
for the treatment of pharmaceutical industry wastewater (El Gohary et al, 
1995; Oz et al., 2004; Rosen et al., 1998). It has a lower capital cost than 
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more advanced treatment methods and a limited operational requirement; it is 
generally more environmentally friendly than harsher chemical methods such 
as chlorination (New et al., 2000). However high energy consumption, the 
production of large amounts of sludge (Sreekanth, 2009) and operational 
problems including colour, foaming and bulking in secondary clarifiers are 
associated with activated sludge plants (Oz et al., 2004).  
 
Factors which affect the efficiency of activated sludge facilities for the 
treatment of pharmaceutical wastewater include HRT, temperature, pH, 
dissolved oxygen, organic load, the microbial community, the presence of 
toxic or recalcitrant substances and the batch operation of pharmaceutical 
production facilities (La Para et al., 2000; La Para et al., 2001a and b; La Para 
et al., 2002; New et al., 2000; Suman Raj and Anjaneyulu, 2005). These 
variables require modification for adaptation to pharmaceutical industry 
wastewater.  
 
Temperature is a key factor in the efficiency of activated sludge facilities. It 
has an important role in selecting individual microbial species and overall 
microbial diversity in the activated sludge (La Para et al., 2000). Some 
pharmaceutical production facilities produce wastewater at high temperature 
which may affect the efficiency of activated sludge (AS) plants (La Para et al., 
2000, La Para et al., 2001b). Therefore water from high temperature 
processes must be cooled prior to treatment by AS increasing time and cost 
of treatment. 
 
Operation of AS plants at lower pH enhances the removal of acidic 
pharmaceuticals. Low pH enhances the removal of acidic pharmaceuticals 
due to adsorption of the API onto sludge particles where they are biologically 
degraded (Urase et al., 2005). The sludge must then be treated for the 
removal of APIs.  
 
The variable nature of pharmaceutical wastewater due to batch processing 
and the intermittent production of wastewater may lead to shock loads, which 
negatively affect the stability of the microbial community and result in a 
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deterioration of bacterial flocs and loss of biomass to final effluent (La Para et 
al., 2002). In samples taken 15 days apart influent wastewater characteristics 
changed significantly while effluent quality remained high. Loading at high 
COD can reduce the efficiency of an activated sludge system. Above 4000 
mg/L COD, the wastewater becomes unsuitable for AS treatment (Suman Raj 
and Anjaneyulu, 2005). Between 1500 and 4000 mg/L COD, AS produced 
consistently high COD removal using acclimised mixed consortia. In addition, 
AS is not effective in wastewater with COD levels above 4000 mg/L.  
 
The impact of pharmaceuticals on AS process appeared to be negligible 
under usual operational conditions (Stamatelatou et al., 2003). However at 
higher concentrations, which may be expected in the wastewater of 
pharmaceutical manufacturing facilities, they may become inhibitory. Above 2 
mg/L triclosan, significant reduction in nitrite consumption was noted 
(Dokianakis et al., 2004). There was a paucity of literature showing the 
removal of APIs from pharmaceutical manufacturing facilities. However from 
municipal facilities it has been shown that removal efficiency is dependent on 
the APIs present.  Table 2.1 shows that AS was more efficient for the removal 
of some APIs in municipal facilities than others. β-Lactam and quinlone drugs 
in particular appeared to be susceptible to aerobic oxidation. In a WWTP in 
Brisbane Australia, β-Lactam antibiotics showed high biodegradability due to 
hydraulic cleavage of the β-lactam ring. Lincomycin and sulphonamides were 
least affected by AS treatment. Similar studies have also found that the 
efficiency of the process was dependent on the compound under 
investigation. Ibuprofen, naproxen, bezafibrate and estrogens (estrone, 
estradiol, and ethinylestradiol) showed a high degree of removal. 
Sulfamethoxazole, carbamazepine and diclofenac showed limited removal 
(Clara et al., 2005; Joss et al., 2004; Joss et al., 2005). Polar APIs such as 
diclofenac and carbamazepine were poorly adsorbed onto activated sludge 
particles. Polar APIs therefore were removed by biodegradation (Carballa et 
al., 2004). With the development of more metabolically resistant APIs this 
problem is likely to increase (Khetan and Collins, 2007). 
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Table 2.1: Removal of selected pharmaceuticals using activated sludge. 
Pharmaceutical 
class 
Pharmaceutical 
Mean influent 
(ng/L ) 
Mean effluent 
(ng/L ) 
%  
Removal 
Reference 
Antibiotics Amoxicillin 190 n.d. 100 Watkinson et al., 2007 
  
13mg/d/1000 
pop 
n.d. 
100 
Castiglioni et al., 2006 
 Cefaclor 50 n.d. 100 Watkinson et al, 2007 
 Cephalexin 4600 n.d. 100 Watkinson et al., 2007 
 Ciprofloxacin 3800 640 83 Watkinson et al., 2007 
  
259mg/d/1000 
pop 
97mg/d/1000 
pop 
63 
Castiglioni et al., 2006 
 Clarithromycin 
21mg/d/1000 
pop 
55mg/d/1000 
pop
a
 
0 
Castiglioni et al., 2006 
 Clindamycin 2 5 0 Watkinson et al., 2007 
 Enrofloxacin 10 10 0 Watkinson et al., 2007 
 Erythromycin n.d. 
5mg/d/1000 
pop
a
 
0 
Castiglioni et al., 2006 
 Lincomycin 
3.4mg/d/1000 
pop 
5.4 
mg/d/1000 
pop
a
 
0 
Castiglioni et al., 2006 
 Monensin 10 25 
a
 0 Watkinson et al., 2007 
 Nalidixic acid n.d. 55 
a
 0 Watkinson et al., 2007 
 Norfloxacin 170 25 85 Watkinson et al., 2007 
 Ofloxacin 
360mg/d/1000 
pop 
233mg/d/1000 
pop 
35 
Castiglioni et al., 2006 
 Penicillin V 50 30 40 Watkinson et al., 2007 
 Roxithromycin WWTP1: 69 31 55 Clara et al., 2005 
 Spiramycin 
4.8mg/d/1000 
pop 
35mg/d/1000 
pop 
0 
Castiglioni et al., 2006 
 Sulfamethoxazole n.d. <166-<553 0 Lacey et al., 2008 
  
65mg/d/1000 
pop 
10mg/d/1000 
pop 
85 
Castiglioni et al., 2006 
  360 270 25 Watkinson et al., 2007 
 Sulphathiazole 2 n.d. 100 Watkinson et al., 2007 
 Trimethoprim <171-< 57 <67-<360 0 Lacey et al., 2008 
  340 50 85 Watkinson et al., 2007 
Lipid regulators Gemfibrozil <26-<86 <32-<330 0 Lacey et al., 2008 
 Bezafibrate WWTP1:6840 692 90 Clara et al., 2005 
  
50mg/d/1000 
pop 
29mg/d/1000 
pop 
42 
Castiglioni et al., 2006 
 Clofibric acid <222-<740 n.d. 100 Lacey et al., 2008 
  96μg/m
3
/d 84μg/m
3
/d 13 Bernhard et al., 2006 
    
1-4 ** Zwiener and Frimmel, 
2003 
Antiepileptic‘s Carbamazepine 1273μg/m
3
/d 1190μg/m
3
/d 7 Bernhard et al., 2006 
  n.d. 
<0.163–
<0.881
a
 
0 
Lacey et al., 2008 
  
12 mg/d/1000 
pop 
28mg/d/1000 
pop 
0 
Castiglioni et al., 2006 
  
28mg/d/1000 
pop 
 
100 
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  704 952
a
 0 Clara et al., 2005 
  WWTP 1: 280 290 0 Santos et al., 2007 
  WWTP 2: 300 500 0  
  WWTP 3: 290 320 0  
  WWTP 4: 360 370 0  
Antiphlogistic's Diclofenac n.d. <0.743-<2.478 0 Lacey et al., 2008 
  3190 1680 47 Clara et al., 2005 
  2133μg/m
3
/d 1617μg/m
3
/d 24 Bernhard et al., 2006 
    
1-4 ** Zwiener and Frimmel, 
2003 
 Ibuprofen 2448 20 99 Clara et al., 2005 
  6810μg/m
3
/d 212μg/m
3
/d 97 Bernhard et al., 2006 
  < 0.760-3.204 n.d. 100 Lacey et al., 2008 
  
122mg/d/1000 
pop 
28mg/d/1000 
pop 
77 
Castiglioni et al., 2006 
  WWTP 1: 280 290 0 Santos et al., 2007 
  WWTP 2: 300 500 0  
  WWTP 3: 290 320 0  
  WWTP 4: 360 370 0  
    
60** Zwiener and Frimmel, 
2003 
 Ketoprofen WWTP 1: 540 340 37 Santos et al., 2007 
  WWTP 2: 300 210 30  
  WWTP 3: 460 360 22  
  WWTP 4: 1360 410 70  
  WWTP 1: 4040 2620 35 Santos et al., 2007 
  WWTP 2:11140 1180-11830 0-89  
  WWTP 3: 5180 1960 62  
β-Blockers Atenolol 
494mg/d/1000 
pop 
281mg/d/1000 
pop 
43 
Castiglioni et al., 2006 
 
a 
Concentrations of APIs in effluent was greater than influent due to matrix and other 
effects (Herberer et al., 2002; Watkinson et al  2007) n.d.: not detected, all matrices 
are municipal wastewater, with the exception of those marked **, which are synthetic 
pharmaceutical wastewater. 
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2.4.2 Advances in aerobic treatment for pharmaceutical 
wastewater 
 
Variations on AS including sequence batch reactors (SBRs) and membrane 
batch reactors (MBRs) were shown to have added advantages for the 
treatment of pharmaceutical wastewater. SBR is an activated sludge method 
of treatment in which separate tanks for aeration and sedimentation are not 
required and there is no sludge return. The fill, react, settle, draw and idle 
stages take place in one tank as opposed to sequential tanks. This type of 
process was ideal for use in small systems or when land is limited (Ileri et al., 
2003). The four operational modes allow easy modifications of process 
conditions, enhancing the SBRs capacity for meeting effluent quality 
restrictions (Aguado et al., 2008).  
 
MBRs combine activated sludge with membrane technology. There were two 
configurations of MBR, submerged or external mounted to a suspended 
growth bioreactor which allow liquid-solid separation to take place (Yang et 
al., 2006).  Membranes are typically immersed in the aeration tank. This 
allows mixing, keeps solids in suspension and reduces fouling of the 
membrane. Solids are retained on one side of the filter removing the need for 
further treatment. Membrane processes are effective for the removal of bulk 
organics. They can replace traditional methods or operate in combination with 
conventional AS systems or as hybrid systems (Noble, 2006). Advantages of 
MBRs include shorter start-up times and they are suitable where space is 
limited (Yang et al., 2006). Variable wastewater composition and batch 
production may be treated using MBR (Chang et al., 2008). In conventional 
AS systems a sludge sedimentation tank is used to remove solids. In MBRs 
separation of solids is controlled by membranes.  
 
The use of MBR in the treatment of pharmaceutical wastewater is still in its 
early development (Chang et al., 2008). Similarities exist between design 
parameters for municipal and industrial facilities however substantial changes 
in design, control and operational performances exist. For example, the 
running of MBRs at high sludge age in other words the length of time a 
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partical of suspended solids is retained in the process, results in higher 
microbial populations, leading to a lower food to microbial mass ratio and to 
more complete mineralisation (De Wever et al., 2007). It also allows for the 
growth and adaptation of microbes with greater physiological capabilities.  
 
High COD and BOD removal have been demonstrated in pharmaceutical 
production facilities using MBR technology. A 10 m3/d MBR operated at a 
pharmaceutical facility in Taiwan, for example, removed 95 and 99% of COD 
and BOD respectively and showed stable operation to different conditions 
(Chang et al., 2008). The plant consisted of an aeration tank and membrane 
bioreactor and was operated for 140 days. Initial wastewater concentrations 
were 800-11800 mg/L COD and 100-6350 mg/L BOD. The plant showed 
stable operation to different concentrations.  However despite high COD/BOD 
removal MBRs still do not remove all APIs. Estrone, ethinyl estradiol and 
venlafaxine have proven difficult to degrade (Helmig et al., 2007). API removal 
by MBR is shown in Table 2.2.   
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Table 2.2: Removal of selected pharmaceuticals in a variety of waters following MBR treatment. 
Pharmaceutical class Pharmaceutical Influent (ng/L ) Effluent (ng/L ) % Removal Matrix Reference 
Antibiotics Erythromycin 800 
 
34 96 Primary effluent Snyder et al., 2007 
 Monensin 40 
 
n.d. 100 Municipal WW Watkinson et al., 2007 
 Nalidixic acid 330 
 
45 86 Municipal WW Watkinson et al., 2007 
 Roxithromycin 69 
 
117 0 Municipal WW Clara et al., 2005 
 Sulfamethoxazole 23 
 
<10 >56 Primary effluent Snyder et al., 2007 
Lipid regulators Gemfibrozil 74 
 
<10 >86 Secondary effluent Snyder et al., 2007 
 Bezafibrate WWTP1:6840 
 
1550 77 Municipal WW Clara et al., 2005 
 Clofibric acid 92μg/m
3
/d 
 
46μg/m
3
/d 50 Municipal WW Bernhard et al., 2006 
Hormones Androstenedione <10 
 
<10 0 Primary effluent 
 
Snyder et al., 2007 
Antiepileptics Carbamazepine 189 
 
<10 >95 Primary effluent Snyder et al., 2007 
  1287μg/m
3
/d 
 
1119μg/m
3
/d 13 Municipal WW Bernhard et al., 2006 
  952 
 
704 26 Municipal WW Clara et al., 2005 
 Dilantin 192 
 
184 4 Primary effluent Snyder et al., 2007 
Antidepressant Fluoxetine 44 
 
<10 >77 Primary effluent Snyder et al., 2007 
Antiphlogistics Diclofenac 16 
 
<10 >38 Primary effluent 
 
Snyder et al., 2007 
  3190 
 
2140 33 Municipal WW Clara et al., 2005 
 Ibuprofen 2448 
 
20         99 Municipal WW Clara et al., 2005 
  6725 μg/m
3
/d 
 
92μg/m
3
/d 99 Municipal WW Bernhard et al., 2006 
 Naproxen 70 
 
<10 >86 Primary effluent 
 
Snyder et al., 2007 
Analgesics Acetaminophen <10 
 
<10 0 Primary effluent Snyder et al., 2007 
 Hydrocodone 168 
 
< 101 40 Primary effluent Snyder et al., 2007 
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2.4.3 Anaerobic treatment 
 
Anaerobic treatment methods consist of a number of processes in which 
microorganisms breakdown organic components of the wastewater in the 
absence of oxygen. The advantages of anaerobic treatment include its 
enhanced ability over aerobic processes to deal with high strength 
wastewater, low energy inputs, low sludge yield, low nutrient requirements, 
low operating cost, low space requirement and biogas recovery. 
Configurations of anaerobic reactors include upflow anaerobic reactors, 
anaerobic film reactors and upflow anaerobic filters (Chellipan et al., 2006; 
Chen, 1994; Gangagni Rao et al., 2005; Nandy, 2001; Oktem et al., 2007). 
Factors effecting treatment include HRT, temperature, pH, recalcitrant 
substances and biological community. 
 
Anaerobes have been shown to be sensitive to certain compounds, since 
pharmaceuticals are designed to interfere with normal biological processes it 
is predicted that they would have some impact on methanogenesis or 
acetogenesis. Common drugs such as propranolol hydrochloride, diclofenac 
sodium and ofloxacin showed a reduction in methane production which 
correlated with the hydrophobicity of the drug. In a study diclofenac sodium 
and propranolol hydrochloride induced acute inhibitory effects only at high 
concentrations but at lower concentrations the inhibitory effect was negligible 
(Fountoulakis et al., 2008).  
 
Upflow anaerobic stage reactors (UASR) have been shown to be efficient for 
the removal of pharmaceuticals even at high concentrations (Chellipan et al., 
2006; Oktem et al., 2007) However wastewater composition and 
pharmaceuticals present may have a negative affect on the acetogenesis and 
methanogenesis (Oz, 2004; Fountoulakis, 2008). A UASR is a stage reactor 
in which each stage represents a separate compartment. Therefore by 
separating acetogenesis and methanogenesis, recalcitrant substances are in 
an environment more conducive to their degradation. Advantages of UASRs 
include no moving parts or mixing and stability to shock loading. UASRs have 
been suggested as a pre-treatment to activated sludge for trade effluent 
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(Chellipan et al., 2006). This is to reduce the API concentration prior to AS 
treatment and thus improve the treatability of the wastewater using AS. A 
UASR fed with real pharmaceutical wastewater containing the antibiotics 
tylosin and avilamycin showed a high degree of COD and drug removal 
(Chelliapan et al., 2006).  
 
A hybrid upflow anaerobic sludge blanket reactor (UASBR) which combined a 
UASR and anaerobic filter technology from a chemical-synthesis based 
pharmaceutical factory showed significant removal at a much higher organic 
loading rate (OLR) (Oktem et al., 2007). A UASBR operating in thermophilic 
mode (55°C) showed a high COD removal (65-75%) and BOD removal (80-
94%) even at high OLR of 9 kg COD/m3/d (Sreekanth et al., 2009). Hazardous 
solvents, products, intermediates including phenol, 1,2-methoxy phenol, 
dibutyl phthalate, 1-bromo naphthalene, carbamazepine and antipyrine were 
present. With the exception of carbamazepine these hazardous compounds 
were removed. Table 2.3 shows removal of COD and APIs during anaerobic 
treatment of pharmaceutical wastewater. 
 
Table 2.3: Results of anaerobic treatments. 
 
Method 
OLR 
(kg) 
Temp. 
(°C) 
HRT 
(d) 
COD 
% 
removal 
 Specific 
methanogenic 
activity 
API 
API 
% 
removal 
Ref. 
UASR 1.86 37 4 70-75 - Tylosin 75 
Chellipan et 
al., 2006 
HUASR*  9 55 1.7 65-75 320 Carbamazepine 
Not 
degraded 
Sreekanth et 
al., 2009 
HUASR* 8 - 2 72 200 
Bacampicillin 
Sultamicillin 
Tosylate 
- 
Oktem et al., 
2007 
CSTR* 6 35 2.5 71 166 
Ampicillin, 
Amoxicillin 
Bacampicillin 
- 
Oz et al., 
2003 
Fixed film 
fixed bed 
reactor 
10 35 6 76 - Herbal - 
Nandy and 
Kaul, 2001 
UFFR* 
0.11-
0.34 
37 5-15 37-70 - - - 
Moosvi and 
Madamwar, 
2007 
Fixed film 
reactor 
10 35 1.7 60-70 - Bulk drugs - 
Gangagni 
Rao et al., 
2005 
 
*(HUASR) Hybrid upflow anaerobic sludge reactor, (CSTR) Completely stirred tank reactor, 
(UFFR) Upflow fixed film reactor. 
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2.5 Physio-chemical treatment options 
 
Physiochemical treatment options for the purpose of this review are divided 
into four main topics. The efficiency of these methods for the treatment of 
pharmaceutical wastewater varies significantly and is described below. 
 
 membrane processes  
 reverse osmosis 
 activated carbon 
 chlorination  
 
2.5.1 Membrane filtration 
 
For membrane filtration the degree of API, intermediate or raw material 
removal is directly related to the membrane characteristics such as molecular 
weight cut-off, pore size, surface charge, hydrophobicity/hydrophilicity and 
surface morphology. The molecular properties of the particular contaminants 
are also important such as molecular weight, molecular size, acid dissociation 
constant, hydrophobicity/hydrophilicity and the diffusion constant. The feed 
water composition, such as the pH, ionic strength, hardness and level of 
organic matter are also important in determining the efficiency of membrane 
filtration (Bellona et al., 2004).  
 
Several membrane types and applications were evaluated for the removal of 
APIs at pilot- and/or full-scale, including microfiltration, ultrafiltration, 
nanofiltration, reverse osmosis, electrodialysis reversal, membrane 
bioreactors and combinations of membranes in series (Snyder et al., 2007). 
Microfiltration and ultrafiltration have little value for the removal of the vast 
majority of organic contaminants as pore sizes vary from 100–1000 times 
bigger than micropollutants so no direct physical retention takes place. When 
operated as MBRs they have shown some potential for removal. Retention is 
significantly increased above the levels of a secondary clarifier. Micro/ultra 
filtration had a high-energy requirement and a high cost. It was economically 
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viable where sensitive surface waters require advanced treatment or where 
space is limited (Larsen et al., 2004).  
 
2.5.2 Reverse osmosis  
 
Desalinisation of sea and brackish water forms the core of existing research 
into reverse osmosis (RO). While literature on the use of RO for 
pharmaceutical removal is limited, there are reports of pharmaceutical 
removal from municipal wastewater (Watkinson et al., 2007) and for water 
reuse (Drewes et al., 2003). In RO wastewater is allowed to pass through a 
membrane from an area of high pressure to an area of low pressure keeping 
the solute on the pressurised side. There is some debate as to the size 
exclusion range for reverse osmosis membranes. Removal is based more on 
the molecular length and width rather than the molecular mass (Watkinson et 
al., 2007). 
 
 RO in different configurations showed efficient removal of thirty-six personal 
care products and endocrine disrupting chemicals (Snyder et al., 2007). 
These findings are tabulated in Table 2.4. RO membranes removed the 
majority of compounds investigated to levels below the limit of detection. 
However, pentoxifylline, iopromide, DEET, meprobamate, TCEP, gemfibrozil, 
musk ketone and oxybenzone were detected in the permeate of a variety of 
the configurations. It was hypothesised that membrane breaching may be due 
to diffusion into and through the membrane. Short-circuiting of the membrane 
or failure of membrane support media may also have caused breaching of the 
membrane. A number of membranes in series may be the most successful 
method in the removal of trace contaminants (Snyder et al., 2007).  
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Table 2.4: Removal of selected pharmaceuticals following UF, MF or RO treatments. 
Pharmaceutical class Pharmaceutical Treatment method Influent (ng/L ) Effluent (ng/L ) % Removal Matrix 
Antibiotics Oleandomycin MF-RO 20 30 0 Municipal wastewater
a
 
 Cefaclor MF-RO 70 n.d. 100 Municipal wastewater
a
 
 Cephalexin MF-RO 55 n.d. 100 Municipal wastewater
a
 
 Ciprofloxacin MF-RO 110 n.d. 100 Municipal wastewater
a
 
 Clindamycin MF-RO 1 n.d. 100 Municipal wastewater
a
 
 Enrofloxacin MF-RO 40 10 75 Municipal wastewater
a
 
 Erythromycin Ultrafiltration 289 245 15 Secondary effluent
b
 
 Chlortetracycline MF-RO 10 n.d. 100 Municipal wastewater
b
 
 Lincomycin MF-RO 10 1 90 Municipal wastewater
b
 
 Roxithromycin MF-RO 140 15 89 Municipal wastewater
b
 
 Salinomycin MF-RO 5 n.d. 100 Municipal wastewater
b
 
 Sulfamethoxazole MF-RO 255 n.d. 100 Municipal wastewater
b
 
  Ultrafiltration 66 
 
63 5 Secondary effluent
a
 
 Sulphasalazine MF-RO 255 n.d. 100 Municipal wastewater
b
 
 Trimethoprim MF-RO 80 63 21 Municipal wastewater
b
 
  Ultrafiltration 138 113 18 Secondary effluent
a
 
 Tylosin MF-RO 20 5 75 Municipal wastewater
a
 
X-Ray contrast media Iopromide Ultrafiltration 75 79 0 Secondary effluent
b
 
  
RO (virgin membrane) 
RO (fouled membrane) 
265 
278 
<25 
<25 
>91 
  >91 
Saline ground water
b
 
  
RO (virgin membrane) 
RO (fouled membrane) 
165 
125 
 
<25 
<72 
>85 
>42 
Saline ground water
b
 
Lipid regulators Gemfibrozil Ultrafiltration 82 89 0 Secondary effluent
b
 
  
RO (virgin membrane) 
RO (fouled membrane) 
230 
234 
<25 
<25 
>89 
>89 
Saline ground water
b
 
Hormones and oral 
contraceptives 
Androstenedione Ultrafiltration 77 
 
22 71 Secondary effluent
b
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  RO (virgin membrane) 284 
 
<25 >91 Saline ground water
b
 
 Estradiol 
 
Ultrafiltration 87 
 
<1 >99 Secondary effluent
b
 
  
RO (virgin membrane) 
RO (fouled membrane) 
125 
27 
<25 
<25 
>80 
>7 
Saline ground water
b
 
 Estrone Ultrafiltration 78 
 
<1 >99 Secondary effluent
b
 
  
RO (virgin membrane) 
RO (fouled membrane) 
125 
51 
 
<25 
<25 
>80 
>51 
Saline ground water
b
 
 Ethinylestradiol Ultrafiltration 98 
 
<25 >74 Secondary effluent
b
 
  
RO (virgin membrane) 
RO (fouled membrane) 
167 
83 
<25 
<25 
 
>85 
>70 
Saline ground water
b
 
 Progesterone Ultrafiltration 64 
 
1 98 Secondary effluent
b
 
  
RO (virgin membrane) 
RO (fouled membrane) 
285 
250 
 
<25 
<25 
  >91 
>90 
Saline ground water
b
 
 Testosterone Ultrafiltration 81 
 
23 72 Secondary effluent
b
 
Antiepileptic‘s Carbamazepine Ultrafiltration 191 
 
161 16 Secondary effluent
b
 
 Dilantin Ultrafiltration 130 
 
98 25 Secondary effluent
b
 
 
  
RO (virgin membrane) 
RO (fouled membrane) 
259 
239 
 
<25 
<25 
>90 
>90 
0 
Saline ground water
b
 
Antidepressant Fluoxetine Ultrafiltration 45 14 69 Secondary effluent
b
 
  
RO (virgin membrane) 
RO (fouled membrane) 
263 
564 
<25 
<25 
>90 
>96 
Saline ground water
b
 
Antiphlogistic‘s Diclofenac Ultrafiltration 38 37 3 Secondary effluent
b
 
  RO (Virgin Membrane) 26 <25 >4 Saline ground water
b
 
 Naproxen Ultrafiltration 24 21 13 Secondary effluent
b
 
  
RO (virgin membrane) 
RO (fouled membrane) 
118 
91 
<25 
<25 
>79 
>73 
Saline ground water
b
 
Analgesics Acetaminophen Ultrafiltration 18 17 6 Secondary effluent
b
 
 Hydrocodone Ultrafiltration 
 
105 90 14 Secondary effluent
b
 
 
b
Watkinson et al., 2007, 
a
 Snyder et al, 2007
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2.5.3 Activated carbon 
 
Activated carbon (AC) is an established conventional technology for the 
removal of both natural and synthetic organic contaminants (Annesini et al., 
1987; Hrubec et al., 1983). AC is a form of carbon that has been processed to 
make it porous giving it a large surface area for adsorption. It is most 
commonly applied as a powdered feed or in granular form in packed bed 
filters. Granular activated carbon (GAC) can be used as a replacement for 
anthracite media in conventional filters, providing both adsorption and 
filtration. It can be applied following conventional AS treatment as an 
adsorption bed. Carbon regeneration and disposal are environmental 
considerations (Snyder et al., 2007).   
  
Powdered activated carbon (PAC) and GAC at both laboratory scale and full-
scale facilities showed high removal efficiencies (Snyder et al., 2007). PAC, 
which was tested at pilot scale, achieved greater than 90% removal for 
nineteen of twenty-six APIs tested including trimethoprim, carbamazepine and 
acetaminophen. Poorer results were seen where regular regeneration was not 
provided. GAC was tested at two full scale facilities. Facility one showed 
removal to below the limit of detection for all target pharmaceuticals. Facility 
two in contrast showed very limited removal. Facility one provides regular 
regeneration which accounts for the conflicting results. While GAC was also 
found to be highly effective in this study, hydrophilic contaminants have been 
noted to break through GAC more easily than hydrophobic contaminants. The 
steam-treatment of GAC was highlighted as significantly increasing its 
absorption capacity. The filtration step prior to the treatment of micropollutants 
by PAC is important (Hartig et al., 2001). The filtration step reduces the 
carbon demand of the wastewater due to less blocking of the micropores by 
high molecular weight compounds. Consequently PAC is only suitable for the 
treatment of pre-treated or wastewaters with a low organic loading. 
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2.5.4 Chlorination 
 
Chlorination has been shown to be effective for the removal of 
pharmaceuticals including 17 α-ethinylestradiol and 17 β-estradiol (Alum et 
al., 2004) and sulfonamides (Qiang et al., 2006). Chlorine dioxide is also 
effective for the removal of sulfamethoxazole, roxithromycin, 17α-
ethinylestradiol and diclofenac (Khetan and Collins, 2007). Chlorination and 
ozonation when compared for the removal of bisphenol A, 17β-estradiol, and 
17α-ethinyl estradiol and by-product estrogenicity from distilled water showed 
comparable results with ozonation resulting in 75-99% removal (Alum et al., 
2004). Residual chlorine and ozone was found to be low with >99% loss of the 
parent compound. 
 
Acetaminophen, diclofenac, sulfamethoxazole and fluoroquinolone all become 
oxidised during chlorination. By-products of acetaminophen include the toxic 
by-products N-acetyl-p-benzoquinone imine and 1,4-benzoquinone. Both 
metoprolol and sulfamethoxazole form chloramines as one of their oxidation 
products (Pinkston and Sedlak, 2004). Chloramines are known carcinogens. 
 
2.6 Oxidation reactions 
 
The biological and physiochemical treatment methods described previously 
have shown limited success for the treatment of pharmaceutical wastewater. 
However the development of oxidation processes has shown varying higher 
degrees of success over the traditional treatment methods. Over the last 
twenty years various advanced oxidation processes have been developed 
(Carey, 1992). Oxidation reactions have primarily been used to supplement 
not replace conventional systems and to enhance the treatment of refractory 
organic pollutants (Balcioğlu and Ötker, 2003). This technology has been 
successfully applied to the treatment of pharmaceuticals (Khetan and Collins, 
2007). Advanced oxidation processes (AOPs) are technologies that utilise 
hydroxyl and other radicals to oxidize compounds to various by-products and 
inert endproducts (Klavarioti et al., 2009). For AOPs to take place a chemical 
agent such as hydrogen peroxide, ozone, transition metals and metal oxides 
is required. In conjunction with this, an energy source such as ultraviolet-
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visible radiation, electric current, gamma-radiation and ultrasound is 
necessary (Ikehata et al., 2006). The oxidation –reduction reactions are made 
more rapid by the addition of an energy source hence the term advanced 
oxidation processes. AOPs are based on the production of free radicals in 
particular the hydroxyl radical. AOPs frequently include ozonation coupled 
with hydrogen peroxide and ultra violet (UV) light. Fenton‘s and TiO2 
photocatalysis were also employed. Heterogeneous mixtures of ozone, 
hydrogen peroxide, Fenton‘s and titanium dioxide in light and dark have 
revealed a range of suitable treatment methods depending on the properties 
of the pharmaceutical and economic considerations (Carey, 1992; Ikehata et 
al., 2006).   
 
Filtration or adsorption methods simply transfer the pollutants from the liquid 
to solid phase or concentrate in brine waste streams, which then required 
further treatment. AOPs however allow for the conversion of pollutants to less 
harmful and more biodegradable compounds (Ikehata et al., 2006). The 
ultimate aim of AOPs is the mineralisation of pollutants, with conversion to 
carbon dioxide, water, nitrogen and other minerals. AOPs may have changed 
a compound‘s polarity and the number of functional groups which affected the 
functionality of the pharmaceutical in the body. Original medicinal modes of 
action then ceased e.g. antibiotics which have been hydroxylated should not 
promote the formation of resistant strains (Ternes et al., 2003). However 
degradation compounds must be identified and monitored as they may be 
more toxic than the parent compounds (Vogna et al., 2002). Photocatalytic 
degradation studies using the analgesic drug, buspirone, have revealed that 
the intermediates produced reflected those found in biotransformation in 
animal models (Calza et al., 2004a). Methods that produced fewer 
intermediates must be developed to allow for effective modelling and 
application (Gaya and Abdullah, 2008).  
 
Photoinitiated AOPs may be coupled with other biological, physical and 
chemical methods for mineralisation. Pretreatments such as micro or ultra 
filtration, reverse osmosis followed by an AOP have proved effective for the 
treatment of industrial wastewater (Ollis, 2003). AOPs may have enhanced 
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biodegradability as a pretreatment method to biological treatment (Cokgor et 
al., 2004; Oller et al., 2007). They may be used as a tertiary treatment, post 
activated sludge treatment. AOPs also handled fluctuating flow rates and 
compositions with less difficulty than microbes, as the same level of 
adaptation to the wastewater is not necessary (Ikehata et al., 2006).  
 
Cost of both the chemical agent and the energy source has proved, in the 
past, a major block to implementation of AOPs on an industrial scale (Legrini 
et al., 1993). By using solar irradiation the capital cost of AOPs was 
substantially reduced (Trovo et al., 2008). Natural compounds as well as 
carbonate, bicarbonate and chloride ions may lead to a reduction in treatment 
efficiency as these compounds may act as antioxidants quenching the radical 
scavengers (Ikehata et al., 2006).  
 
2.6.1 Ozonation 
 
Ozone has been applied to the treatment of waters primarily due to its strong 
disinfection and sterilisation properties (Araña et al., 2002). Its application for 
the treatment of waters containing pharmaceutical residues is now a broad 
area of research (Alum et al., 2004; Andreozzi et al., 2005; Andreozzi et al., 
2006; Balcioğlu and Ökter, 2003; Cokgor et al., 2004; Dantes et al., 2008; 
Ternes et al., 2003). Ozone may be implemented as the principle treatment 
method or to enhance the biodegradability and efficiency of subsequent 
treatment (Cokgor et al., 2004). Ozone production was an energy intensive 
process, making it costly to implement. An ozone treatment system may have 
increased the energy demand over a conventional wastewater treatment plant 
by 40-50% (Larsen et al., 2004).  
  
A number of published works shows the breakdown of pharmaceuticals using 
ozone in water (Andreozzi et al., 2003a and b; Alum et al., 2004; Vogna et al., 
2004a).  A significant contribution to this work has been in the area of 
antibiotic removal (Andreozzi et al., 2005; Andreozzi et al., 2006; Balcioğlu 
and Ökter, 2003; Dantes et al., 2008; Ternes et al., 2003).  A summary of 
results can be seen in Table 2.5. Although results in terms of degree of 
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removal and mineralisation of pharmaceuticals in water or synthetic industrial 
effluent were available, a significant gap in the literature exists regarding 
ozonation of pharmaceuticals in real pharmaceutical wastewater (Cokgor et 
al., 2004). Furthermore details of process optimisation and kinetics for the 
elimination of pharmaceuticals using ozone were limited (Arslan-Alaton and 
Caglayan, 2005).  
  
Recent kinetics studies on pharmaceuticals including amoxicillin, lincomycin, 
clofibric acid, acetaminophen, bisphenol A, 17-estradiol, and 17-ethynyl 
estradiol showed ozone attack on aromatic rings and amino groups (Alum et 
al., 2004; Andreozzi et al., 2003 a and b; Andreozzi et al., 2005; Andreozzi et 
al., 2006; Arslan-Alaton and Caglayan, 2005). A kinetic study of the effect of 
ozone attack on the antibiotic amoxicillin showed direct attack on the phenolic 
ring leading to the formation of hydroxyl derivative intermediates, with no 
evidence of oxidation of the sulphur atom (Andreozzi et al., 2005).   A kinetic 
analysis of the effect of 5-10 mg/L O3 on four beta blockers, namely 
acebutolol, atenolol, metoprolol and propranolol from reverse osmosis 
permeate showed ozone attack on aromatic rings and amine groups (Benner 
et al., 2008). The reaction of the aromatic structure is independent of solution 
pH. However amine groups did not react directly with ozone and so the 
reactivity of amines strongly depended on the pKa of the amine and the pH of 
the solution.  
 
As with all oxidation processes degradation products must be analysed as 
they may be more toxic than the parent compound (Ikehata et al., 2006; 
Andreozzi et al., 2006). Microtox analysis showed a slight increase in acute 
toxicity in the first stage of ozonation of sulfamethoxazole (Dantes et al. 
2008). It also must be considered that other compounds in the waste stream 
other than the target pharmaceutical may produce more harmful by-products 
as a consequence of the ozonation process. Brine from a RO process was an 
example of this. The RO concentrate contained 1200 μg/L bromide (Benner et 
al., 2008). Since ozonation of bromide results in the formation of bromate, a 
potential human carcinogen, levels of its production were monitored.  
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Table 2.5: Results on the treatment efficiency of ozonation for a variety of pharmaceuticals. 
Pharmaceutical class Pharmaceutical Treatment efficiency Matrix Reference 
Antibiotic Clarithromycin >76% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
 Erythromycin >92% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
 Roxithromycin >91% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
 Sulfamethoxazole >92% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
 Trimethoprim >85% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
Lipid regulator Clofibric Acid 100% removal  at 20 min O3, Distilled water Andreozzi et al., 2003a 
  
50% removal at 5 mg/L O3 
>59% removal at 10-15 mg/L O3 
Municipal wastewater Ternes et al., 2003 
 Fenofibric >62% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
Hormones and 
oral contraceptives 
17α-ethinyl estradiol 
17β-estradiol 
>99% removal *Chlor/O3 Distilled water Alum et al., 2004 
Antiepileptic Carbamazepine >98% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
β-blockers Atenolol 
61% removal at 5 mg/L O3 
>86% removal at 10-15 mg/L O3 
Municipal wastewater Ternes et al., 2003 
 Celiprolol >82% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
 Metoprolol 
78%  removal at 5 mg/L O3, 
> 93% removal at 10-15 mg/L O3 
Municipal wastewater Ternes et al., 2003 
 Propanol > 72% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
 Sotalol >96% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
Antiphlogistics Diclofenac >96% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
  100% removal after 10 min Distilled water Vogna et al., 2004a 
 Ibuprofen 
48% removal at 5 mg/L O3 
> 62% removal at 10-15 mg/L O3 
Municipal wastewater Ternes et al., 2003 
 Indomethacin > 50% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
 Naproxen > 50% removal at 5-15 mg/L O3 Municipal wastewater Ternes et al., 2003 
Analgesic Acetaminophen Mineralisation  of ca. 30% for O3 Distilled water Andreozzi et al., 2003b 
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2.6.2 Perozonation 
 
Perozonation, a combination of hydrogen peroxide and ozone, has been 
successfully used to degrade penicillin formulation effluent (Arslan-Alaton et 
al., 2004; Balcioglu and Okter, 2003; Cokgor et al., 2004). The conjugate base 
of H2O2 at low concentrations increases the rate of decomposition of O3 into 
hydroxyl radicals (Balcioğlu and Ökter, 2003). 30% removal of COD in 
penicillin formulation effluent was accomplished using ozonation alone 
(Arslan-Alaton et al., 2004). Removal efficiency was enhanced through the 
addition of H2O2, to a maximum of 76% in the presence of 2 mM H2O2. 
However it was found that a certain fraction of the resulting COD was non-
biodegradable in the subsequent biotreatment. This inert fraction of the waste 
remained in the effluent. Only overall COD loading was monitored here and 
not actual penicillin levels or breakdown compounds. Thus, the true treatment 
efficiency of the method in terms of the penicillin removal is unclear. Other 
studies involving penicillin showed COD and aromaticity increased from 69% 
and 29% for ozone alone to 95% and 90% in the presence of 20 mM 
hydrogen peroxide (Balcioğlu and Ökter, 2003). The presence of UV 
increased the COD removal in penicillin formulation wastewater to almost 
100%. For synthetic formulation effluent containing the antibiotics ceftriaxone 
and enrofloxacin only slight increases in efficiency were noted following the 
addition of hydrogen peroxide.  
  
Combined UV, O3 and H2O2 treatment was applied to municipal wastewater 
treatment plant effluent containing seventeen pharmaceuticals including 
antibiotics, β-blockers, antiepileptics, antiphlogistics and lipid lowering agents 
at a German Municipal WWTP (Ternes et al. 2003). The influent and effluent 
concentrations for a variety of pharmaceuticals using hydrogen peroxide are 
shown in Table 2.6. 
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Table 2.6: Removal efficiency for a variety of pharmaceuticals using hydrogen peroxide. 
Pharmaceutical 
class 
Pharmaceutical Treatment method Treatment efficiency Matrix Reference 
Antibiotics Ceftriaxone H2O2/O3 82% COD removal 
Synthetic 
pharmaceutical 
wastewater 
Balcioğlu and Ökter, 2003 
 Enrofloxacin H2O2/O3 79% COD removal 
Synthetic 
pharmaceutical 
wastewater 
Balcioğlu and Ökter, 2003 
 Penicillin 
H2O2/O3, 
H2O2/O3/biological 
COD removal: 83% H2O2 
Antibiotic 
formulation effluent 
Arslan-Alaton et al., 2004 
  H2O2/O3 71% COD removal 
Synthetic 
pharmaceutical 
wastewater 
Balcioğlu and Ökter, 2003 
  
H2O2/UV, 
Fe
2+
/H2O2, 
Fe
3+
/H2O2, 
Fe
2+
/H2O2/UV 
Fe
3+
/H2O2/UV 
COD removal 
H2O2/UV 22% 
Fe
2+
/H2O2/UV 56%, 
Fe
3+
/H2O2/UV 66%, 
Fe
2+
/H2O2 61%, 
Fe
3+
/H2O2 46% 
Antibiotic 
formulation effluent 
Arslan-Alton and Dogruel, 
2004 
Lipid-regulator Clofibric acid H2O2/UV 
90% Removal after 60 min 
with poor mineralisation 
Distilled water Andreozzi et al., 2003a 
Hormones and oral 
contraceptives 
Ethinylestradiol 
and estradiol 
H2O2/UV >95% removal  UV/H2O2 
Spiked synthetic 
drinking water 
and river water 
Rosenfeldt and Linden, 2004 
Antiepileptic Carbamazepine H2O2/UV 
Removal after 
4min TOC removal of 35% 
Distilled water Vogna et al., 2004b 
Antiphlogistics Diclofenac H2O2 
Removal after 100min at 
50 mg/L API conc. 
Distilled water Pérez-Estrada et al., 2005b 
  Fe
3+
, H2O2 
Removal after 60min 
Mineralisation: 100min of 
sunlight 
Demineralised water Pérez-Estrada et al., 2005a 
  Fe
3+
/H2O2/UV Total mineralisation in <60min Distilled water Ravina et al., 2002 
Analgesic Acetaminophen H2O2 Mineralisation of 40% Distilled water Andreozzi et al., 2003b 
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2.6.3 Direct photolysis 
 
Photolysis occurs due to the direct breakdown of a compound by the 
absorption of light (Legrini et. al., 1993). Many pharmaceuticals are readily 
susceptible to photolytic transformation. APIs that do not absorb light above 
290 nm are more resistant to direct photolysis (Khetan and Collins, 2007).  
Lamps employed in the removal of micropollutants focus mainly on low and 
medium pressure mercury lamps. Low pressure mercury lamps 
characteristically generate light at 254 nm while medium pressure lamps emit 
their energy at multiple wavelengths. Electrons in the outer orbital of the 
molecules present in the wastewater absorb photons, become unstable and 
may split or become reactive (Takashi et al., 2007). 
 
Using an 110 W, 254 nm UV lamp at 313 K and 0.5 g/L, a 70% conversion of 
0.25 L of 2-chloropyridine (typically found in effluent of pharmaceutical 
processing) was achieved in 20 minutes (Stapleton et al., 2006). Mefenamic 
acid was observed to undergo direct photolysis with a half-life of 33 hours 
under direct noon sunlight in mid-October at 45° latitude (Werner et al, 2005). 
Carbamazepine and clofibric acid have photodegradation half-life times of 100 
days in winter at 50° N. Conversely sulfamethoxazole, diclofenac, ofloxacin 
and propranolol undergo faster degradation with half-lives of 2.4, 5.0, 10.6 
and 16.8 days respectively.  
 
A fundamental parameter that determines the rate of degradation for 
photolysis is the decadic molar adsorption coefficient which is a measure of 
the capacity of a compound to absorb photons. Ibuprofen, diphenhydramine, 
phenazone, and phenytoin have decadic molar adsorption coefficients of 256 
M-1 cm-1, 388 M-1 cm-1, 8906 M-1 cm-1 and 1260 M-1cm-1(Yuan et al., 2009). As 
indicated by the decadic molar extinction coefficients, 27.4% removal of 5μm 
initial concentration of ibuprofen, 26.3% of diphenhydramine, 95.8% and 
87.8% degradation for phenazone and phenytoin. The experiment was carried 
out using 110 W low pressure lamp producing monochromatic UV light at 254 
nm in a 500 mL quartz reactor. Only 6% removal of the antibiotic 
metronidazole with a low-pressure and 12% with a medium pressure mercury 
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lamp after 5 min exposure occured. Metronidazole has an absorption centred 
at about 310 nm since the low pressure lamp only emits light at 254 nm this 
reflects its low removal. UV bench scale collimated beam apparatus was used 
focused at a 70 x 50 mm crystallization dish (surface area 34.2 cm2 with 100 
mL of 6 µM metronidazole (Yuan et al., 2009).   
 
2.6.4 TiO2 photocatalysis  
 
Photocatalysis is the acceleration of a photochemical transformation by the 
action of a catalyst (Chatterjee and Dasgupta, 2005; Dalrymple et al., 2007; 
Herrmann, 2005). A catalyst such as TiO2 or iron(II) was required to 
accelerate light mediated breakdown of pharmaceuticals. Most photocatalysts 
are semiconductor metal oxides which characteristically possess a narrow 
band gap. Photons of light cause excitation of electrons in the photocatalyst. 
Electrons in the valence band which gain sufficient energy will change levels 
from the valence to the conduction band creating an electron-hole pair. The 
electron hole pair will migrate to the surface of the catalyst, where it either 
recombines or undergoes redox reactions with compounds absorbed onto the 
catalyst. Hydroxyl radicals are produced as a consequence of the interaction 
between electron holes and water or hydrogen peroxide. Superoxide radicals 
may also be formed as a result of the reaction between the electron hole and 
water. Radicals formed degrade impurities in the water relatively 
unselectively, reacting with impurities in the wastewater as well as the target 
pharmaceuticals (L‘homme et al., 2008).       
 
Since the degradation of chlorobiphenyls and biphenyls from aqueous media 
using TiO2 photocatalysis was first reported (Carey et al., 1976) the literature 
on the removal of micro pollutants from aqueous media using TiO2 has grown 
considerably (Addamo et al., 2005; Doll and Frimmel, 2005a, b and c; Pérez-
Estrada et al., 2005a). Titania was the most widely investigated of the 
heterogeneous photocatalysts due to their cost effectiveness, inert nature and 
photostability (Gaya and Abdullah, 2008). Investigations into the removal of 
the pharmaceuticals using TiO2, included but was not limited to work on 
antibiotics, lipid regulators, x-ray contrast media, antiepileptics and 
antiphlogistics (Addamo et al., 2005; Doll and Frimmel, 2005 a, b and c; 
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Perez-Estrada et al., 2005 a; Ravina at al., 2002). Results can be seen in 
Table 2.7. TiO2 removal of organics as a tertiary treatment employing solar 
light and 2.3 g/L TiO2, the TOC was reduced from 130 mg/L to 7 mg/L and 
total elimination of coliforms in less than 60 minutes (Araña et al. 2002). 
 
TiO2 photocatalysis with visible irradiation was effective for the detoxification 
of the pharmaceutical salbutamol in water (Sakkas et al., 2007). The most 
favourable values for drug abatement were 649 mg/L of TiO2 at a pH of 7.4 
irradiated with a 1500 W xenon lamp for 30 minutes which resulted in 93% 
degradation. A toxicological evaluation of the breakdown of salbutamol and its 
metabolites was undertaken. An initial toxicity of 4% increased to a maximum 
of 54% inhibition after 15 minutes. From 15 to 60 minutes of irradiation 
inhibition decreased to less than 1%. The major drawback of the study is that 
real wastewater was not employed. In real wastewater the matrix may 
interfere with the degradation of the salbutamol. For example, the presence of 
ions will reduce degradation rates as they absorb to the TiO2 surface (Malato 
et al., 2002).  
 
TiO2 is available at a relatively modest price and would be recyclable in an 
industrial application when fixed on films or beads, reducing the quantities of 
TiO2 required (Legrini et al., 1993). Furthermore solar studies have proved 
effective for a wide range of pharmaceuticals replacing the expense of 
generating UV light. There are difficulties in implementation on a commercial 
scale due to the number of operating parameters e.g. type and geometry of 
reactor, the photocatalyst, optimum energy use and wavelength of radiation. 
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Table 2.7: Treatment efficiencies for pharmaceuticals using the photocatalyst TiO2. 
Pharmaceutical 
class 
Pharmaceutical 
Treatment 
method 
Glass Light source Treatment efficiency Matrix Reference 
Antibiotics Lincomycin 
TiO2/UV, 
 
Pyrex 
Med pressure Hg 
lamp 
98%  removal within 2h Distilled water 
Addamo et al., 
2005 
 Ranitidine 
TiO2/UV, 
 
Pyrex 
Med pressure Hg 
lamp 
98% removal within 2h Distilled water 
Addamo et al., 
2005 
 Tetracycline 
TiO2/UV, 
 
Quartz 
Med pressure Hg 
lamp 
98% removal within 2h Distilled water 
Addamo et al., 
2005 
X-ray contrast 
media 
Iomeprol 
Cross flow 
microfiltration 
TiO2 
Quartz 
Low pressure Hg 
lamp 
Degradation: 
Hombikat UV100: 6.9% 
Degussa P25 2.9% 
Demineralised water 
Doll and Frimmel, 
2005 a 
  TiO2 Quartz Short arc Xe lamp 
Degradation: 
Hombikat UV100: 27.4% 
Degussa P25 15.6% 
Hombikat UV100: 93% 
Degussa P25 15% 
Demineralised water 
bog-lake water 
(DOC: 6 mg/L) 
Doll and Frimmel 
2005 b 
  TiO2 Quartz Short arc Xe lamp 
Theoretically de-
iodinated: 
Hombikat UV100: 57.7% 
Degussa P25 25.5% 
Demineralised and 
bog-lake water 
Doll and Frimmel, 
2005 c 
  TiO2 Quartz Short arc Xe lamp, 
40 min degradation: 200 
mg/L to 59 mg/L 
Demineralised water 
Doll and Frimmel, 
2004 
Antiepileptic Carbamazepine 
Cross flow 
microfiltration 
TiO2, 
Quartz 
Low pressure Hg 
lamp 
 
Degradation: 
Hombikat UV100: 7.2% 
Degussa P25: 3.8% 
Demineralised water 
Doll and Frimmel, 
2005 a 
Antiphlogistics Diclofenac TiO2 Pyrex 
Solar irradiation in 
CPC 
100% removal 50 mg/L in 
200min 
Distilled water 
Pérez-Estrada et 
al., 2005b 
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2.6.5 Fenton’s reaction  
 
Fenton‘s chemistry involves reactions of hydrogen peroxide in the presence of 
iron to generate hydroxyl radicals (Carey, 1992). Ultraviolet light enhances 
this generation by the photoreduction of Fe(III) to Fe(II). Since iron is 
abundant and non-toxic, Fenton‘s reaction is a viable option for wastewater 
treatment. Photo-Fenton‘s reaction has been used for the degradation of 
diclofenac (Pérez-Estrada et al., 2005b; Ravina et al., 2002). Compound 
parabolic collectors have also been used. Results for varying Fenton‘s 
reactions, lamps used and reactor configurations are shown in Table 2.8.  
 
Fenton‘s (Fe2+/ H2O2) and Fenton‘s-like (Fe
3+/H2O2) reactions were compared 
for both dark and photo-assisted reactions (Arslan-Alaton and Dogruel, 2004). 
After 40 minutes advanced oxidation by Fe2+/H2O2 at pH3, penicillin was 
completely removed. Higher COD and TOC removals were obtained with dark 
Fenton‘s (Fe2+/H2O2) at pH3 compared with dark Fenton‘s-like (Fe
3+/H2O2). 
Photo-assisted reactions using UV-C provided only slightly higher removal 
efficiencies. TOC removal was higher with photo-Fenton‘s reaction and COD 
removal was slightly higher with photo-Fenton‘s-like reactions. 
 
Since Fenton‘s reactions operate at room temperature and normal pressure 
and highly complicated apparatus are not required, there should be a smooth 
transition from laboratory scale to large scale (Kavitha and Palanivelu, 2004). 
On the other hand, the strong dependence on the aqueous solution pH 
(optimum pH 2–4 for the production of OH· radicals) and on the 
concentrations of hydrogen peroxide and ferric/ferrous ions and the disposal 
of the iron sludge are factors which need to be taken into consideration 
(Shemer et al., 2006). One possibility is the partial use of Fenton‘s reactions 
to produce a non-toxic and biodegradable intermediate which could then be 
treated in an inexpensive biological step to achieve complete mineralisation 
(Muñoz et al., 2006). 
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Table 2.8: Pharmaceutical treatment efficiencies using Fenton’s reaction. 
Pharmaceutical 
class 
Pharmaceutical 
Treatment 
method 
Reactor configuration 
Light 
source 
Treatment efficiency Matrix Reference 
Antibiotics Penicillin 
O3/OH−, 
H2O2/UV-C, 
Fe
2+
/H2O2, 
Fe
3+
/H2O2, 
Fe
2+
/H2O2/UV-C 
Fe
3+
/H2O2/UV-C 
2L capacity annular Plexiglas 
reactor 
 
21W low 
pressure Hg 
lamp, 
quartz. 
CODR:  O3/pH11 49%, 
H2O2 (30 mM)/UV/pH7 22%, 
Photo-Fenton‘s 56% 
Photo-Fenton‘s-like 66% 
Dark Fenton‘s  61%, 
Dark Fenton‘s-like 46% 
Antibiotic 
formulation 
effluent 
Arslan-Alton 
and Dogruel, 
2004 
Antiphlogistics Diclofenac Fe
3+
, H2O2 
CPC  solar pilot plant 
Total volume: 35L, 
Illuminated volume: 22L 
Irradiated collector: 3.08m
2
 
Solar, Pyrex 
with 80% 
transmittivity 
between 
320-400nm. 
Degradation following 60min 
and mineralisation following 
100min exposure to sunlight 
Demineralised 
water 
Pérez-
Estrada et 
al., 2005a 
  Fe
3+
/H2O2/UV-C 
Irradiated volume 900 mL. Total 
volume of the solution recycled 
in photo-reactor: 1400 mL. 
400W low 
pressure Hg 
lamp. 
Total mineralisation in 
<60min 
Distilled water 
Ravina et al., 
2002 
Antibiotic Amoxicillin 
FeOx/H2O2/UV-A 
Fe(NO3)3/H2O2/UV
-A 
Upflow reactor with irradiated 
volume of 280 mL and a total 
volume of 800 mL. 
Recycled in reactor 
15W black 
light 
fluorescent 
lamp 
84% degradation after 1min. 
62% degradation after 1min. 
 
WWTP 
effluent 
Trovo et al., 
2008 
Analgesic Paracetamol 
FeOx/H2O2/UV-A 
Fe(NO3)3/H2O2/UV
-A 
Upflow reactor with irradiated 
volume of 280 mL and a total 
volume of 800 mL. 
Recycled in reactor 
15W black 
light 
fluorescent 
lamp 
98% degradation after 5min 
53% degradation after 5min 
WWTP 
effluent 
Trovo et al., 
2008 
Anti-bacterial Metronidazole 
UV 
UV/H2O2 
H2O2/Fe
2+
 
UV/H2O2/Fe
2+
 
Bench scale UV collimated 
beam apparatus 70x50mm. 
Crystallisation dish containing 
100 mL of solution with surface 
area of 34.2cm
2
, open to the 
atmosphere. 
Medium 
pressure Hg 
lamp 200-
400nm 
wavelength. 
12% degradation after 5min 
64% degradation after 5min 
76% degradation after 5min 
94% degradation after 5min 
Deionised 
water 
 
Shemer et 
al., 2006 
Lipid regulator Bezafibrate 
FeOX/H2O2/UV-A 
Fe(NO3)3/H2O2/UV
-A 
Upflow reactor with irradiated 
volume of 280 mL and a total 
volume of 800 mL. 
Recycled in reactor 
15W black 
light 
fluorescent 
lamp 
98% degradation after 5min 
89% degradation after 5min 
WWTP 
effluent 
Trovo et al., 
2008 
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2.6.6 Photocatalytic reactors for water treatment 
 
One of the major impediments to the commercialisation of photocatalytic 
water treatment was the high cost of generating artificial radiation. Therefore, 
solar photocatalytic reactors have received considerable interest. The design 
of the reactor is extremely important to ensure efficient conversion of the 
incident solar radiation to charge carriers (Bahnemann, 2004). There are four 
frequently used reactor configurations: parabolic trough reactor (PTR), thin 
film fixed bed reactor (TFFBR), compound parabolic collector (CPC) and 
double skin sheet reactor (DSSR) (Bahnemann, 2004).  
 
PTRs concentrate sunlight into a focal line using parabolic mirrors. They have 
(using Degussa P25 particles (0.1%) as TiO2 photocatalyst) reduced the 
concentration of trichloroethylene in contaminated water from 200 ng/L to 5 
ng/L  (Goswami, 1997). A TFFBR consists of a sloping plate coated with the 
photocatalyst and rinsed with the polluted water in a very thin film. The DSSR 
is a flat and transparent structured plexiglass® box. The polluted water and 
the photocatalyst can be pumped through channels in the box. A CPC is a 
combination of parabolic concentrators and flat static systems. Reactors can 
also be classified into concentrating and non-concentrating. Table 2.9 
compares these types of reactors.  
  
CPCs are low concentration collectors which are a good option for solar 
photocatalysis since they combine the better features of concentrating and 
non-concentrating collectors and none of the disadvantages. The 
photoreactor is tubular so that water can be pumped easily. CPCs use direct 
and diffuse solar radiation efficiently without solar tracking. The water did not 
heat up and there was no evaporation of volatile compounds (Malato et al., 
2007). 
 
Four different reactors – PTC, CPC, tubular collector and V shaped trough 
collector - were compared for their ability to degrade oxalic acid in an aqueous 
suspension of TiO2 (Bandala et al, 2004). The performance of the four 
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detectors was similar in terms of energy accumulated however the tubular 
collectors produced the least degradation.  
 
More recently, other reactors have been developed to overcome some of the 
problems associated with these reactors (Cernigoj et al., 2007; Danion et al., 
2004; Puma and Yue, 2001; Zhang et al., 2004). TiO2 was mostly applied in 
powder form and either it had to be separated at the end (which is time-
consuming and costly) or it was immobilised on a rigid support as a thin film 
(which limited the contact between the reactants and catalyst and thus the 
reaction rate). A Carberry type photoreactor combines the compact and 
convenient parabolic collectors with glass tubes and turbulent flow with the 
immobilised catalyst. It was used to degrade 4-chlorophenol as a model 
organic compound. Its photocatalytic activity was 3.8 times higher than a 
configuration of two TiO2 slides (which served as an approximation of a 
TFFBR) (Cernigoj et al., 2007). Other reactors are the optical fibre reactor 
(Danion et al., 2004), corrugated plate reactor (Zhang et al., 2004), fountain 
reactor with a parabolic profile (Puma and Yue, 2001), cylindrical photoreactor 
with TiO2 immobilised on fibreglass cloth (Horikoshi et al., 2002), Taylor vortex 
reactor (Dutta and Ray, 2004), fluidised photoreactors (Lee et al., 2003), 
spinning disc reactor (Yatmaz et al., 2005) and labyrinth flow photoreactor 
with an immobilised TiO2 bed (Mozia et al., 2005). 
 
There has been very limited large-scale application of photocatalysis to 
wastewater treatment so far. One of these is located at the Plataforma Solar 
de Almería in Spain, a compound parabolic collector plant. However, the 
efficiency achieved at laboratory and pilot scale has not been achieved in 
these larger systems. One of the reasons for this is that small scale studies 
often fail to take into account the effect of other substances in the 
wastewaters. For example, the presence of natural organic matter and 
carbamazepine retards the photodegradation of clofibric acid (Doll and 
Frimmel, 2005b). Not all compounds were affected. In the treatment of 
wastewaters from a resins factory which contained phenol, phthalic acid, 
fumaric acid, maleic acid, glycols, xylene, toluene, methanol, butanol and 
phenylethylene amounting to 600 mg/L TOC, there was complete TOC 
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degradation within 44 minutes of 36.1 W/m2 illumination of a dilute solution 
using 0.1 g/L of Degussa P25 and 7 mmol/L sodium peroxydisulfate as the 
additional oxidising agent (Malato et al., 1996). 
 
CPCs have also been used to compare heterogeneous solar photocatalysis 
and solar photo-Fenton‘s reactions for the degradation of methyl-
phenylglycine contaminated wastewaters (Muñoz et al, 2006). A life cycle 
assessment was done whereby the environmental impact was assessed by 
identifying and quantifying energy and materials usage and waste discharges 
impacts and evaluation of opportunities for environmental improvements over 
the whole life cycle. While both processes degraded 100% of the MPG from 
500 mg/L, the environmental performance of solar photo-Fenton‘s coupled to 
biological treatment was 80-90% better than that of coupled heterogeneous 
photocatalysis to biological treatment. This was mainly due to the large CPC 
field (2150 m2) and the electricity consumption of the TiO2 microfiltration. 
 
The TiO2 band-gap only overlaps with 5% of the solar spectrum. Other 
catalysts may be found which correspond better and could improve the 
efficiency of photoreactors. Other possibilities were changing catalyst 
structure and composition, the addition of electron acceptors or doping and 
deposition with metal ions and oxides (Gryglik et al., 2004, Rios-Enriquez and 
Shahin, 2004).  
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Table 2.9: Comparison of reactor types (Bockelmann et al., 1995; Malato 
et al., 2007). 
 
 Concentrating Non-concentrating 
Example PTR and CPC TFFBR and DSSR. 
Advantages 
Turbulent flow conditions which 
favour mass transfer and avoid 
catalyst sedimentation problems 
Total global irradiation is usable. 
 Two axis sun tracking system High optical efficiency 
 
Closed reactor no vaporisation of 
volatile components 
Low manufacturing costs. 
 
Smaller reactor tube area which is 
able to support higher pressures 
and a large amount of area per 
unit volume (Mehos and Turchi, 
1992) 
No additional H2O2 necessary since 
there is effective transfer of air into the 
water film. 
  High quantum efficiency 
  No heating needed 
Disadvantages Only direct irradiation can be used. The volatile reactants can vaporise 
 Low optical efficiency 
The catalyst is not protected from 
pollution. 
 
Since sun-tracking is needed there 
are high investment costs. 
A large catalyst area is needed when 
purifying large volumes of wastewater. 
 
The TiO2 needs to be separated 
from the purified water. 
There is low mass transfer due to the 
laminar flow conditions. 
 
Water over-heating can lead to 
leaks and corrosion. 
Requires significantly more 
photoreactor area. 
 Additional H2O2 may be needed.  
 
 
2.7 Electrochemical treatment options 
 
Ultrasonic irradiation has been considered as a means of removing estrogenic 
compounds from contaminated water (Belgiorno et al., 2007; Suri et al., 
2007). In ultrasonic irradiation sound waves are generated which create OH 
radicals as a result of the decomposition of water (Makino et al., 1982). 
Hormones, for example, estradiol, estrone and ethinylestradiol, were 
examined in single component batch and flow through reactors using 0.6, 2 
and 4kW ultrasound sources (Suri et al., 2007). Results showed 80-90% 
reduction in the hormones within a 40-60 minute period and results are shown 
in Table 2.10. Further investigations in this area would be useful to determine 
the toxicity of breakdown products and to examine the feasibility of larger 
scale applications of the technology.  
 
Electrochemistry is a method for the treatment of wastewater (Chen, 2004). 
The treatment of acetaminophen using anodic oxidation with a boron-doped 
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diamond electrode has been successful during small scale investigations 
(Brillas et al., 2005). This process allows complete mineralisation of the 
acetaminophen due to the generation of large concentrations of hydroxyl 
radicals by the electrode. The BDD electrode was efficient even at low 
concentrations. BDD has high thermal conductivity, wide band gap, high e- 
and hole mobilities, high breakdown electric fields, hardness, optical 
transparency and chemical inertness (Chen, 2004). Future investigations are 
necessary for both of these technologies to determine the toxicity of 
breakdown products and to examine the feasibility of larger scale applications. 
Diamond anodes may produce OH· radicals with high current efficiency. This 
was dependent on the mass transport of organic compounds to the anode not 
being a limiting factor (Kraft et al., 2003).  
 
Table 2.10:  Removal of a variety of hormones using ultrasound (Suri et 
al., 2007, matrix Milli-Q water). 
 
Pharmaceutical class Pharmaceutical % removal in 60min (*35min) 
Hormones and oral 
contraceptives 
17α-dihydroequilin 99 
Equilin 64* 
17α-estradiol 98 
17β-estradiol 97 
Estrone 98 
Estriol 87 
17α-ethinylestradiol 91 
Norgestrel 95 
   
 
2.8 Summary 
 
This was a literature review of options for the treatment of pharmaceutical 
wastewater, focusing on the removal of pharmaceuticals. Biological, physical 
and chemical methods were reviewed. There was an extensive list of tables 
showing API reduction based on different treatment methods. The 
advantages and disadvantages of the technologies investigated in this review 
were included in Table 2.11.  
 
Pharmaceutical production facility wastewater represented a challenge for 
both the management of the facility and legislators to ensure a high standard 
of effluent. Effluent should have low oxygen demand, low solids and should 
be free from other hazardous constituents such as APIs. Concerns have been 
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raised about ecosystems, antibiotic resistance and endocrine disrupters but 
the consequences of long term exposure to low concentrations of APIs were 
still not fully known. Where releases from pharmaceutical production facilities 
are regulated, little attention was paid to the API concentration of the 
wastewater. BOD, COD, pH and SS were normally the only wastewater 
characteristics that were routinely monitored. AS treatment is the most 
common and economical treatment method used for pharmaceutical 
wastewater. However, it was ineffective for the removal of a large number of 
APIs from wastewaters. 
 
A significant amount of research in the area had focused on municipal 
wastewater, as data from municipal wastewater plants were relatively 
accessible. However, research into wastewaters from pharmaceutical 
manufacturing plants was more problematic due to difficulties in accessing 
information. Nevertheless, treatment technologies that work for municipal 
wastewaters should also be suitable with modification for industrial 
wastewaters.  
 
AS was the traditional method of choice for the treatment of pharmaceutical 
wastewater. It has been only partially successful for the removal of the oxygen 
demand for the high COD wastewaters such as pharmaceutical wastewater 
and has proven to be only partly successful in effectively destroying 
pharmaceutical compounds. The efficiency of removal was usually dependent 
on properties of the pharmaceutical under investigation, such as polarity. AS 
is capable of partially removing estrogens (Joss et al, 2004) but not lipid 
regulators such as gemfibrozil and clofibric acid (Bernhard et al., 2006; Lacey 
et al., 2008; Snyder et al., 2007; Zwiener and Frimmel, 2003). Modification of 
AS methods may improve API removal efficiency such as operating at longer 
HRT or operating at low pH for the removal of acidic APIs. Shock loads 
disrupting the treatment efficiency of the plant were a major disadvantage of 
conventional AS systems. Biological treatment methods in general show 
considerable variation in the level of pharmaceutical degradation. For 
example, BFRs degraded some compounds but not clofibric acid and 
diclofenac (Zweiner and Frimmel, 2003). MBRs while only slightly more 
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efficient than AS and UASRs were efficient even at high concentrations for the 
removal of some APIs (Chelliapan et al., 2006). However MBRs were shown 
to be efficient for COD and BOD removal. Running MBRs at longer sludge 
ages may improve API removal.  
 
Physical methods such as filtration, AC and RO were also discussed in this 
review. Micro and ultra filtration were not effective for the removal of 
pharmaceuticals as the pore size is 100 to 1000 times bigger than the 
pharmaceutical. RO has been shown to remove a number of pharmaceuticals 
to below the limit of detection however membrane breaching remained 
problematic (Synder et al., 2007). AC was an established method for the 
removal of micropollutants and had proven successful where regular 
regeneration of the carbon was provided. The main disadvantage of RO and 
AC methods was that the APIs was just removed from the wastewater but 
was not degraded. The chemical treatments of flocculation-settling/filtration 
did not eliminate endocrine disruptive compounds (Kulik et al., 2008) and 
chlorination removed some pharmaceuticals but many of the by-products 
were toxic (Pinkston and Sedlak, 2004). 
 
AOPs offered a number of advantages over traditional methods. They 
degrade relatively unselectively contaminants in the wastewater ultimately 
leading to their mineralisation. They could be used as a pre-AS method to 
improve the biodegradable or as the main treatment method. Disadvantages 
included the need to monitor intermediates as they may be more toxic than 
the parent compound as well as the cost and removal of chemical agents. 
Ozonation, perozonation, direct photolysis, TiO2 photocatalysis, solar 
photocatalysis, Fenton‘s reaction and ultrasonic irradiation have all been 
applied for the treatment of waters containing pharmaceuticals with varying 
degrees of success. Ozonation and Fenton‘s oxidation have in particular 
shown significantly enhanced removal rates for the more recalcitrant 
pharmaceuticals from wastewaters. Comparisons among these technologies 
are problematic, however, as the studies were carried out on different 
wastewater types. Research is required in this area to improve treatment 
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efficiencies, identify degradation compounds and to determine the cost and 
feasibility of full-scale applications.  
 
The concentrations of APIs and other constituents of wastewaters from 
pharmaceutical industries represented a significant knowledge gap. The 
retrofitting or operational changes to existing wastewater treatment facilities, 
for the enhanced removal of APIs from industrial wastewaters remained an 
important avenue of research.   
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Table 2.11: Characteristics, advantages and limitations of treatment 
methods 
Method Characteristics Advantages Limitations 
Biological    
AS Aerated microbial digestion Economical Shock loads effect stability 
 Treats bulk organic waste Widely used  
SBR 
Two or more AS tanks 
operated in sequence 
Easy to modify process Shock loads effect stability 
BFR 
Microbes fix to support 
material 
Stable operation Low 
downtime 
Blockage due to build-up 
of cells 
MBR 
Combine AS plant with 
membrane technology 
Suited to limited space 
Contaminants concentrate 
in brine 
UASBR 
Anaerobic stage reactor  with 
separate acetogenesis and 
methanogenesis stages 
Less sensitive to operation 
variables and shock loads 
No moving parts / mixing 
 
Physical    
Microfiltration/ 
Nanofiltration 
Filtration High quality effluent 
Unsuccessful for removal 
of most APIs 
  Suitable for limited space 
Expensive/ energy 
intensive 
RO 
Membrane technology using 
pressure to force a liquid 
through the membrane 
Multibarrier approach 
provides high quality 
effluent. 
Membrane breeching, only 
retains contaminant 
AC 
Adsorbs and filters 
contaminants applied as 
powdered or granular feed 
GAC: is easily recovered, 
steam treatment enhances 
adsorption 
PAC: fed continually, only 
suitable for relatively clean 
waters; GAC requires 
regular regeneration 
Chemical    
Chlorination 
Addition of chlorine, commonly 
used to disinfect drinking water 
Strong disinfection 
properties 
Produces disinfection by-
products that have been 
linked with cancer 
Flocculation 
Coagulating and flocculating 
agent is added to cause 
contaminants to settle 
May remove small sized 
contaminants e.g. 
hormones 
Expensive 
O3 
Oxidation process, addition of 
O3 
Allows mineralisation of 
APIs 
Energy intensive/ 
expensive 
 
Used as an alternative to 
chlorination 
Strong disinfection 
properties, clean 
 
Perozonation Oxidation process 
More effective than ozone 
alone 
Energy intensive/ 
expensive 
 Mix of O3 and H2O2 
Allows for  mineralisation 
of APIs 
 
Direct 
Photolysis 
Direct breakdown of a 
compound by the absorption of 
light 
Inexpensive; allows for 
mineralisation of APIs 
Dependent on 
geographical region for 
direct sunlight 
TiO2 
Creation of hydroxyl and super 
oxide radicals which react with 
impurities in the wastewater 
Fixed to beads/film for 
removal/ recycling; 
mineralisation of APIs 
Energy intensive/ 
expensive 
Fenton‘s 
Produce OH· which react with 
APIs, coupling with UV 
enhances generation 
Allows for mineralisation of 
APIs; Iron is abundant and 
non-toxic 
Disposal of iron sludge; 
energy 
intensive/expensive 
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3. Materials and methods 
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3.1 Analytical method development and validation for 
the detection of three APIs in industrial wastewater 
 
3.1.1 Chemicals and materials 
 
Famotidine, tamsulosin hydrochloride and solifenacin succinate were donated 
by Astellas Ireland Pharmaceutical Limited. Water (mobile phase), acetonitrile 
and methanol were LC-MS grade and purchased from Fisher Scientific Ltd. 
Acetonitrile (0.1% ammonium acetate) and water (0.1% ammonium acetate) 
were LC-MS grade and purchased from Sigma-Aldrich Chemical Company. 
Dichlorodimethylsilane and toluene were reagent grade and purchased from 
Sigma-Aldrich Chemical Company. Formic acid (98% purity) and 25% 
ammonium hydroxide solution were analytical grade and purchased from 
Fluka. Two reverse phase Luna-PFP columns (column dimensions 150x4.6 
mm and 5μm particle size, 150x2.0 mm and 5 μm particle size) and SPE (3 
mL/200 mg) cartridges were purchased from Phenomenex. HPLC vials 
(APEX Scientific) and centrifuge vials (Fisher Scientific) were amber glass 
and silanised to prevent API degradation by light or adsorption onto glass. All 
solvents used in analysis were filtered through Pall nylon filters (0.2 μm pore 
size, 47 mm diameter) and degassed by sonication for 30 minutes prior to 
use. Whatman no. 3 glass fibre filters were used for sample filtration.  
 
3.1.2 Glassware preparation 
 
All glassware used was silanised by rinsing thoroughly with a 10% (v/v) 
solution of dichlorodimethylsilane in toluene followed by two toluene rinses 
and then two methanol rinses. This was to prevent any API adsorbing to the 
glassware (Lacey et al., 2008). 
 
3.1.3 Sample preparation  
 
Standards were prepared by dissolving 0.1 g of each API in 100 mL of 
methanol resulting in a 1 mg/mL stock standard and stored for up to 1 month 
at 4°C. A 100 μg/mL mixed working solution was prepared in mobile phase A. 
The working solution was used to prepare the standards for the SPE-HPLC 
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method. For the SPE-LC-MS/MS method stock standards were diluted to 
appropriate working solutions to the range of standards under investigation.   
 
3.1.4 Sample collection  
 
2 L wastewater samples were collected in plastic sampling bottles at the 
Astellas wastewater treatment facility at Mulhuddart, Co. Dublin and 
transferred on return to laboratory to silanised amber glass Winchester 
bottles. Samples used in method development and validation were collected 
on several dates between June and October 2009. Samples collected were 
typically between pH 7 and 9 and were low in solids. Samples were filtered 
through Whatman glassfibre filters to remove any particulates and adjusted to 
pH 3. Two 2 L weekly influent and effluent samples were collected between 
November 2009 and April 2010 to fulfil the requirements of the monitoring 
programme.  
 
3.1.5 Method development 
 
A primary aim of this project was to develop a combined analytical method for 
the monitoring of low levels of the three APIs in Astellas pharmaceutical 
wastewater. The method consisted of a concentration, chromatographic 
separation and identification steps. The method development process 
required the separate optimisation of the three analytical processes involved, 
namely solid phase extraction, high pressure liquid chromatography and mass 
spectrometry. Each of the three streams were optimised separately and 
combined. An SPE-HPLC method was validated using ultra-pure water but 
was deemed unsuitable for the monitoring of the APIs without the specificity of 
the mass spectrometry step. Validation of the SPE-LC-MS/MS method was 
conducted to confirm suitability of the method in real wastewater as described 
in section 3.1.6.2. A six month sampling programme was conducted to 
determine both the efficiency of the treatment plant and the concentrations of 
pharmaceuticals released by the production facility to the municipal sewer.  
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3.1.5.1 SPE method development  
 
3.1.5.1.1 SPE cartridge selection   
 
Four SPE cartridges, Strata-X, Strata-X-C, Strata-X-CW and Strata-X-AW 
were investigated to determine the optimum cartridge for the recovery of the 
three APIs. The methods used for the extraction of the three APIs from ultra-
pure water are shown in Table 3.1. A 12 position vacuum manifold purchased 
from phenomenex was used in all SPE experiments. 100 mL of ultra-pure 
water was spiked with 5 mg/L of each API. Pre and post-extraction spiked 
samples were compared to determine the percentage recovery. The optimum 
cartridge determined by this experiment underwent validation in the 
combined SPE-HPLC and SPE-LC-MS/MS method. 
 
Table 3.1: Individual methods used for determining the optimum SPE 
cartridge for the concentration of the three APIs adapted from 
Phenomenex Strata products general guidelines. 
 
 Strata-X Strata-X-C Strata-X-CW Strata-X-AW 
1.Condition Methanol Methanol Methanol Methanol 
2.Equilibrate Water Water Water Water 
3.Load pH 3 adjusted pH 3 adjusted 
pH 4.5 
adjusted 
pH 3 
adjusted 
4.Wash 1 5% methanol 
0.1% 
phosphoric 
acid 
25 mM 
ammonium 
acetate 
Water 
5.Dry 3 min 3 min - - 
6.Wash 2 - Methanol Methanol Methanol 
7.Dry - - 3 min - 
8.Elute 
50:50 
methanol: 
acetonitrile 
5% ammonium 
hydroxide in 
methanol 
2% formic acid 
in 20:80 
methanol: 
acetonitrile 
2% 
ammonium 
hydroxide in 
methanol 
 
 
3.1.5.1.2 Validated SPE method 
 
The Strata-X-C cartridge was used in the validated method. The steps in the 
method are shown in Table 3.2. The SPE method is the manufacturers 
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recommended method (Technical data sheet, 2008) and it produced effective 
results. Therefore no further optimisation was deemed necessary.  
 
 
Table 3.2: SPE method used including volumes and the purpose of the 
steps. 
 
Step Description Volume Purpose 
1 
Sample pre-treatment: 
Filtered and pH 3 adjusted 
2 L Remove particulates and acidify 
2 Condition: methanol 6 mL To wet the cartridge 
3 Equilibrate: water 6 mL 
Wash away methanol prepare for sample 
loading 
4 Sample loading 25 mL Load sample 
5 Wash 1: 0.1%  phosphoric acid 6 mL Remove acidic/neutral interferences 
 Dry  under vacuum 3 min Prepare for methanol wash 
 Wash 2: methanol 6 mL Remove hydrophobic interferences 
6 
Elute: 5% ammonium hydroxide 
solution 
6 mL Basic solution to release analytes 
 
 
3.1.5.2 HPLC method development 
 
The primary aim of the HPLC method development was to develop a single 
optimised method that was suitable for transfer to the mass spectrometer for 
the three pharmaceuticals produced by Astellas Ireland Pharmaceutical 
Limited at their chemical synthesis plant in Mulhuddart, Co. Dublin. 
Wavelength, column, mobile phase, gradient and injection volume were the 
parameters to be optimised. The HPLC system used in the method 
development process was an Agilent 1100 Series high-performance LC 
(HPLC) system with a fixed wavelength UV detector.  
 
3.1.5.2.1 Wavelength optimisation 
 
Optimum wavelength was determined for famotidine, tamsulosin 
hydrochloride and solifenacin succinate by UV scanning from 190 to 400 nm 
on a Beckman DU 520 general purpose UV/VIS spectrophotometer with a 
path length of 1 cm. APIs were dissolved in HPLC grade water at a 
concentration of 10 mg/L. A quartz cuvette purchased from Fisher Scientific 
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Ltd. was used. 205 nm was optimum for famotidine and tamsulosin while 
solifenacin had an optimum wavelength of 215 nm.  
 
3.1.5.2.2 Stationary phase optimisation  
 
Famotidine has proven difficult to retain under reverse phase conditions on a 
C-18 column due to its polar nature (Zhong et al., 2001). Therefore the PFP 
column which has enhanced mechanisms of retention over a C-18 column 
was adopted. In contrast tamsulosin hydrochloride and solifenacin succinate 
are non-polar.   
 
3.1.5.2.3 Mobile phase optimisation 
 
Initial method development used acetonitrile and water with a 0.1% 
ammonium acetate buffer. Three single isocratic methods for each of the 
three APIs were first developed, followed by the development of a single 
gradient method. However, while good response and peak shape were 
attained using this mobile phase, the acetonitrile was expensive and problems 
with security of supply arose. It was therefore decided to move to a methanol 
based mobile phase.  
 
The relationship between pH and pKa is important in relation to mobile phase 
and sample pH in HPLC. To ensure good peak shape all analyte molecules 
should be protonated or deprotonated. If the analyte molecules are present in 
more than one form this can result in peak broadening. A low pH (at least 2 
pH units below the pKa of the analyte) ensured that all molecules will be in 
the protonated form (McMaster, 2007). The pH which is a log measurement 
of the number of hydrogen ions present in a solution was adjusted to pH 3. 
 
 pH = -log[H+] 
 
The pka (acid dissociation constant) of each of the three APIs are 6.8, 8.4 
and 8.5 for famotidine, tamsulosin and solifenacin respectively (Degim et al., 
2001; Maniscalco et al., 2006). Defined as the negative log of the 
dissociation constant, pKa, is a measure of strength of an acid or base. 
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 pK
a 
= -log(K
a
) 
It determines if a molecule or atom group in a molecule will be protonated or 
deprotonated in solution at a certain pH using the Henderson–Hasselbalch 
equation. 
pH= pKa + log([A-]/[HA]) 
 
Mobile phase was adjusted using formic acid to pH 3. Peak shape was good 
so no buffer was used.  
 
3.1.5.3 Mass spectrometry method development  
 
A Brüker Daltonics Esquire-LC ion trap mass spectrometer with an 
electrospray ionisation interface at atmospheric pressure was used for 
analysis. 1 mg/L standards of each of the three analytes were directly infused 
into the mass spectrometer to determine molecular and fragment ions for the 
three analytes in positive and negative mode. Formic acid in positive mode 
and ammonium hydroxide in negative mode were added to determine 
optimum sample composition. The electrospray ionisation conditions including 
capillary, end plate, skims, capillary exit offsets, octopoles, trap drive, lenses 
and fragmentation amplitudes were individually optimised using software on 
the mass spectrometer. Nebuliser conditions including dry gas pressure, dry 
gas flow and temperature were optimised manually. Following optimisation of 
mass spectrometry conditions LC gradient conditions were reoptimised using 
a low flowrate of 0.3 mL/min and narrow bore LC column (150x2.0 mm, 5 µm 
pore size). 
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3.1.6 Method validation  
 
3.1.6.1 SPE-HPLC validation 
 
Validation of the SPE-HPLC method for water sample analysis was completed 
in ultra-pure water. Accuracy, precision, linearity, limit of detection, limit of 
quantitation and selectivity were examined.  SPE recovery was determined by 
spiking ultra-pure water with mixed standard and extracting with Strata-X-C 
cartridges in triplicate. The detected concentrations were compared with 
standard solutions. Standard ranges are shown in Table 3.3.  
 
Table 3.3: Standard ranges used for SPE-HPLC validation. 
 
 
 
 
3.1.6.2 SPE-LC-MS/MS validation  
 
Influent and effluent samples were used in the validation of the SPE-LC-
MS/MS method. Precision, intermediate precision, linearity, LOD, LOQ and % 
ion suppression were examined. SPE recovery was determined by spiking 
influent and effluent with mixed standard and extracting with Strata-X-C 
cartridges in triplicate. Pre-extraction standard addition was compared with 
post-extraction standard addition to real wastewater samples. Standard 
addition was used for the quantitation of the level of the APIs in the 
wastewater as it accounts for signal suppression or enhancement caused by 
the matrix. Standard ranges used are shown in Table 3.4. 
 
Table 3.4: Standard ranges used in standard addition for SPE-LC-MS/MS 
validation. 
API Standard range (μg/L) 
Famotidine 5.0-60  
Tamsulosin hydrochloride 2.5-60  
Solifenacin succinate 10-60  
API Influent (μg/L) Effluent (μg/L) 
Famotidine 400-5000 400-5000 
Tamsulosin hydrochloride 1-15  0.8-18  
Solifenacin succinate 6-50  6-16  
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3.1.7 Validated method conditions 
 
3.1.7.1 Validated SPE-HPLC conditions 
 
The solid phase extraction procedure is outlined in Table 3.2. Each step used 
two cartridge volumes (6 mL) of solution. Different loading volumes and 
reconstitution volumes were used for the SPE-HPLC and SPE-LC-MS/MS 
methods. For the SPE-HPLC method the loading volumes used was 100 mL 
and reconstituted in 500 µL. Following elution and collection of samples in 20 
mL vials the sample was dried on a Genovac MiVac centrifuge dryer and 
reconstituted in mobile phase A for analysis. 
 
Gradient conditions and wavelength are shown in Tables 3.5. The HPLC 
column used was a Luna-PFP reverse phase column (dimension 150x4.6 mm 
and 5 μm particle size).  Analysis was carried out at ambient temperature. 
Mobile phase A consisted of 10:90 (v/v) methanol: water with 0.1% formic 
acid and mobile phase B was 90:10 (v/v) methanol: water with 0.1% formic 
acid. The injection volume used was 50 μL and flowrate was 1 mL/min. 
 
3.1.7.2 Validated SPE-LC-MS/MS conditions 
 
The SPE method used was as described above however the sample loading 
volume used was 25 mL and reconstituted in 2.5 mL. The HPLC system 
consisted of an Agilent 1100 Series high-performance LC (HPLC) system with 
a diode array detector (D.A.D.). A Brüker Daltonics Esquire~LC ion trap MS 
with an electrospray ionisation interface at atmospheric pressure was used for 
mass spectral analysis. The HPLC column used was a Luna-PFP reverse 
phase column (dimension 150x2.0 mm and 5 μm particle size).  Analysis was 
carried out at ambient temperature. Mobile phase A consisted of 10:90(v/v) 
methanol: water with 0.1% formic acid and mobile phase B was 90:10(v/v) 
methanol: water with 0.1% formic acid. The injection volume used was 20 μL 
and flowrate was 0.3 mL/min. Gradient conditions are shown in Table 3.5. ESI 
and nebuliser conditions are shown in Table 3.6. Wavelengths monitored by 
D.A.D. analyser were 205 nm, 210 nm, 215 nm, 254 nm and 270 nm. 
 
 
 
72 
 
 
        Table 3.5: Validated gradient and wavelength conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6: SPE-LC-MS/MS validated method optimised ESI and 
nebuliser conditions. 
 
Parameter Optimised condition 
Dry gas pressure 50 PSI 
Dry gas flow 8 L/min 
Temperature 325 °C 
Capillary 4500 V 
End plate 913.11 V 
Skim 1 30.3 V 
Cap exit offset 66.39 V 
Octopole 3.95 V 
Octopole delta 1.53 V 
Trap drive 52.95 
Skim 2 9.84 V 
Oct. R.F 226.23 Vpp 
Lens 1 -2.48 
Lens 2 -57.54 
Frag. amp. 1.73 V 
 
3.1.8 COD analysis 
 
COD measurement was conducted using a standard HACH method and the 
results were provided by Astellas. No correlation was observed between COD 
and analyte concentration for any of the three APIs.  
Gradient Wavelength switching 
             SPE-HPLC SPE-LC-MS/MS  
Time Mobile phase Mobile phase Time Wavelength 
(min) A (%) B (%) A (%) B (%) (min) (nm) 
0 90 10 95 5 0 205 
3 90 10 95 5 5.5 254 
4 55 45 45 55 8.5 205 
15 55 45 45 55 16.0 254 
16 40 60 25 75 20.5 215 
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3.2 Photo-Fenton’s optimisation for the removal of 
APIs from water 
 
3.2.1 Chemicals and materials 
 
Famotidine, tamsulosin hydrochloride and solifenacin succinate were donated 
by Astellas Ireland Pharmaceutical Limited. Reaction solutions were prepared 
with water obtained from a Millipore Milli-Q system. Water (mobile phase), 
acetonitrile and methanol were LC-MS grade and were purchased from Fisher 
Scientific Ltd. Fe(II) sulfate heptahydrate (99.5% purity) and formic acid (98% 
purity) were analytical grade and purchased from Fluka. Hydrogen peroxide 
(30% purity) was purchased from Sigma-Aldrich. Nylon syringe filters (2 µm) 
and two reverse phase Luna-PFP column dimensions (150x4.6 mm and 5 μm 
particle size, 150x2.0 mm and 5 μm particle size) were purchased from 
Phenomenex. HPLC vials (APEX Scientific) were amber glass and silanised 
to prevent degradation by light or adsorption onto glass. All solvents used in 
HPLC analysis were filtered through Pall nylon filters (0.2 μm pore size, 47 
mm diameter) and degassed by sonication for 30 minutes prior to use.  
 
3.2.2 Reactor configuration  
 
The reactor configuration used in all experiments is shown in Figure 3.1. The 
light source consisted of a 400 W Defender portable halogen work light with a 
400 W halogen bulb purchased from B&Q Ireland Ltd (R7 230-240V). The 
reactor consisted of a borosilicate glass immersion well (model 7857), 290 
mm in length and 45 mm internal diameter. The reaction solution was 
maintained at 21 ˚C. 
 
Figure 3.1: Reaction set-up for photo-Fenton’s experiments. 
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3.2.3 Experimental procedures 
 
The halogen lamp was turned on 30 minutes before the beginning of the 
experiment to ensure steady output of light. 100 mL solutions of Fe(II) and 
API were made up separately and mixed immediately before the experiment 
began to avoid any complexing of the API and Fe(II) (Méndez-Arriaga et al., 
2010). The reaction solution (200 mL) was adjusted to pH3 using 5M HCL 
solution. The 0 min sample was taken prior to the addition of hydrogen 
peroxide. The solution was stirred throughout the 2 hour experiment and the 
temperature maintained at 21 °C. Samples were taken at 0, 5, 10, 15, 20, 30, 
40, 50, 60, 80, 100 and 120 minutes. All samples taken were filtered through 
0.2 μm nylon syringe filters and analysed by HPLC.  Methanol and sodium 
sulphite were investigated as possible quenching agents. No suitable 
quenching agent was identified, therefore samples were not quenched. As a 
result the reaction time was extended to include the time up to the HPLC 
analysis. This was only applied for famotidine, degradation between the time 
of sampling and analysis was not noted with tamsulosin and solifenacin. 
HPLC runs were started 35 min into the experiment.  HPLC methods were all 
isocratic with 6 min runtime, 50 µL injection volume, 1 mL/min flowrate and 
PFP column. All mobile phases were methanol: water with 0.1% formic acid. 
Percentage organic was 15% for famotidine, 46% for tamsulosin and 70% for 
solifenacin. 
 
3.2.4 Optimisation of famotidine removal by photo-Fenton’s 
oxidation 
 
0.012 mM iron(II) and 20 mM H2O2 were the concentrations used in initial 
experiments to determine the effect of different reactants on the degradation 
of famotidine at 0.1 mM. Light, H2O2/light, H2O2, Fe(II)/light, Fe(II) and dark 
Fenton‘s processes were compared. Concentration ranges used were based 
on those previously reported (Mèndez-Arriaga et al., 2010). Photo-Fenton‘s 
process was optimised by first increasing Fe(II) concentrations between 
(0.012-0.120 mM Fe(II)) then decreasing H2O2 concentrations (5-20 mM 
H2O2) which were in excess. Fe(II) concentrations were further increased to 
maintain optimum degradation (0.120-0.180 mM Fe(II)). Experimental results 
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were fitted to both first and second order rate equations. Good straight line 
fits were obtained using only first order rate equations. 
 
3.2.5 Optimisation of tamsulosin hydrochloride and 
solifenacin succinate removal by photo-Fenton’s oxidation 
 
Optimisation of tamsulosin hydrochloride and solifenacin succinate conditions 
began at the optimum reactant concentrations for the removal of famotidine 
at 0.12 mM Fe(II), 5 mM H2O2. Complete removal was noted after the first 
sample was taken. Fe(II) concentrations between 0.03-0.09 mM Fe(II) were 
investigated for both analytes. Experimental results were analysed kinetically 
using first order rate equations. The effect of the different reactants at 
optimised conditions was also investigated. Light, H2O2/light, H2O2, 
Fe(II)/light, Fe(II) and dark Fenton‘s processes were compared. 
 
3.2.6 Determination of intermediates by LC-MS 
 
The reaction solution (200 mL) was adjusted to pH 3 using 5 M HCL solution. 
The 0 min sample was taken prior to the addition of hydrogen peroxide. The 
solution was stirred throughout the 7 hour experiment and the temperature 
maintained at 21°C. Samples were taken at 0, 15, 30, 45, 60, 90, 120, 240, 
300, 315, 330, 345, 360, 390 and 420 minutes. After 300 minutes there was 
a further addition of H2O2. All samples taken were filtered through 0.2 μm 
nylon syringe filters and analysed immediately by LC-MS. LC-MS methods 
were all isocratic with 10 min runtime, 20 µL injection volume, 0.3 mL/min 
and PFP column. All mobile phases were methanol: water with 0.1% formic 
acid. Percentage organic was 15% for famotidine, 46% tamsulosin and 70% 
solifenacin. Optimum nebuliser and ESI conditions for individual APIs were 
used as described in section 4.1.4. The mass spectrometer had a lower 
mass to charge cut-off limit of 80m/z. 
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4. Results and discussion 
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4.1 Analytical method development 
 
Identifying the requirements of the analytical method was the first step in its 
development (outlined in section 4.1.1). The subsequent development 
process had three separate streams: the development of the SPE method 
(concentration step), HPLC method (separation step) and MS method 
(identification step). Following separate optimisation of the three streams the 
methods were amalgamated and final optimisation completed (Figure 4.1). 
The method was then validated in influent and effluent samples and applied 
to a six month sampling programme. The results and discussion of the 
development process of the SPE-LC-MS/MS method are set out and 
discussed in the following sections.  
 
 
 
Figure 4.1: Method development process. 
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4.1.1 Method requirements, considerations and applications 
 
1. One method was required for efficient and routine analysis of all three 
APIs in production at Astellas Ireland Pharmaceutical Limited 
manufacturing facility at Mullhuddart, Co. Dublin. While individual 
methods for the three pharmaceuticals are available (Table 4.1), no 
method combining any of the three APIs is available in the literature.  
 
2. The method must be simple, rapid, reproducible and inexpensive for 
routine analysis.  
 
3. Solvents, mobile phase additives and columns used in SPE and HPLC 
must be transferable to LC-MS should the MS be needed to enhance 
selectivity and sensitivity in real wastewater analysis. 
 
4. The method must be validated to ensure the quality of the results. 
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Table 4.1: Available methods for the analysis of the three APIs under investigation showing type of LC, MP compositions, 
RT and the method of detection used. 
 
API Type of LC Column MP RT Detection Reference 
Famotidine Ion exchange 
Cation 
Exchange 
Isocratic 
20% acetonitrile: 80 % sodium acetate buffer 
(0.1M) with glacial acetic acid (0.1M pH5) 
 
5.1min UV, 230nm Ashiru et al., 2007 
Famotidine UPLC C-18 
Gradient (5-90%  B) 
A) 5 mM  NH4Ac/acetic acid (pH 4.8) 
(B) 2:1 acetonitrile:methanol 
 
1.9min 
+ve mode MS 
338>>259,189m/z 
Petrovic et al., 2006 
Famotidine Reverse phase C-18 
Gradient (5-100% A) 
A) acetonitrile 
B) water 0.1% formic acid 
Not cited 
+ve mode MS 
338>>259,189m/z 
Jelić et al., 2009 
Tamsulosin Reverse phase C-8 
Gradient 
 
A) water (0.1%) formic acid 
B) water: acetonitrile: formic acid (50:50:0.1%). 
 
4.2min 
+ve mode MS 
409>>271,228m/z 
Keski-Rahkonen et al., 
2007 
Solifenacin Reverse phase C-8 
Isocratic 
2 mM ammonium formate (pH 3.0, with formic 
acid) in water: acetonitrile (15:85, v/v). 
1.8min 
+ve mode MS 
363.3 >> 110.2m/z 
Mistri et al., 2008 
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4.1.2 Plant description 
 
 
 
 
 
Figure 4.2: Wastewater flows (a) from production through wastewater 
system and (b) through wastewater treatment plant showing sampling 
points 
 
A description of flows of wastewater from production to municipal wastewater 
treatment is shown in Figure 4.2. In process plants P1 and P2 famotidine and 
solifenacin succinate are produced. These two processes are produced by 
two independent plants housed in the one building which enter one local 
wastewater pit (WWC2). Tamsulosin hydrochloride is produced in a smaller 
multipurpose production facility P3 for the manufacture of low dosage high 
strength pharmaceutical materials. The wastewater from this process enters a 
second local wastewater pit (WWC3). Wastewaters from all three production 
facilities as well as from the incinerator enter the wastewater treatment facility 
through the pH adjust tank. In the pH adjust tank the wastewater is adjusted 
to between pH 6 and 9 by the addition of sulphuric acid or caustic soda. The 
water trickles through a series of weirs from the pH adjust tank to activated 
P1
P2
P3
WWC2
WWC3
AS Lagoon
WWC
(pH adjust 
tank) Balancing 
Tank
Ringsend 
WWTP
WWB
(Preparation 
tank)
Municipal
Sewer
(b) 
(a) 
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sludge lagoons. A second feed is added at night through WWB. This contains 
nutrients to feed the microbial populations in the lagoons. Water enters from 
the pH adjust tank on a continual basis. Following activated sludge treatment 
in the lagoons water is discharged to a balancing tank, which is released each 
afternoon to the municipal sewer, which ultimately brings the wastewater to 
Ringsend WWTP in Co. Dublin for final municipal treatment. Monitoring of 
wastewater quality including COD and microbial analysis is carried out onsite. 
This ensures the wastewater treatment plant is operating to specifications and 
a healthy mixed consortium of microorganisms is present.   
 
The two sampling points for this project are at the pH adjust (influent to 
wastewater treatment) and balancing tank (effluent from wastewater 
treatment). Samples were collected in plastic bottles onsite in accordance with 
the plants safety regulations and transferred on return to laboratory silanised 
amber glass Winchester bottles. The length of time samples were left in 
plastic bottles was kept at a minimum to avoid adherence of the APIs to the 
bottle wall. 
 
4.1.2 Sample pre-treatment  
 
Solid phase extraction is used for both sample clean-up and concentration of 
samples. Due to a gap in the literature in relation to actual concentrations of 
pharmaceuticals in industry wastewater, the target concentration ranges were 
largely unknown. However, from environmental levels and levels measured at 
sewage treatment facilities, it was thought that the likely concentration would 
be in the μg/L or ng/L  range (Gomez et al., 2010; Lopez-Rolden et al., 2010). 
Furthermore, the reaction vessels are generally first solvent-washed then 
water washed to remove the solvent. The water washes form the bulk of the 
liquid entering the wastewater treatment plant. It was therefore expected that 
levels of analyte in the wastewater would be low and so it was anticipated that 
a sample concentration step would be necessary.  
 
Solid phase extraction and liquid-liquid extraction are the main processes 
used in the extraction and clean-up of samples. While liquid-liquid extraction 
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is the more traditional method, solid phase extraction was chosen as the 
method of choice for the following reasons: 
 
 No emulsions are formed 
 Better and more reproducible recoveries 
 Cleaner extracts are achievable 
 Interferences and matrix components can be removed more selectively 
 Lower quantities of solvents are required 
 Lower volumes of waste solvents are produced (Simpson, 2000) 
 
Using a sorbent based on polarity was unlikely to be suitable as famotidine is 
polar while tamsulosin hydrochloride and solifenacin succinate are non-polar 
molecules. All three drugs are mildly basic therefore a strong cation 
exchange resin is theoretically the most suitable choice for the extraction of 
all three analytes from a single mixture. The decision pathway for selecting 
the cation exchange cartridge is highlighted in Figure 4.3. 
 
83 
 
 
 
 
  
Figure 4.3: SPE selection chart modified from Phenomenex, Inc., UK.
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To confirm this experimentally four different cartridges were investigated, 
based both on polarity and ion exchange to determine the optimum cartridge 
for the extraction of all three analytes from a single mixture. Strata-X (polar 
non-polar interactions), Strata-X-C (mixed mode, strong–cation exchange 
resin), Strata-X-CW (mixed mode, weak–cation exchange resin) and Strata-X-
AW (a mixed mode, weak anion exchange) cartridges were investigated using 
the method recommended by the manufacturer (described in section 3.1.5.1). 
Famotidine was poorly recovered from all cartridges investigated with the 
exception of the Strata-X-C (Figure 4.4). Tamsulosin hydrochloride was 
recovered well on each cartridge except the anion exchange resin (X-AW). 
Strata-X showed the best retention of the highly non-polar, solifenacin 
followed closely by the X-C and X-AW, while the X-CW cartridge showed no 
retention of the drug. Therefore, the cation exchange resin Strata-X-C was 
selected as optimum for the combined analysis of all three APIs.  
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Figure 4.4 Recovery of three APIs on different cartridge types, Strata-X (polar – 
non-polar interactions), X-C (strong cation exchange), X-CW (weak cation 
exchange) and X-AW (weak anion exchange). 
85 
 
The Strata-X-C cartridge is a mixed mode cartridge which functions on the 
basis of both ion exchange and polarity. The polymeric backbone provides 
polar, non-polar interactions. The samples were acidified following collection 
to pH3 (sampling procedure is outlined in section 3.1.4) and so in acidic 
solutions basic wastewater constituents were expected to bond with the 
negatively charged functional group of the Strata-X-C resin (Figure 4.5). 
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Figure 4.5: Strata-X-C reverse phase and cation exchange resin sample 
interaction with famotidine. 
 
 
 
 
4.1.3 HPLC method development 
 
Due to the complex nature of the wastewater a separation method is 
necessary. Both HPLC and GC are widely used for the monitoring of 
micropollutants and each has advantages and disadvantages. Lower standard 
deviations are associated with LC-ESI-MS over GC-MS; however, GC-MS 
methods generally have a lower LOD (Fatta et al., 2007). The analytes under 
investigation are non-volatile and would require derivatisation for GC analysis. 
This contributes to the sample preparation time. Therefore HPLC was chosen 
as the separation method of choice.  
 
4.1.3.1 Wavelength optimisation 
 
HPLC optimisation began with the determination of the optimum wavelength 
for the monitoring of the three APIs. The UV-Vis spectra of the three APIs 
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each at a concentration of 10 mg/L in HPLC grade water are shown in Figure 
4.6. Famotidine (280nm) and tamsulosin hydrochloride (270nm) show 
significant peaks at higher wavelengths. Solifenacin succinate shows limited 
absorbance at higher wavelengths. Higher absorbances were observed for all 
three analytes at lower wavelengths, famotidine (205nm), tamsulosin (205nm) 
and solifenacin (215nm). While the higher wavelengths could be used to 
improve selectivity for famotidine and tamsulosin this would also result in 
decreased sensitivity.  
 
 
 
Figure 4.6: UV spectra of three APIs at neutral pH. 
 
 
The molar extinction coefficient for each of the three APIs was 19570.3, 
31991.0, 16072.3 cm−1M-1 for famotidine, tamsulosin and solifenacin 
respectively. The molar extinction coefficient was calculated by dividing the 
UV absorbance (cm−1) at the chosen wavelength by the molar concentration 
(M). This coefficient is an expression of the UV energy absorption and a low 
absorption might imply low degradation of the drug as a result of UV light 
(Kim et al. 2009). 
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4.1.3.2 Stationary phase optimisation 
 
The polarities of the three APIs vary greatly: famotidine is a highly hydrophilic 
compound and tamsulosin and solifenacin are hydrophobic. Reverse phase 
methods using C-18 columns have been developed for tamsulosin and 
solifenacin (Keski-Rahkonen et al. 2007; Mistri et al. 2008). While there are 
some methods that use a C-18 column for the retention of famotidine they 
typically have complicated mobile phases with additives that are unsuitable 
for MS and/or had very short retention times. In general, famotidine is difficult 
to retain under reverse phase conditions using a C-18 column (Zhong et al. 
2001).  What is required is a phase that offers both the hydrophobic 
characteristics of a C-18 and the ability to act as a hydrogen bond acceptor. 
The PFP phase meets both of these requirements. The PFP column (Figure 
4.7) has the hydrophobic characteristics of a C-18 column for the reverse 
phase retention of tamsulosin and solifenacin and also has hydrogen bonding 
acceptor properties that are needed for optimised interaction with famotidine.  
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Figure 4.7: Example of interaction between Pentyfluorophenyl propyl 
ligand attached to silica and famotidine. The PFP phase has enhanced 
mechanisms of bonding over C-18 stationary phase. Its main 
mechanisms of interaction are hydrogen bonding, dipole-dipole, 
aromatic and hydrophobic interactions. The PFP column was chosen 
due to the difficulty in retaining famotidine on the C-18 column. 
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4.1.3.3 Mobile phase optimisation 
 
Mobile phase optimisation began with development of individual isocratic 
methods for the separate analysis of the three APIs. This showed the % 
organic required for the elution of the three pharmaceuticals. These methods 
were then combined to determine the optimum gradient conditions for the 
elution of the three APIs in a single combined method. 
 
Independent isocratic methods were first developed for all three APIs using 
acetonitrile with a 0.1% ammonium acetate buffer on a PFP column (Table 
4.2). This determined the approximate organic percentage of the mobile 
phase required for the analytes to elute. Standard curves were produced for 
each of the three analytes and gave high R values at low concentrations (0.2-
5 mg/L).  
 
Table 4.2: Individual methods for the analysis of the three APIs. 
Analyte % ACN 
Retention time 
(min) 
Wavelength 
(min) 
R 
Famotidine 10 5.5 205 0.9973 
Tamsulosin 35 6.5 205 0.9989 
Solifenacin 65 7.9 215 0.9961 
 
 
Due to a large difference in mobile phase composition used between the 
three methods, a single isocratic method is not appropriate for the analysis of 
all three APIs due to long analysis times and peak broadening. Therefore, a 
gradient method was developed to analyse for all three APIs at the same 
time. One problem that arose in developing the gradient method was that the 
low wavelengths at which the three analytes absorb caused significant 
baseline drift. As a result, wavelength switching had to be employed to 
account for the drift. In other words, the wavelength was increased to 254 nm 
at steps in the gradient. Initial method development was conducted using 10 
% to 65 % acetonitrile with a 0.1 % ammonium acetate buffer (Figure 4.8).  
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100 % M.P. A 
35 % M.P. A 
15 % M.P. A 
Mobile phase (M.P.) A: 10 % ACN (0.1% A.A.) 
Mobile phase (M.P.) B: 65 % ACN (0.1 % A.A.) 
famotidine 
tamsulosin 
solifenacin 
254 nm 254 nm 205 nm 205 nm 254 nm 215 nm 
famotidine 
tamsulosin 
solifenacin 
Figure 4.8: 0-5 mg/L overlay of famotidine, tamsulosin hydrochloride and 
solifenacin succinate. The top chromatogram shows the effect of changes 
in mobile phase composition on the chromatogram. The bottom 
chromatogram shows arrows indicating the points at which the wavelength 
was changed. 
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Although good R values (Figure 4.9), responses and peak shapes were 
achieved, problems arose with the availability and price of acetonitrile (Sigma 
Aldrich price: Acetonitrile 0.1 % Ammonium acetate (€77.67 /2.5L) during the 
method development phase and in Autumn 2008 a switch was made to a 
methanol-based mobile phase (10 % to 90 %). Formic acid (0.1 %) was 
added to the methanol/water mobile phase to adjust it to pH 3 which resulted 
in enhanced response and peak shape. Acidification is also recommended 
for reproducible retention times (Petrovic et al., 2005).  It was not necessary 
to add a buffer since peak shape was deemed acceptable. Standard injection 
volume of 50 µg/L and flowrate of 1 mL/min were used. No improvement in 
peak shape was noted with changes in these parameters. Slight 
reoptimisation of gradients was necessary on changing to low flowrate (0.3 
mL/min), lower injection volume (20 µL) and narrow bore column for MS 
analysis. Figure 4.10 shows a chromatogram using low flow-rate, lower 
injection volume and narrow bore column.   
 
 
Figure 4.9: 0-5 mg/L standard curve of combined famotidine, 
tamsulosin hydrochloride and solifenacin succinate method. 
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Figure 4.10: Chromatogram of 5 mg/L standard using switched 
wavelength on HPLC. Methanol mobile phase with 0.1% formic acid, a 
narrow bore column, 0.3 mL/min flowrate and 20 µL injection. 
 
 
4.1.4 Mass spectrometry optimisation 
 
Mass spectrometry is an analytical technique that measures the mass-to- 
charge ratio of charged particles. In LC-MS/MS, a HPLC is used as the 
separation technique the sample is then pumped into a mass spectrometer. 
There the sample is vaporised, ionized and accelerated through a series of 
electrical and vacuum gradients to the ion trap. In the trap the ions are then 
separated on the basis of mass to charge. Target ions are then fragmented, 
separated a second time and sent to the detector. A mass spectrum is 
produced showing relative abundance of ions as a function of the mass to 
charge ratio.  
 
LC-MS offers enhanced sensitivity and specificity over HPLC alone. Due to 
the presence of other co-eluting matrix components UV detection was not 
specific enough for the quantitation of analytes and therefore mass 
spectrometry detection was used. Tandem MS was used both for compound 
identification and quantitation. The MS was operated in positive mode. The 
MH+ ions were isolated in the ion-trap for subsequent fragmentation. Under 
multiple reaction monitoring (MRM) mode breakdown of each of the molecular 
ions was monitored. Two MRM transitions were monitored to confirm the 
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identity of each API. Molecular and product ions were determined under 
tandem mass spectrometry conditions in positive and negative modes and are 
shown in Table 4.3 and Figure 4.11. Positive mode was optimum for all three 
APIs. While monitored ions were determined by direct infusion of standards, 
other LC-ESI-MS/MS methods in the literature also monitored similar MRM 
transitions: molecular ion 338 m/z to product ions 259 and 189 m/z for 
famotidine (Jelic et al., 2009; Petrovic et al., 2006), molecular ion 409 m/z to 
product ions 271, 228 and 148 m/z for tamsulosin (Keshi- Rahkonen et al., 
2007) and molecular ion 363 m/z to 110 m/z for solifenacin (Mistri et al., 
2008). 
 
The positive mode showed higher sensitivity than the negative mode for all 
three analytes. Formic acid (to enhance ionisation in positive mode) and 
ammonium hydroxide (to enhance ionisation in negative mode) were added to 
each standard to determine optimum sample composition for ionisation. 
Formic acid was found to have negligible signal enhancement for all three 
analytes in positive mode. Ammonium hydroxide also showed negligible 
signal enhancement in negative mode. Mass spectrometry parameters were 
optimised by direct infusion of standards for each analyte individually and are 
also shown in Table 4.3. ESI parameters were optimised automatically using 
Brüker Daltonics software. Nebuliser conditions were optimised manually by 
changing a parameter and waiting for the signal response to adapt. 
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Table 4.3: Nebuliser and electrospray ionisation conditions, also molecular and product ions. Average ESI conditions did 
not show as high a response as the tamsulosin optimum for each of the APIs. Molecular and product ions as indicated by 
direct infusion of standards in positive mode. 
 
 API Famotidine  Tamsulosin Solifenacin Optimised condition 
 Mol. Weight (g/mol) 337 408 362 - 
 Mol. Ion (m/z) 338(M+H)
+
 409(M+H)
+
 363(M+H)
+
 - 
 
Product ions (m/z) 
259(M+2H)
+
 
189(M+2H)
+
 
228(M)
+
 
271(M)
+
 
110(M)
+
 
236(M)
+
 
- 
      
ESI Capillary (V) 4500 4500 4500 4500 
 End plate (V) 775.4 913.1 740.0 913.1 
 Skim 1 (V) 15.0 30.3 38.7 30.3 
 Cap exit offset (V) 50.0 66.4 77.9 66.4 
 Octopole (V) 3.6 4.0 3.5 4.0 
 Octopole delta (V) 2.2 1.5 2.6 1.5 
 Trap drive 55.0 53.0 49.7 53.0 
 Skim 2 (V) 7.4 9.8 13.0 9.8 
 Oct. R.F. (Vpp) 197.5 226.2 209.8 226.2 
 Lens 1 -5.0 -2.5 -3.1 -2.5 
 Lens 2 -60.0 -57.5 -56.4 -57.5 
 Frag. Amp. (V) 1.8 1.7 1.8 1.7 
Nebulizer Dry gas pressure (PSI) - - - 50PSI 
 Dry gas flow (L/min) - - - 8Lmin
-1
 
 Temperature (˚C) - - - 325ºC 
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Figure 4.11: Molecular and product ions for (a) famotidine molecular ion 
338m/z [MS], (b) famotidine product ion 259, 189m/z [MS/MS], (c) 
tamsulosin molecular ion 409m/z [MS], (d) tamsulosin product ion 271, 
228, 148m/z [MS/MS], (e) solifenacin molecular ion 363m/z [MS], (f) 
solifenacin product ion 236, 110m/z [MS/MS].                                  
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4.1.5 Detection of APIs in real wastewater 
 
Initial SPE-LC-MS/MS experiments with real wastewater samples 
demonstrated qualitatively the presence of the pharmaceuticals in all 
wastewater samples (Figures 4.12, 4.13 and 4.14). Samples shown were 
collected on the 27th and 28th of October 2009. A higher response of the APIs 
in effluent compared to the influent highlighted the need to monitor ionisation 
effects caused by matrix components as the presence of other compounds in 
the matrix may lead to signal suppression or enhancement (Taylor, 2005).  
 
Signals of famotidine and tamsulosin were greater than ten times the noise 
level and therefore above the LOQ and solifenacin was detected above the 
LOD at more than three times the noise level (Fajgelj and Ambrus, 2000). 
Solifenacin had been out of production since summer 2009. It was therefore 
anticipated that when production resumed that concentrations would increase. 
The SPE concentration of 10X used was therefore considered suitable for 
method validation. 
 
There are three main methods used for quantitation. They are internal 
standards, external standards and standard addition. External standards are 
the simplest method but do not account for any matrix effects. Standard 
addition or internal standards can be used to account for different ionisation 
between samples. Standard addition involves spiking the sample with known 
quantities of the analyte of interest. In comparison internal standard uses a 
similar but not the same compound as the analyte of interest. The ratio of 
internal standard signal to analyte signal as a function of analyte 
concentration is used for quantitation. The main disadvantage with the internal 
standard method is the difficulty in finding compounds that match closely 
enough the analyte of interest but are still readily distinguishable by the 
instrument. Therefore standard addition was used as the method of choice for 
validation of the SPE-LC-MS/MS method and the sampling programme. 
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 (a) 
(a) 
(a) 
(b) 
(b) 
(b) 
Figure 4.12: (a) influent and (b) effluent samples showing extracted ion 
chromatogram for famotidine [ms/ms]. 
Figure 4.13: (a) influent and (b) effluent samples showing extracted ion 
chromatogram for tamsulosin hydrochloride [ms/ms]. 
Figure 4.14: (a) influent and (b) effluent samples showing extracted ion 
chromatogram for solifenacin succinate [ms/ms]. 
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4.1.6 Validation of SPE-HPLC method  
 
SPE-HPLC methods are available and validated for the analysis of certain 
pharmaceuticals in complex matrices (Babic et al., 2006). It was anticipated 
throughout the development process that a confirmation step such as MS 
would be necessary. However, a SPE-HPLC method without the MS step 
offers advantages: 
 
1. The ease of availability of HPLC instruments over LC-MS 
2. Time saved on MS method development 
3. No suppression or enhancement of ionisation by matrix components 
 
The SPE-HPLC method was validated using spiked ultra-pure water. 
Selectivity, linearity, LOD, LOQ, precision and recovery were determined. All 
SPE-HPLC validation data are shown in Table 4.4. All validation was 
conducted using standards that underwent SPE. Concentrations shown are 
representative of SPE of 100 mL of spiked ultra-pure water. Comparison of 
chromatograms for spiked and unspiked ultra-pure water was used to 
determine the selectivity of the analytical method. Unlike LC-MS, HPLC alone 
cannot provide compound confirmation. Therefore compound retention time 
and the absence of false positives from the comparison of spiked vs. unspiked 
water were used for confirming compound selectivity (Figures 4.15 and 4.16). 
 
 
Figure 4.12: Chromatogram of unspiked water for the analysis of 
famotidine, tamsulosin hydrochloride and solifenacin succinate 
showing series of injection peaks. 
 
 
Injection peaks 
98 
 
 
Figure 4.13: Chromatogram of water spiked to 60 μg/L with famotidine, 
tamsulosin hydrochloride and solifenacin succinate. 
 
Linearity of response was determined for famotidine, tamsulosin hydrochloride 
and solifenacin succinate using at least five concentrations. Each standard 
was injected three times. Standard curves were prepared by plotting 
concentration of analyte in the spiked water vs. peak area units. Blanks were 
also prepared for quality control. Coefficients of correlation were all >0.995 
confirming the linearity of the method. R values correspond with similar 
methods in the literature (Malintan and Mohd, 2006). 
 
Recoveries were determined at low, medium and high concentrations (n=3). 
Ultra-pure water was spiked to a concentration of 20, 40 and 60 μg/L. The 
concentration recovered from the Strata-X-C cartridge was compared to the 
initial spiking concentration. Recovery ranged from 87.4 ± 0.8% to 90.1 ± 
2.9% for famotidine, 95.2 ± 1.4% to 100.7 ± 4.1% for tamsulosin hydrochloride 
and 88.2 ± 4.3 to 99.2 ± 4.2% recovery for solifenacin succinate. 
 
 
For the determination of the LOD and LOQ, standards were serially diluted 
until the signal-to-noise ratio reached a value of 3:1 for the LOD and an LOQ 
of 10:1 (Lacey et al., 2008). Precision is defined as the degree to which 
repeated measurements under unchanged conditions show the same results 
and accuracy defined as the closeness of repeat measurements to their true 
value were determined at low (20 μg/L), medium (40 μg/L) and high (60 μg/L) 
quality control levels at three replicates per concentration (n=3) (Hospodsky et 
Tamsulosin 
 
Solifenacin 
Famotidine 
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al., 2010). The values for the intra-day precision were 19.2 ± 0.5 μg/L to 60.9 
± 0.8 μg/L for low and high levels, while inter day variability values were 18.0 
± 5.8 μg/L to 60.8 ± 1.2 μg/L. 
 
Following validation the method was applied to real wastewater samples. 
Both spiked and unspiked influent samples were analysed (Figure 4.17). 
However, the method was not applied to the six month monitoring of the 
wastewater. A very large famotidine peak in the early part of the 
chromatogram where other matrix components elute is seen in the influent 
samples. It is possible that other components of the wastewater may be co-
eluting therefore a confirmation step is necessary.   
 
Further optimisation of the method may result in greater specificity such as 
optimisation of the SPE washes for higher selectivity in the removal of 
interferences. However washes were concentrated with a 100% methanol 
wash for removal of polar interferences and an acid wash for the removal of 
acidic interferences. Interferences may be intermediates or impurities in the 
production process which may have similar structures. Optimisation of 
washes is time consuming and the same washes may remove both the 
analyte of interest and the interference. Further optimisation of the SPE-
HPLC method was therefore not continued.  
 
A similar method for the quantitation of pharmaceuticals in industrial 
wastewater used UV spectra at the retention time (RT) of the APIs as a 
confirmation step. This method had a similar LOQ from 1.5-100 µg/L. A 
number of the peaks shown in the real wastewater samples were not 
confirmed when compared to UV spectra. This highlighted the requirement 
for a confirmation step even for relatively clean chromatograms and in areas 
of the chromatogram where matrix components are usually less problematic 
(Babic et al., 2006). 
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Table 4.4: SPE-HPLC validation parameters including range, LOD, LOQ, linearity, line equation, SPE recovery, precision 
and accuracy for each API. All validation parameters shown were evaluated  in ultra-pure water. 
 
Concentration 
(µg/L) 
Famotidine Tamsulosin Solifenacin 
Range of calibration curve (µg/L)  5.0-60 2.5-60 10-60 
LOD (μg/L)  2.0 1.0 2.5 
LOQ (μg/L)  5.0 2.5 10 
Slope of calibration curve (m)  83.1±0.3 142.3±0.4 44.5±0.3 
Y-axis intercept (c) (mAU)  -68.7±6.1 -86.4±5.1 -51.0±7.5 
Coefficient of correlation (R)  0.9970±0.0003 0.9969±0.0004 0.9950±0.0007 
     
SPE Recovery 
Mean  concentration  ± %CV 
20 87.9±8.0 95.6±0.5 92.3±1.3 
40 87.4±0.8 95.2±1.4 88.2±4.3 
60 90.1±2.9 100.7±4.1 99.2±4.2 
     
Inter-day 
Mean concentration ± %CV (% Bias) 
20 18.0±6.8(10.0) 19.5±0.2(2.3) 19.6±1.9(1.9) 
40 35.9±6.3(10.2) 38.3±1.0(4.3) 38.7±3.8(3.2) 
60 57.1±6.1(4.9) 60.3±0.3(-0.5) 60.8±1.2(-1.3) 
     
Intra-day 
Mean concentration ± %CV (% Bias) 
20 19.2±0.5(3.9) 19.7±0.5(1.7) 19.4±0.8(2.9) 
40 37.7±1.4(5.8) 38.1±0.3(4.7) 37.8 ± 0.8(5.4) 
60 60.5±0.4 (-0.8) 60.9±0.8 (-1.5) 61.4 ± 0.5 (-2.4) 
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Figure 4.14: Application of SPE-HPLC method (a) 20 µg/L spiked ultra-pure water showing famotidine, 
tamsulosin and solifenacin (b) 20 µg/L spiked real wastewater sample (c) unspiked influent sample. The early 
elution of famotidine with other contaminants may lead to interfering peaks. Co-elution of other constituents in 
the water may lead to the large peak seen at the same retention time as famotidine in the samples. Without the 
confirmation offered by mass spectrometry this peak cannot be identified as famotidine with a high degree of 
certainty.   
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4.1.7 Validation of SPE-LC-MS/MS method  
 
Mass spectrometry is commonly used for the analysis of low concentrations of 
target analytes in waters (Gros et al., 2006; Lὸpez-Rolden et al., 2010; 
Petrovic et al., 2006).  
 
The method was validated in both influent and effluent sample matrices and 
all validation data are presented in Table 4.5. Linearity was determined using 
regression analysis between the peak area ratios and concentration. 
Correlations of R>0.9 were obtained for all APIs. In the case of famotidine 
R>0.99 was recorded for standard addition in both influent and effluent 
samples. However, due to the presence of much higher concentrations of the 
API in the wastewater a higher range of standards was used.  
 
The LOD and LOQ are very low for both tamsulosin and solifenacin in influent 
and effluent. The low ionisation of famotidine has led to a much higher LOD 
and LOQ in both matrices. The precision of the overall method was 
determined from six injections of a low level spiked standard and intermediate 
precision by injection of six replicates of a low-level spiked sample. Precision 
and intermediate precision were less than 15% in all cases. While 15% is a 
high variance, it is typical when using standard addition for SPE-LC-MS/MS 
methods for micro-pollutants in complex matrices (Hernando et al., 2004; 
Lacey et al., 2008).  
 
To quantify the level of ion suppression or enhancement, in both influent and 
effluent samples, a sample was extracted and then spiked with a standard 
solution of each analyte. Spiked extracted wastewater samples were 
compared to extracted standards in distilled water. Unspiked wastewater 
samples were also analysed to determine the level of target compounds 
present in the sample prior to spiking. Any difference in the signal obtained 
from the spiked wastewater sample from that of the spiked distilled water was 
due to matrix components. High signal suppression in the influent was 
contrasted by enhancement of signal in the effluent for all analytes is likely to 
be due to the presence of different matrix components. 
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Recoveries were determined by comparing pre-extraction and post-extraction 
spiked influent and effluent samples. Recoveries were greater than 91% for all 
three APIs in both influent and effluent. Studies of SPE methods are not 
common in the literature for the recovery of the three APIs under 
investigation. Acceptable recoveries have been reported from 50-96% for 
these APIs using a variety of cartridges (Gros et al., 2006; Chambers et al., 
2008). 
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Table 4.5: SPE-LC-MS/MS validation results in influent and effluent wastewaters. 
 
  Famotidine Tamsulosin Solifenacin 
Influent Range of calibration curve 0.4-5.0 mg/L 1-15 µg/L 6-50 µg/L 
 Slope of calibration curve (m) 1x10
5
 2x10
7
 4x10
6
 
 Y-axis intercept (c) (Intens.) -12394 -14796 -11496 
 LOD (µg/L) 100 0.4 2.0 
 LOQ (µg/L) 400 1.0 6.0 
 % Precision (%CV) n=6 2.5 14.8 11.9 
 % Intermediate precision (%CV) n=6 7.8 11.0 8.7 
 Coefficient of correlation (R) 0.9940 0.9775 0.9707 
 % SPE recovery 114.6 103.2 91.2 
 % Ion suppression 41.8 23.1 51.3 
     
Effluent Range of calibration curve 0.4-5.0 mg/L 0.8-18 µg/L 6.0-16 µg/L 
 Slope of calibration curve (m) 1x10
5
 2x10
7
 2x10
6
 
 Y-axis intercept (c) (Intens.) 30457 8360.9 3522.3 
 LOD (µg/L) 110 0.3 4.0 
 LOQ (µg/L) 400 0.8 6.0 
 % Precision (%CV) n=6 2.0 11.0 10.9 
 % Intermediate precision (%CV) n=6 1.7 6.8 10.2 
 Coefficient of correlation (R) 0.9912 0.9815 0.9301 
 % SPE recovery 116.2 96.3 114.8 
 % Ion suppression -49.3 -49.1 -72.4 
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4.2 Results of the sampling programme 
 
4.2.1 Occurrence of the APIs in wastewater 
 
Influent and effluent samples were collected on a weekly basis from the onsite 
wastewater treatment plant from November 2009 to April 2010 (26 weeks). All 
three analytes under investigation were detected in both influent and effluent 
at different times during the study. 
 
Famotidine and tamsulosin hydrochloride were detected in 85 and 88% of 
influent samples and 100 and 96% of effluent samples respectively. 
Solifenacin succinate was detected less frequently at 65% in both influent and 
effluent samples. Solifenacin succinate was out of production from summer 
2009 until January of 2010 which likely accounts for the less frequent 
detection of the pharmaceutical. The very low LOQ of tamsulosin 
hydrochloride meant that despite its low level production it was almost always 
detected in the wastewater at trace concentrations.   
 
Of the three drugs famotidine was present at the highest concentrations 
(average 1.6 mg/L in influent, 2.6 mg/L in effluent). On average it was 
detected at two orders of magnitude higher than solifenacin (0.039 mg/L in 
influent, 0.028 mg/L in effluent) and three orders of magnitude higher than 
tamsulosin (0.005 mg/L in influent, 0.004 mg/L in effluent). Famotidine is 
produced in the highest amounts of the three pharmaceuticals at 385 Kg of 
famotidine per batch which represents a yield of approximately 65%. Each 
batch takes approximately 10 days and often two batches are in production 
simultaneously. During the monitoring period with the exception of the 
Christmas shutdown period (22nd December to 6th January) the famotidine 
process averaged two batches every two weeks.  
 
A summary of the occurrence of the three APIs over the six month monitoring 
period from November 2009 to April 2010 is shown in Table 4.6. Student 
paired t-test showing difference between influent and effluent samples with 
95% confidence limit. For both famotidine and solifenacin the influent and 
effluent are significantly different. In the case of tamsulosin, the influent and 
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effluent are not significantly different Appendix C shows the monthly 
summaries of results. 
 
Table 4.6: Occurrence of APIs in wastewater over 6 month period from 
November 2009 to April 2010. Minimum, maximum, median and average 
concentrations are shown for 26 weekly influent and effluent samples. 
 
API WW* n>LOD %Freq 
Min  
( mg/L) 
Max 
( mg/L) 
Median 
( mg/L) 
Average 
( mg/L) 
t-test 
 
Sig  
(2- 
tailed) 
Famotidine 
I 22 85 
<LOQ 
(0.4) 
5.8 1.5 1.6 
-3.347 0.003 
E 26 100 0.7 7.3 2.0 2.6 
Tamsulosin  
I 23 88 
<LOQ 
(0.001) 
0.019 0.003 0.005 
0.104 0.918 
E 25 96 
<LOQ 
(0.0008) 
0.032 0.003 0.004 
Solifenacin  
I 17 65 
<LOQ 
(0.006) 
0.174 0.027 0.039 
2.283 0.031 
E 17 65 0.007 0.079 0.018 0.028 
*Wastewater (WW), influent (I), effluent (E) 
 
The concentrations detected for famotidine in particular were much higher 
than originally expected. However, they are broadly in line with the 
concentrations detected in two studies reporting concentrations of 
pharmaceuticals in effluents from large industrial complexes in Korea and 
India.  Larsson et al., 2007 reported concentrations of pharmaceuticals in 
effluent from a common effluent treatment plant in India serving 
approximately 90 bulk drug manufacturers. The antibiotic ciprofloxacin was 
detected at concentrations up to 31 mg/L and the H2-receptor antagonist 
ranitidine at concentrations as high as 0.16 mg/L. The Korean study focused 
on APIs in the effluent from both individual manufacturing facilities and 
pharmaceutical complexes and reported levels of up to 43.9 mg/L of the 
antibiotic lincomycin and 0.15 mg/L of the antiepileptic carbamazepine (Sim 
et. al., 2011). The concentrations of famotidine in this work (max detected 7.3 
mg/L) are broadly the same order of magnitude as those in the Korean and 
Indian studies.   
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Pharmaceuticals have been detected in effluents from municipal and hospital 
wastewaters and surface waters typically in ng/L to low ug/L ranges. Table 
4.7 shows that industrial wastewater contains higher concentrations of 
pharmaceuticals than municipal and hospital wastewater in the majority of 
cases. It has been generally accepted that the main route of entry of 
pharmaceuticals into the environment is through human ingestion and 
excretion and subsequent release through municipal facilities (Khetan and 
Collins, 2007). This work together with the Indian and Korean cases suggests 
that concentrations of APIs released by the pharmaceutical industry may be 
contributing a higher environmental loading than previously acknowledged. 
 
Table 4.7: Typical concentrations of pharmaceuticals released into the 
environment from different sources (µg/L). 
 
ND not determined [1] Sim et al., 2011[2] Kosma et al., 2010, [3] Brown et al., 2006, [4] 
Larsson et al., 2007  
 
4.2.2 Trends in API concentration over sampling period  
 
Trends in famotidine influent and effluent concentrations over the analysis 
period are shown in Figure 4.18. After a pre-Christmas ramp-up in production, 
levels of famotidine in the influent rose to a maximum concentration of 5.8 
mg/L. According to a previous study this would correspond to approximately 
1.65 Kg or 0.4% of the overall yield of famotidine (Cullen, 2009). During the 
Wastewater Hospital Industrial Municipal  
 Min. Max. Min. Max. Min. Max. Ref. 
Caffeine 
12.1 45.7 2.26 262 1.94 75.7 [1] 
12.3 42.0 ND ND 17.1 113.2 [2] 
Carbamazepine 
0.018 6.08 0.035 19.1 0.095 21.6 [1] 
n.d. 1.7 ND ND n.d. 1.1 [2] 
Diclofenac 
0.028 6.88 160 203 0.094 0.523 [1] 
n.d. 6.3 ND ND n.d. 3.9 [2] 
Ibuprofen 7.0 8.9 ND ND 2.8 25.4 [2] 
Trimethoprim 
0.028 7.26 0.056 162 0.036 1.51 [1] 
5 2.9 ND ND 0.18 1.4 [3] 
Ciprofloxacin 
0.460 5.03 0.528 34.6 0.124 0.246 [1] 
0.8 2 ND ND 0.2 1 [3] 
ND ND 28,000 31,000 ND ND [4] 
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Christmas shutdown (23rd December- 6th of January 2010) levels of 
famotidine in the influent fell to a minimum of 0 mg/L on the 12th of January. 
Concentrations of famotidine in the effluent fell at a slower rate to a low on the 
26th of January of 1.2 mg/L. This was two weeks later than the low point in the 
influent and over a month after the shutdown period began. 
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Figure 4.15: Influent and effluent concentrations of famotidine from November 2009 to April 2010
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Tamsulosin hydrochloride is produced in a small multipurpose unit for the low 
level production of potent APIs. Approximately 15Kg of tamsulosin is 
produced per batch (approximately every 2 weeks). A low concentration of 
tamsulosin was detected throughout the monitoring period in both influent and 
effluent at a mean value of 0.003 mg/L (Figure 4.19). Maximum values of 
tamsulosin were 0.019 mg/L on the 26th of January 2010 in influent and 0.032 
mg/L in the effluent on the 18th of March 2010. On the 11th of January 2010 
the number of carbon filtration units in the final step of the process was halved 
from two to one which saw a yield increase of 0.6Kg per batch. However it 
corresponds with a large increase in tamsulosin in the influent seen at the end 
of each tamsulosin production cycle. Concentrations of tamsulosin in the 
effluent remained at a more steady concentration than the cyclic two week 
pattern seen in the influent.    
 
Solifenacin succinate was out of production from summer 2009 until the 12th 
of January 2010. Solifenacin reached a max concentration of 0.174 mg/L in 
the influent and 0.079 mg/L in the effluent (Figure 4.20). Astellas have stated 
that eight batches of solifenacin were made from the 12th of January to the 
22nd of April at a yield of 200Kg of solifenacin succinate per batch. A new 
solifenacin process was introduced on the 22nd of April (towards the end of 
this analysis period). The new process increases the yield per batch by 
150Kg.  
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Figure 4.16: Influent and effluent concentrations of tamsulosin hydrochloride from November 2009 to April 2010 
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Figure 4.17: Influent and effluent concentrations of solifenacin succinate from November 2009 to April 2010. 
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4.2.3 Treatment efficiency of onsite treatment plant 
 
The concentrations of the three APIs in influent and effluent appear to be broadly 
similar. This indicates that the treatment facility (described in Appendix B) is 
ineffective for the removal of the APIs. The wastewater treatment plant consists 
of a basic activated sludge tank which is batch fed at night to keep the activated 
sludge consortium alive although there is no sludge settlement tank or tertiary 
treatment and no sludge is ever removed from the plant indicating that it may be 
washed out with the effluent.   
 
4.2.3.1 Efficiency of plant for removal of famotidine 
 
The concentrations of famotidine in the effluent exceeded the concentration in 
the influent 77% of the time. Influent concentrations had a median value of 1.5 
mg/L as compared to 2.0 mg/L in the effluent. The activated sludge in the 
lagoons is batch fed at night with a feed that is made up in wash water from a 
step in the famotidine production cycle. According to Astellas concentrations of 
famotidine in this filtrate were significant, with approximately 20 kg of famotidine 
dissolved in the 1700 litre filtrate. It is likely that this is the source of the higher 
concentrations of famotidine in the effluent. Since July 2010, this filtrate is no 
longer used to make up the feed and the new feed is made up with filtrate that 
contains about 0.5 kg of famotidine. Generally, high concentrations of the API in 
the effluent suggest that the treatment facility is ineffective for its removal. 
Famotidine has been effectively treated at municipal treatment facilities when 
operated at a longer HRT (up to 14 days) (Clara et al., 2005). Polar drugs like 
famotidine are generally removed in AS systems by biodegradation (Carballa et 
al., 2004). Of the three APIs investigated famotidine appears to be the most 
metabolically resistant. It is released from the body relatively unchanged and has 
no major metabolites. Metabolically resistant pharmaceuticals tend to be more 
resistant to AS treatment (Khetan and Collins, 2007).  
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4.2.3.2 Efficiency of plant for removal of tamsulosin hydrochloride 
 
Tamsulosin hydrochloride remained in the wastewater throughout the monitoring 
periods at trace concentrations. The median influent and effluent concentrations 
over the six month period were the same at 0.003 mg/L. The average 
concentration of tamsulosin in the influent was only marginally higher than the 
effluent at 0.005 mg/L in comparison to 0.004 mg/L. These results indicate that 
there was no removal of tamsulosin hydrochloride by the treatment facility.  
 
4.2.3.3 Efficiency of plant for removal of solifenacin succinate 
 
The average concentration of solifenacin was 0.039 mg/L in the influent and 
0.028 mg/L in the effluent. This corresponds to an average removal of 28% from 
November 2009 to April 2010. During the period from November to January 
solifenacin was out of production and concentrations dropped sharply in the 
influent but remained high in the effluent. When examining the period when 
solifenacin was in production, the percentage removal rises to 40%.  Polarity of 
the API appears to be an important factor when considering removal efficiencies 
from AS plants. Polar drugs adsorb less onto the activated sludge particles. 
Solifenacin appears to have the highest removal efficiency but is also the most 
non-polar of the three APIs (Carballa et al., 2004). 
 
4.2.4 Pharmaceutical wastewater regulations 
 
In many parts of the world pharmaceutical wastewater is released into the 
environment without any treatment (Enick and Moore, 2007). At Astellas Ireland 
Pharmaceutical Limited the wastewater is treated at onsite wastewater 
treatment plant and then released to municipal sewer where it is treated again at 
a municipal sewage treatment plant. Wastewater from pharmaceutical facilities 
in Europe is subject to regulation through their IPPC licences. These waste 
licences tend to focus on COD, BOD, nitrates, phosphates and metals. There is 
little regulation on the releases of APIs. ‗Ireland seems to be the only jurisdiction 
where regulatory limits have been placed on the release of APIs from industrial 
facilities‘ (Helmig et al., 2007). However, to the authors knowledge Wyeth 
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Pharmaceutical Ltd. in Newbridge, Co. Kildare is the only production facility with 
such limits (Table 4.8). There is no such limit on the APIs released by Astellas 
(IPPC licence, 2006). The levels of famotidine detected in the Astellas 
wastewater are higher than the discharge limits for all the APIs at the Newbridge 
facility. However famotidine does not have the same environmental significance 
as the antibiotics and EDCs produced at the Wyeth facility. Any possible future 
requirement may not have as low a limit. This highlights the need to assign 
environmental risk data to drugs to determine if limiting discharge of certain 
pharmaceuticals to the environment is necessary.  
 
Table 4.8: Discharge limits Wyeth, Newbridge (Molyneaux, 2009). 
 
API  mg/L 
Lederle (antibiotic) 1 
Tranquilisers 0.5 
Oral contraceptives 0.02 
Hormone replacement therapy 0.02 
 
4.2.5 Treatment options for the reduction of API concentration 
in wastewater 
 
Treatment options for the removal of APIs from industrial wastewater are 
discussed extensively in Chapter 2. The simplest solution for the treatment of 
APIs is the extension of HRT for the enhanced removal of more metabolically 
resistant APIs such as famotidine. Retrofitting of existing treatment plants for the 
enhanced removal of pharmaceuticals is an economic solution. MBRs followed 
by ozonation have been successfully applied for retrofitting of pharmaceutical 
facilities (Helmig et al., 2007). Removal of pharmaceuticals from wastewater 
using photo-Fenton‘s oxidation has been widely successful in bench scale 
studies (Ay and Kargi, 2010; Mèndez-Arriaga, 2010; Shemer et al., 2006; Xu et 
al., 2009). However no reference to photo-Fenton‘s degradation of the three 
APIs in this project is available in the literature. A study of the application of 
Fenton‘s reaction for the removal of the APIs is presented and discussed in the 
following sections. 
116 
 
4.3 Fenton’s oxidation 
 
4.3.1 Introduction to Fenton’s oxidation 
 
Fenton‘s reaction has been used successfully for the removal of pharmaceuticals 
from wastewater (Arslan-Alaton and Dogruel, 2004; Pérez-Estrada et al., 2005b; 
Ravina et al., 2002). Fenton‘s reagent consists of hydrogen peroxide, iron(II) and 
light. Iron salts and hydrogen peroxide are inexpensive and readily available. 
Disadvantages of Fenton‘s reaction include the need to remove the iron salts 
following treatment as well as the requirement for pH neutralisation. The main 
reactions are outlined below many other side reactions occur the exact 
schematic of these reaction remains a source of some debate. 
 
Hydrogen peroxide alone is a strong oxidant, but is ineffective for the degradation 
of concentrated refractory compounds. It can be activated using iron salts in the 
dark Fenton‘s reaction (Alegría et al., 2003),   
 
Fe2+ + H2O2 → Fe
3++OH·+OH- 
 
UV light also reacts with H2O2 to create hydroxyl radicals  
 
H2O2[+UV] → 2OH
· 
 
Important factors in the optimisation of Fenton‘s conditions include pH, 
temperature, and concentration of hydrogen peroxide, iron salts and pollutant. 
The photo-Fentons oxidation process was optimised in terms of complete 
removal of the parent compound after the first sample was taken using the 
minimum concentrations of Fe(II) and H2O2. An acidic environment is necessary 
for the decomposition of H2O2 due to the abundance of free H
+. The reaction is 
slowed down at very low pH values (<2.0) due to the formation of complex iron 
species and formation of the oxonium ion [H3O2]
+. At higher pH (pH > 4) the 
generation of hydroxyl radicals gets slower because of the formation of ferric-
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hydroxo complexes (Tekin et al., 2006). Generally, the pH value is considered 
optimum at approximately 3. 
 
2Fe2+ + H2O2 + 2H
+ → 2Fe3+ + 2H2O 
 
The ratio of iron to hydrogen peroxide is important. If the concentration of Fe2+ 
exceeds hydrogen peroxide concentration then chemical coagulation will occur, 
resulting in the settling out of iron salts and pollutants rather than chemical 
oxidation (Neyens and Baeyens, 2003) 
 
[Fe2+] > [H2O2]……….chemical coagulation 
[Fe2+] < [H2O2]……….chemical oxidation 
 
By applying light to the Fenton‘s process additional hydroxyl radicals are 
generated and ferric ions are reduced into ferrous. Iron salts absorb light up to 
approximately 400nm (Figure 4.21), therefore solar light may be used, removing 
the need for UV lamp (Pérez et al., 2002). The photo-Fenton‘s process equation 
is as follows: 
Fe3+ + H2O + hv → Fe
2+ +OH∙ + H+ 
 
 
Figure 4.18: Absorbance spectrum of Fe(III) in comparison with solar 
spectrum and halogen lamp spectrum adapted from Ibáñez et al., 2009. 
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4.3.2 Kinetic evaluation 
 
The degradation of each of the three pharmaceuticals predominantly exhibits a 
mono-exponential trend and so pseudo-first order kinetics can be applied. The 
pseudo-first order rate equation is: 
tk
C
C
app)ln(
0  
 
where, kapp is the apparent pseudo-first order rate constant, C0 is the initial 
concentration prior to the addition of H2O2 and t is the reaction time. A plot of 
ln(C0/C) vs t gives a straight line with the slope of kapp the pseudo first order rate 
constant. The half-life (t1/2) expresses the time (min) it takes for half of the initial 
concentration of the API to degrade. 
 
t1/2 = ln(2)/kapp 
 
kapp and t1/2 are used to compare the efficiency of different reactions and 
concentrations of reactants for the optimisation of removal techniques (Keane et 
al., 2011).  
 
As discussed later in this chapter, at lower iron(II) concentrations the reaction 
fits the first order equation well with R values >0.95. This was due to an excess 
of H2O2. The cycling of Fe
3+ back to Fe2+ by the halogen lamp may have been 
the rate determining step making Fe2+ the rate limiting reactant. As the iron(II) 
concentration was increased the R values generally decreased indicating that 
the reaction was fitting the pseudo-first order equation less well and moving 
more towards a second order model.   
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4.3.3 Choosing a quenching agent 
 
4.3.3.1 Demonstrating the requirement for a quenching agent 
 
Fenton‘s reaction is self-propagating with the cycling of ferric and ferrous iron 
together with hydrogen peroxide creating radicals. Therefore after a sample has 
been taken the reaction requires quenching. Failure to do this leads to 
inaccurate results if the analysis is not performed immediately in a time-
controlled manner (Figure 4.22). However, simply controlling the time over which 
the analysis is performed is not ideal. Analytical issues arise such as difficulty 
with the analysis of the first few minutes of an experiment, the inability to rerun 
samples and practicalities relating to the availability of instruments. Some 
commonly used agents in the quenching of Fenton‘s experiment include 
methanol, acetone, sodium sulphite and sodium thiosulphate (Chu, 2005; 
Karimi, 2009; Khan et al., 2009; Zimbron and Reardon, 2009). All quenching 
experiments were carried out at 0.1 mM famotidine, 0.012 mM Fe(II) and 20 mM 
H2O2.
 
Figure 4.19: Famotidine experiment analysed on the same day vs. the 
following day. Three replicate experiments were carried out, all three were 
analysed on the same day by HPLC with about 20% removal noted. One 
experiment was analysed again after 18 hours. Famotidine was detected in 
lower concentrations (approx. 45% removal). 
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 4.3.3.2 Sodium sulphite as a quenching agent 
 
The oxygen scavenging agent sodium sulphite was tested as a quenching 
agent. One drop of 20% w/v sodium sulphite solution per 1  mL of sample was 
added to samples taken during photo-Fenton‘s oxidation. Results showed that 
rather than stopping the reaction the sodium sulphite enhanced degradation of 
famotidine as compared to unquenched samples. Samples were analysed 
immediately, were kept in the dark at 4°C for 18 hours and analysed again by 
HPLC. Samples analysed immediately had 79% of the initial concentration 
remaining and after 18 hours famotidine was no longer detectable in the sample. 
 
4.3.3.3 Methanol as a quenching agent 
 
Methanol was also investigated as a possible quenching agent. Quenching of 
samples using 0.1 to 1 mL of methanol per 1 mL of sample showed that 
concentrations of greater than 1 mL methanol per 1 mL of sample would be 
required (Figures 4.23 and 4.24). At 1 mL methanol peak shape was severely 
affected during chromatographic analysis. Therefore methanol was not 
considered a suitable quenching agent for use with the famotidine HPLC method 
used.  
 
Figure 4.20: Effect of methanol on quenching. 0.1 mL methanol was 
unsuccessful for the quenching of 1 mL of sample. 
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Figure 4.21: Methanol added vs Ct/C0 for 5min sample exhibits a linear 
relationship. Assuming Ct/C0 of 0.8 (from 5min sample for day 1 in Figure 
4.23) is fully quenched then 1.8 mL of methanol would be required per  mL 
of sample taken to quench the reaction. 
 
 
4.3.3.4 Time-controlled experiment  
 
Due to the difficulty finding a suitable quenching agent, no quenching agent was 
used and the analysis was run in a strict time-controlled manner (Figure 4.25). 
The chromatographic run was started at 35min into the Fenton‘s experiment, 
beginning with two blanks. Run time for each of the three analytes using 
individual methods was 6 minutes. While good reproducibility was achieved this 
method was not considered ideal. There is a number of practical considerations 
around the use of the HPLC, such as the inability to rerun samples or the 
invalidity of an experiment if the HPLC run stopped. Of particular importance is 
difficulty in monitoring the first few minutes of the experiment, the identification 
of relatively short living intermediates and kinetic analysis of results. However 
due to the difficulty in identifying a suitable quenching agent it was decided to 
proceed with the time-controlled method. A large decrease between the 0 min 
sample and the 5 min sample for famotidine suggested that degradation was 
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continued in the time between sampling and analysis on HPLC. For all further 
reactions for famotidine graphs take into account the time between sampling 
and analysis. A significant reduction was not noted between 0 and 5 minute 
samples for tamsulosin and solifenacin. 
 
Figure 4.22: Repeat experiments conducted in time-controlled manner 
gave reproducible results. 
 
 
4.3.4. Optimisation of Fenton‘s oxidation for famotidine removal 
 
4.3.4.1 The effect of different reactants on famotidine degradation  
 
Experiments to determine the effect of the different reactants in the photo-
Fenton‘s process showed that photolysis, iron(II) (12µM) with and without light 
resulted in no degradation (Figure 4.26). The famotidine/Fe(II) solution was 
stable in the light or dark at pH3.  Any degradation in any of the Fenton‘s 
processes was only seen on the addition of the hydrogen peroxide. At 20 mM 
hydrogen peroxide 11% of the famotidine was removed. A marginal 
improvement was observed with the use of the halogen lamp (approx. 5% after 
120min). Dark Fenton‘s oxidation showed more than double the degradation 
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than hydrogen peroxide alone at 20 mM H2O2. Again a marginal increase in 
removal was noted with the use of the halogen lamp possibly due to the 
decomposition of hydrogen peroxide to hydroxyl radicals (approx. 5% after 
120min). There is an abundance of literature which describes the use of a UV 
light source in the degradation of a range of micro-pollutants by photo-Fenton‘s 
oxidation due to much higher degradation rate with the use of UV lamps (Feng 
et al., 2005; Mèndez-Arriaga, 2010; Shemer et al., 2006; Trovo et al., 2008). The 
UV lamp provides greater decomposition of hydrogen peroxide to hydroxyl 
radicals and enhanced cycling of ferric and ferrous iron. A halogen lamp was 
used in this scenario to mimic sunlight for a low energy, low cost alternative. 
Degradation of famotidine by the processes tested were in the sequence 
iron(II)/H2O2/Light (25% removal at 60 min) > iron(II)/H2O2 (23% removal at 60 
min) > H2O2/Light (12% removal at 60 min) > H2O2 (11% removal at 60 min) > 
iron(II) (0% removal at 60 min), iron(II)/light (0% removal at 60 min) and 
photolysis (0% removal at 60 min) (Figure 4.26).  
 
Figure 4.23: Effect of different reactants on famotidine degradation. 
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4.3.4.2 Famotidine light-Fenton’s reactions 
 
Photo-Fenton‘s optimisation began with varying Fe(II) concentrations as it is 
normally considered the limiting reactant (Pérez et al., 2002). Concentrations 
monitored were 0.012 mM, 0.03 mM, 0.06 mM, 0.09 mM and 0.12 mM Fe(II) at 
20 mM hydrogen peroxide (Figure 4.27). Following initial optimisation of Fe(II) 
concentration, the high H2O2 concentration was reduced with small increases in 
Fe(II) concentration to ensure optimal removal was maintained e.g. 0.3 mM 
Fe(II) increase corresponds to a 10 mM decrease in H2O2. Concentrations 
monitored ranged between 0.12-0.18 mM Fe(II) and 5-20 mM H2O2 (Figure 
4.26). The highest removal was seen in the sequence 0.18 mM Fe(II)/5 mM 
H2O2 (99% removal at 60 min), 0.12 mM Fe(II)/20 mM H2O2 (99% removal at 60 
min) > 0.15 mM Fe(II)/10 mM H2O2 (98% removal at 60 min) > 0.15 mM Fe(II)/5 
mM H2O2 (97% removal at 60 min) > 0.09 mM Fe(II)/20 mM H2O2 (90% removal 
at 60 min) > 0.12 mM Fe(II)/10 mM H2O2 (75% removal at 60 min) > 0.06 mM 
Fe(II)/20 mM H2O2 (66% removal at 60 min) > 0.03 mM Fe(II)/20 mM H2O2 (51% 
removal at 60 min) > 0.012 mM Fe(II)/20 mM H2O2 (25% removal at 60 min) 
(Figures 4.27 and 4.28). 
 
Figure 4.24: Famotidine degradation at different Fe(II) concentrations. 
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Figure 4.25: Famotidine degradation at different H2O2/Fe(II) concentrations 
 
4.3.4.3 Kinetic evaluation of results 
 
In this kinetic evaluation of results the effects of changes in initial concentrations 
of Fe(II) and H2O2 on kapp and t1/2 were investigated. Degradation of famotidine 
using photo-Fenton‘s and dark-Fenton‘s oxidation follows pseudo-first-order 
degradation. The role of different Fe(II) concentrations was first investigated at 
20 mM H2O2 and 0.1 mM famotidine. Fe(II) was varied between 0.012 mM Fe(II) 
and 0.120 mM Fe(II). The degradation follows the pseudo-first-order kinetic 
model (Figure 4.29). A graph (Figure 4.30a) of Fe(II) concentration vs. kapp is 
exponential (R=0.9774). Fe(II) is important in initiating the generation of HO∙ 
radicals. A graph of Fe(II) concentration vs t1/2 drops exponentially with the 
addition of Fe(II) (R=0.9562) (Figure 4.30b). The half-life, t1/2 is the length of time 
in minutes it takes half the famotidine to react.  
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Figure 4.26: Pseudo-first-order kinetics, different Fe(II) concentrations 
(0.012 mM – 0.120 mM Fe(II)), 20 mM H2O2. 
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Figure 4.27: Famotidine (a) Effect of Fe(II) concentration on kapp, 
exponential relationship noted between addition of Fe(II) and kapp. (b) 
Effect of Fe(II) concentration on t1/2. Inverse exponential trend between t1/2 
and addition of Fe(II). 
 
 
Figu
re 
(a) 
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Fe(II) optimisation was conducted with an excess of H2O2. Following initial 
optimisation of Fe(II), concentrations of H2O2 were reduced (Figure 4.31). When 
H2O2 concentrations were decreased the % removal of famotidine also 
decreased.  In order to maintain optimum degradation, concentrations of Fe(II) 
were increased. Concentrations of varying Fe(II) and H2O2 between 0.12–0.15 
mM Fe(II), 5-20 mM H2O2 were investigation during the optimisation process, 
only one concentration was changed at a time. Large decreases in H2O2 
required only minor increases in Fe(II) to maintain optimum degradation e.g. 0.3 
mM Fe(II) increase corresponds to a 10 mM decrease in H2O2.  
 
 
 
 
Figure 4.28: First order kinetics, different Fe(II) concentrations (0.12 mM – 
0.15 mM Fe(II)), 5-10 mM H2O2. 
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4.3.5 Optimisation of Fenton’s oxidation for removal tamsulosin 
hydrochloride  
 
4.3.5.1 Light-Fenton’s degradation of tamsulosin hydrochloride 
 
Optimisation of tamsulosin hydrochloride degradation by photo-Fenton‘s 
oxidation began at the optimum concentration for famotidine removal at 0.12 
mM Fe(II), 5 mM H2O2, which showed complete removal after the first sample 
was taken. Different concentrations of Fe(II) were investigated between 0.03 
and 0.09 mM Fe(II). Optimum degradation was in the sequence 0.09 mM Fe(II) 
(99.7% removal at 10 min) > 0.06 mM Fe(II) (93.5% removal at 10 min)  > 0.045 
mM Fe(II) (49% removal at 10 min) > 0.03 mM Fe(II) (42% removal at 10 min) 
(Figure 4.32). 
 
 
Figure 4.29: Effect of different Fe(II) concentrations on tamsulosin 
hydrochloride (100 µM) degradation by photo-Fenton’s oxidation 
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4.3.5.2 The effect of different reactants on tamsulosin hydrochloride 
degradation 
 
At the optimum concentration for the removal of tamsulosin hydrochloride 0.09 
mM Fe(II)/5 mM H2O2/light the effect of the different reactants in the photo-
Fenton‘s process were investigated. No or extremely low degradation of 
tamsulosin was noted at 0.09 mM Fe(II), Fe(II)/Light, 5 mM H2O2, H2O2/Light or 
light (Figure 4.33). At 5 mM H2O very limited oxidation of tamsulosin 
hydrochloride occurred. This highlights that H2O2 at reasonable concentrations 
is not sufficient for the removal of tamsulosin hydrochloride from aqueous 
solutions, with or without the addition of light. Similarly to famotidine in Figure 
4.24, Fe(II) and Fe(II)/Light did not degrade the pharmaceutical and 
Fe(II)/tamsulosin solutions were stable. When Fe(II) and H2O2 were combined 
the removal increased dramatically to 4% remaining at 10 min. Photo-Fenton‘s 
oxidation improved removal to 0.3% remaining. 
 
Figure 4.30: Effect of different reactants on tamsulosin hydrochloride 
degradation. 
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4.3.5.3 Kinetic evaluation of results  
 
In this kinetic evaluation of results the effects of changes in initial concentrations 
of Fe(II) on kapp and t1/2 were investigated. Degradation of tamsulosin 
hydrochloride using photo-Fenton‘s and dark Fenton‘s oxidation follows pseudo-
first-order degradation. The role of different Fe(II) concentrations was first 
investigated at 5 mM H2O2 as this was the optimum determined from famotidine 
degradation studies and 0.1 mM tamsulosin hydrochloride. Fe(II) was varied 
between 0.012 mM Fe(II) and 0.09 mM Fe(II). The degradation follows the 
pseudo-first-order kinetic model (Figure 4.34). A graph (Figure 4.35a) of Fe(II) 
concentration vs. kapp shows exponential increase in kapp with Fe(II) 
concentration (R 0.9965). Famotidine showed a linear graph rather than the 
exponential seen here for tamsulosin. The conditions for famotidine used 20 mM 
H2O2 whereas 5 mM H2O2 was used in this set of experiments. H2O2 was 
present at much higher concentrations in the famotidine set of experiments. A 
graph (Figure 4.35b) of Fe(II) concentration vs. t1/2 (min) exhibits inverse 
exponential degradation (R=0.9965). 
 
Figure 4.31: Pseudo-first-order kinetics, different Fe(II) concentrations 
(0.012 mM – 0.09 mM Fe(II)), 5 mM H2O2. 
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Figure 4.32: (a) Effect of Fe(II) concentration on kapp. An exponential 
relationship exists between kapp and the addition of Fe(II). (b) Effect of 
Fe(II) concentration on t1/2. An inverse exponential plot is noted between 
t1/2 and addition of Fe(II). 
 
(a) 
(b) 
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4.3.6 Optimisation of Fenton’s oxidation for removal solifenacin 
succinate 
 
4.3.6.1 Light-Fenton’s degradation of solifenacin succinate 
 
Optimisation of solifenacin succinate began at the optimum concentration for 
famotidine removal at 0.12 mM Fe(II), 5 mM H2O2, which showed complete 
removal after the first sample was taken. Different concentrations of Fe(II) were 
investigated between 0.03 and 0.09 mM Fe(II) (Figure 4.36). Optimum 
degradation was in the sequence 0.09 mM Fe(II), 5 mM H2O2 (100% removal at 
10 min) > 0.06 mM Fe(II), 5 mM H2O2 (93% removal at 10 min)> 0.045 mM 
Fe(II), 5 mM H2O2 (86% removal at 10 min) >> 0.03 mM Fe(II), 5 mM H2O2 (52% 
removal at 10 min). Degradation at 0.03 mM Fe(II), 5 mM H2O2 was significantly 
lower than 0.045 mM Fe(II), 5 mM H2O2.  
 
Figure 4.33: Degradation of solifenacin succinate using Fenton’s 
oxidation. 
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4.3.6.2 The effect of different reactants on solifenacin succinate 
degradation 
 
At the optimum concentration for the removal of solifenacin succinate 0.09 mM 
Fe(II)/5 mM H2O2/light the effect of the different reactants in the photo-Fenton‘s 
process was investigated. At 0.09 mM Fe(II), Fe(II)/light, 5 mM H2O2, H2O2/light 
or light no degradation of solifenacin was observed (Figure 4.37). As was the 
case with tamsulosin at 5 mM H2O2 negligable oxidation of solifenacin succinate 
occurred. Similarly to both famotidine and tamsulosin in Figure 4.24 and Figure 
4.31, Fe(II) and Fe(II)/light did not degrade the pharmaceutical and 
Fe(II)/solifenacin solutions were stable. The addition of H2O2 and Fe(II) in 
combination dramatically increased to 100% with or without the addition of light. 
 
 
Figure 4.34: Effect of different reactants on solifenacin succinate 
degradation. 
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4.3.6.3 Kinetic evaluation of results 
 
In this kinetic evaluation of results the effects of changes in initial concentrations 
of Fe(II) on kapp and t1/2 were investigated. Degradation of solifenacin succinate 
using photo-Fenton‘s and Fenton‘s oxidation follows pseudo-first-order 
degradation. The role of different Fe(II) concentrations was first investigated at 5 
mM H2O2 as this was optimum determined from famotidine and tamsulosin 
hydrochloride degradation studies and 0.1 mM solifenacin succinate. Fe(II) was 
varied between 0.03 mM Fe(II) and 0.06 mM Fe(II). The degradation follows the 
pseudo-first-order kinetic model (Figure 4.38).  0.03 mM Fe(II) had a much lower 
kapp than both 0.045 and 0.06 mM Fe(II). Figure 4.39 shows (a) effect of Fe(II) 
concentration on kapp. and (b) effect of Fe(II) concentration on t1/2.  
 
 
Figure 4.35: First order kinetics, different Fe(II) concentrations (0.3mM – 
0.06mM Fe(II)), 5mM H2O2. 
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Figure 4.36: (a) Effect of Fe(II) concentration on kapp, fitted to linear plot  (b) 
Effect of Fe(II) concentration on t1/2, fitted to linear plot. 
 
(a) 
(b) 
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4.3.7 Summary of photo-Fenton’s optimisation experiments 
 
Photo-Fenton‘s oxidation effectively removed all three APIs from aqueous 
solutions. Tables 4.9 and 4.10 show a summary of Fenton‘s results including 
kapp, t1/2, R and % removal for all Fenton‘s optimisation experiments. 
Investigation of the effect of different reactants in the Fenton‘s process on the 
removal of all three APIs showed no or very limited removal by photolysis, Fe(II) 
and Fe(II)/light. For famotidine at 20 mM H2O2, approximately 11% removal was 
seen with the addition of H2O2, which was slightly increased with the use of light. 
Tamsulosin and solifenacin showed no degradation at 5 mM H2O2 in the light or 
dark.  
 
Dark Fenton‘s oxidation showed double the degradation of H2O2 alone at 0.012 
mM Fe(II)/20 mM H2O2 for famotidine and again the use of the halogen lamp 
slightly improved the removal. Dark Fenton‘s oxidation resulted in only 4% 
tamsulosin remaining at 10 minutes at 0.09 mM Fe(II), 5 mM H2O2. The use of 
the halogen lamp increased removal with only 0.3% remaining. Dark Fenton‘s 
oxidation of solifenacin had 0% remaining at 10 minutes at 0.09 mM Fe(II), 5 
mM H2O2. 
 
In famotidine photo-Fenton‘s reactions between 0.012 mM Fe(II) and 0.120 mM 
Fe(II) at 20 mM H2O2 optimal removal occurred at 0.120 mM. Photo-Fenton‘s 
reactions for both tamsulosin hydrochloride and solifenacin succinate between 
0.012 mM Fe(II) and 0.090 mM Fe(II) at 5  mM H2O2 exhibited optimal removal 
at 0.090 mM Fe(II).  
 
Comparison of Fenton‘s processes with other photocatalytic and advanced 
oxidation methods in the literature and even between reports describing 
Fenton‘s process is problematic. Different conditions including different light 
sources, reactor types and concentrations of pharmaceuticals, iron(II) and 
hydrogen peroxide are common. Fenton‘s process such as electro-Fenton‘s and 
Fenton‘s-like reactions are also difficult to compare. Fenton‘s oxidation has also 
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been investigated for different wastewater types. In terms of removal of APIs 
and/or reduction in TOC, COD or DOC. There is no standard method for 
assessing efficiency of process. Time-based kinetics modelling are commonly 
used as the rate constant and half-life can be used to compare the efficiency of 
processes even between different types of process. Fenton‘s and photo-
Fenton‘s degradation followed pseudo-first order degradation for all three APIs 
at the concentrations used.  
 
Table 4.9: Summary of Fenton’s oxidation experiments carried out 
showing % removal and first order kinetics of famotidine degradation at 
different Fe(II) and H2O2 concentrations. 
 
Process Fe/H2O2/Light 
% remaining at 
60 min 
R kapp (min
-1
) t1/2 (min) 
Photo-Fenton‘s 
0.012/20/light 75 0.9805 3.827x10
-3
 182.4 
0.03/20/light 49 0.9515 8.770x10
-3
 78.8 
0.06/20/light 34 0.9661 2.213x10
-2
 31.4 
0.09/20/light 10 0.9046 4.257x10
-2
 16.3 
0.12/20/light 1 0.9175 6.247x10
-2
 11.1 
0.12/10/light 25 0.9210 2.099x10
-2
 33.0 
0.15/10/light 2 0.8754 6.656x10
-2
 10.4 
0.15/05/light 3 0.9266 5.807x10
-2
 11.9 
0.18/05/light 1 0.9382 6.993x10
-2
 9.9 
Photolysis -/-/light 100 - - - 
Dark Fenton‘s 0.012/20/- 77 0.9515 3.118x10
-3
 223.6 
Hydrolysis 
-/20/- 89 0.9137 1.395x10
-3
 495.1 
-/20/light 88 0.9407 1.570x10
-3
 433.2 
Fe(II) processes 
0.012/-/light 100 - - - 
0.012/-/- 100 - - - 
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Table 4.10: Summary of Fenton’s oxidation experiments carried out showing % removal and first order kinetics of 
tamsulosin hydrochloride and solifenacin succinate degradation at different Fe(II) and H2O2 concentrations. 
  Tamsulosin hydrochloride Solifenacin succinate 
Process Fe/H2O2/Light 
% remaining at 
10 min 
R kapp (min
-1
) t1/2 (min) 
% remaining 
at 10 min 
R kapp (min
-1
) t1/2 (min) 
Photo-Fenton‘s 
0.012/5/light 77 0.9608 0.0050 138.6 - - - - 
0.030/5/light 58 0.9707 0.0147 47.2 48.3 0.8856 0.012 57.8 
0.045/5/light 51 0.9731 0.0423 16.4 14.4 0.9852 0.213 3.3 
0.060/5/light 6.5 0.9144 0.1072 6.5 6.8 0.9962 0.262 2.6 
0.090/5/light 0.3 0.9877 0.5103 1.4 0 - - - 
0.120/5/light 0 - - - 0 - - - 
Photolysis -/-/light 96 - - - 98 - - - 
Dark Fenton‘s 0.090/5/- 4 - - - 0 - - - 
Hydroxylation 
-/5/- 99 - - - 99 - - - 
-/5/light 96 - - - 97 - - - 
Fe(II) processes 
0.090/-/light 100 - - - 97 - - - 
0.090/-/- 100 - - - 100 - - - 
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One method for comparing optimum conditions by comparing the ratio of 
API: Fe(II): H2O2 concentration. Table 4.11 compares removal efficiency of 
the three APIs in this study with methods in the literature. The average API: 
Fe(II): H2O2 ratio in the methods is approximately 1:1:50. Fe(II) ratio ranged 
from 0.2-4.2 and H2O2 from 1.4-116.3. The order of magnitude between 
optimum API and Fe(II) ratios was typically the same. H2O2 was typically 1-2 
orders of magnitude higher than API and Fe(II) concentration. 
 
0.18 mM Fe(II)/5 mM H2O2 was required for the removal of famotidine in 
comparison to 0.09 mM Fe(II)/5 mM H2O2 for tamsulosin and solifenacin. The 
higher concentrations of iron required for the removal of famotidine may be 
due to its suspected iron chelation and antioxidant properties. Due to the 
presence of amine, thiozole and thioether groups on the famotidine structure 
it has strong complexing properties. It complexes with a number of metals 
including copper and iron (Muller and Burrows, 1998; Stargrove et al., 2008). 
This results in inhibition of HO∙ radicals generation in Fe2+/H2O2 reaction 
mixtures by famotidine (van Zyl et al., 1993). However, from Figure 4.24 no 
reduction in famotidine was noted in experiments with 0.1 mM famotidine at 
0.012 mM Fe(II) with and without light. However the final optimised 
concentration was much higher at 0.18 mM Fe(II) and perhaps at these 
concentrations complexing may be occurring. The antioxidant properties of 
famotidine have been investigated in gastric disease pathology as an 
inhibitor of oxidation induced damage (Ahmadi et al., 2010; Sener-Muratoglu, 
2001). The exact mechanism of its action as a radical scavenger is unclear. 
However, it has been reported that famotidine has weak hydrogen peroxide 
scavenging activity (Ahmadi et al., 2010) but it acts as a HO∙ radical 
scavenger (Sener-Muratoglu, 2001).  
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Table 4.11: Comparison of different methods for the treatment of APIs using photo-Fenton’s oxidation. Appendix D 
contains an extensive list of rate equations and conditions for literature examples of pharmaceuticals treated by Fenton’s 
processes. 
 
Pharmaceutical pH APIs (mM) Fe(II) (mM) H2O2 (mM) k 
kapp  
(min
-1
) 
%Removal 
Ratio 
API; Fe(II); H2O2 
Ref. 
Famotidine 3 0.1 0.15 5 1 0.05807 97 1; 1.5; 50 This study 
Famotidine 3 0.1 0.18 5 1 0.06993 99 1; 1.8; 50 This study 
Tamsulosin 3 0.1 0.09 5 1 0.5103 99 1; 0.9; 50 This study 
Tamsulosin 3 0.1 0.06 5 1 0.1072 93.5 1; 0.6; 50 This study 
Solifenacin 3 0.1 0.06 5 1 0.262 96.7 1; 0.6; 50 This study 
Solifenacin 3 0.1 0.045 5 1 0.213 97.4 1; 0.45; 50 This study 
Melatonin 3.0 0.086 0.1 10 1 0.25 100 1; 1.16; 116.3 Xu et al., 2009 
Melatonin 3.0 0.086 0.05 10 1 0.18 100 1; 0.58; 116.3 Xu et al., 2009 
Metronidazole 3.5 0.006 0.00588 0.0294 2 0.00248 73 1; 0.98; 4.9 Shemer et al., 2006 
Metronidazole 3.5 0.006 0.01176 0.0294 2 0.00383 73 1; 0.2; 4.9 Shemer et al., 2006 
Amoxicillin 3.5 10 mg/L 25 mg/L 500 mg/L - - 100 1; 2.5; 50 Ay and Kargi, 2010 
Amoxicillin 3.5 105 mg/L 50 mg/L 500 mg/L - - 100 1; 0.48; 4.8 Ay and Kargi, 2010 
Amoxicillin 3.5 105 mg/L 25 mg/L 255 mg/L - - 100 1; 0.24; 2.4 Ay and Kargi, 2010 
Ibuprofen 3 0.87 0.32 1.2 - - 100 1; 0.4; 1.4 Mèndez-Arriaga, 2010 
       Average 1; 1.2; 42.9  
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4.3.8 Intermediate study 
 
The identification of intermediates is an important step in the evaluation of the 
photo-Fenton‘s process. Some intermediates can be more toxic than the parent 
compound or may be biologically active. A particularly recalcitrant intermediate 
may be formed and not degraded. Intermediates shown from other catalysis or 
oxidation studies may suggest different degradation pathways. It has been 
shown in the case of other APIs that degradation follows different pathways 
depending on the treatment applied (Perez-Estrada et al., 2005a).  Calza et al., 
2004a has shown that intermediate products in photodegradation studies reflect 
biotransformation in animal models. Therefore metabolites are a useful guide in 
identifying intermediates. For each API intermediates were identified during a 
seven hour photo-Fenton‘s experiment detected by LC-MS. After 5 hours a 
second addition of H2O2 was added. 
 
4.3.8.1 Intermediates produced by photo-Fenton’s oxidation of famotidine 
 
Famotidine results are for 100 µM famotidine degraded using 0.09 mM Fe(II), 20 
mM H2O2 and light. Figure 4.40 shows degradation with time of the ions present 
at 0 min. There is a number of ions present at 0 min other than the famotidine 
ion at m/z 338. The famotidine ion (338 m/z) is approximately 8 times more 
intense than the next highest present ion at 0 min. By approximately 150 min the 
famotidine ion is no longer detected. The other ions present are m/z 259, 340, 
360, and 359 (Figure 4.41).  However from Figure 4.42 it can be seen that the 
intermediates linger until approximately 360 min. The presence of the main 
famotidine impurity (A7) is noted. It has a molecular weight of 258 gmol-1 and so 
is likely to be the ion 259m/z. A list of famotidine impurities is shown in Appendix 
E. Famotidine with the sodium adduct is also seen at 359. At 340m/z there is 
also a peak noted, which may be as a result of degradation of the parent 
compound.  
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Figure 4.38: Structure of ions present at 0min for famotidine experiment. 
 
There is formation and degradation of intermediates predominantly over the first 
180 min. After 180 min more recalcitrant ions m/z 354, 370, and 376 lingered 
until about 360 min after which no further intermediates were detected via LC-
MS m/z 354, 372 and 406.9 were present at the highest intensity (Figure 4.42). 
Figure 4.37: Reduction of famotidine ions present at 0min with time. 
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Figure 4.39: Change in peak area units of intermediates present with time. 
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Figure 4.43 shows the structures and proposed degradation pathways for the 
lower molecular weight famotidine intermediates. The possible degradation 
pathway is 264 → 185 → 171 gmol-1. The higher famotidine molecular weight 
structures are seen in Figure 4.44. Structures are proposed for ions with 
molecular weight 353, 369, 370, 371, and 375 gmol-1. One of the main 
intermediates 354 m/z is likely to have the same structure as the impurity A6 
(Appendix E). Transformation of the guanidine is as proposed by Calza et al., 
2004b. No major famotidine metabolites are known to use as a comparison. 
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Figure 4.40: Low molecular weight intermediates of famotidine as 
identified by LC-MS. 
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Figure 4.41: High molecular weight intermediates of famotidine as identified by LC-MS. 
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4.3.8.2 Intermediates produced by photo-Fenton’s oxidation of tamsulosin 
hydrochloride 
 
Conditions used for the tamsulosin experiment are 100 µM tamsulosin 
hydrochloride, 0.045 mM Fe(II) and 5 mM H2O2. The experiment showed 
formation and degradation of intermediates in first 180 min. A large number of 
intermediates were formed. This is due to the large number of hydroxylation 
sites. 13 different ions were noted. No intermediates were noted after 180 min. 
Ions present at 0 min are shown in Figure 4.45. 
 
 
Figure 4.42: Degradation of tamsulosin ions present at 0 min. 
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Tamsulosin (m/z 409), is approximately 14 times more intense than the next 
highest ion at 0 min. By approximately 180 min the tamsulosin ion is no longer 
detected. Intermediates are also no longer detected at 180 min. Nine other ions 
are present at 0 min. The other ions present are m/z 397, 411, 431, 566.5, 
588.5, 679.5 and 701.5. Tamsulosin hydrochloride has a large number of 
impurities. The impurities may be reflected in the large number of ions noted at 0 
min. LC-MS data showing change in intermediates with time during the photo-
Fenton‘s oxidation experiment are shown in Figure 4.46.  
 
Intermediates and degradation pathways for tamsulosin are presented in Figure 
4.47. Proposed structures are mainly as a result of HO∙ radical attack. 
Tamsulosin is readily metabolised in the body. Some of the proposed structures 
are the same as the human metabolites M1 and M4. Main human metabolites of 
tamsulosin are shown in Appendix F. These metabolites are pharmokinetically 
active with a potency in terms of activity in the body of tamsulosin ≈ M4 > M1 > 
M2 ≈ M3 >>AM1 (Taguchi et al., 1997).  
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Figure 4.43: Change in peak area units of intermediates present with time. 
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Figure 4.44: Proposed degradation pathways for tamsulosin hydrochloride.
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4.3.8.3 Intermediates produced by photo-Fenton’s oxidation of solifenacin 
succinate 
 
The conditions for the identification of solifenacin succinate intermediates were 
100 µM solifenacin, 0.045 mM Fe(II) and 5 mM H2O2. Ions present at 0 min are 
shown in Figure 4.48. The ion with the highest intensity is m/z 363 (solifenacin 
succinate). By approximately 30 min the solifenacin ion is no longer detected. 
There are ten other ions present at 0 min. The other ions present are m/z 701, 
566, 476, 445, 395, 379, 377, 363, 347 and 301. LC-MS data showing change in 
intermediates with time are shown in Figure 4.49. Intermediates were also no 
longer detected at 180 min. Formation and degradation of intermediates 
occurred in first 180 min. 17 different ions were noted. Many of them have an 
m/z that reflects the molecular weight of metabolites. Intermediates and 
degradation pathways for solifenacin are presented in Figure 4.50. Appendix G 
shows solifenacin metabolites. No intermediates were noted after 180 min.  
 
 
Figure 4.45: Solifenacin ions present at 0 min. Where multiple peaks for same 
molecular weight exist the retention time of peaks are shown in brackets. 
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Figure 4.46: Change in peak area units of solifenacin intermediates present with time. Where multiple peaks 
for same molecular weight exist the retention time of peaks are shown in brackets. 
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Figure 4.47: Solifenacin degradation pathways of ions seen by LC-MS 
analysis. The 4-R-hydroxy metabolite is pharmokinetically active. 
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Solifenacin has four major metabolites, one metabolite that is pharmokinetically 
active (4R-hydroxy solifenacin) and three inactive metabolites (N-glucuronide, 
N-oxide, and 4R-hydroxy-N-oxide) (Yanagihara et al., 2007). The N-glucuronide 
metabolite is not relevant to this study. The N-oxidation of the quinuclidin ring 
and the 4R-hydroxylation of the tetrahydroisoquinoline ring are likely 
intermediates to occur as a result of OH∙ radical attack. Both the 4-hydroxy 
solifenacin and N-oxide solifenacin have the same molecular weight at 378 
gmol-1) and likely the same m/z (379 m/z). Figure 4.51 shows the chromatogram 
of the 379 m/z ion with multiple peaks. The multiple peaks are likely to represent 
different structures with slightly different affinities to the PFP stationary phase. It 
is likely that these two metabolites are among the structures of the ions seen. 
The extra peaks may be caused by the hydroxyl group being attached to 
different locations on the structure. The three larger peaks possibly represent 
the structures shown in the figure however this would be difficult to show 
definatively without further investigation. The n-oxide metabolite also has the 
same molecular weight this may also be present here. The different structures 
may represent hydroxyl groups at different locations resulting in slightly different 
polarities. 
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Figure 4.48: Six different peaks for ion at m/z 379 suggests different 
structures at same molecular weight. (a) shows formation and reduction of  
peaks with fenton reaction time (b) EIC for m/z 379 showing multiple peaks 
(c) possible structures including metabolite 
(b) 
(a) 
(c) 
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4.3.8.4 Summary of the intermediate study  
 
For each of the three APIs formation and subsequent degradation of 
intermediates in a classic bell shaped curve occurred. Proposed intermediates 
for famotidine showed cleavage of the C-C bonds, HO∙ radical substitution for 
amine groups and guanidine transformation. A large number of intermediates 
was observed for tamsulosin due to the large number of hydroxylation sites as 
well as cleavage of the C-C bonds. Low molecular weight intermediates were 
not seen for solifenacin. HO∙ radical attack on the ringed structures was a 
prominent characteristic of the solifenacin degradation including N-oxidation of 
the quinuclidin ring and the 4R-hydroxylation of the tetrahydroisoquinoline ring. 
 
There were no intermediates identified that formed and did not degrade within 
the seven hour experiment. Earlier reported results indicated that the parent 
compounds were removed successfully by photo-Fenton‘s oxidation. These 
results indicate that a more complete degradation of all three APIs is occurring. 
No particularly recalcitrant intermediates are formed that are not removed by 
photo-Fenton‘s oxidation. While toxicity studies were outside the scope of this 
particular study, some intermediates that are pharmokinetically active for both 
tamsulosin and solifenacin were proposed.   
  
  
157 
 
 
5. Conclusions and further 
research 
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5.1 Main findings and conclusions 
 
As discussed in Chapter 1 the project had three primary aims: 
1. to develop a single  method for the monitoring of all three APIs  
2. to monitor the concentrations in wastewater of the APIs  
3. to investigate a method for the removal of the APIs from the wastewater. 
The extent to which these aims were met and the main findings are outlined 
below: 
 
1. A new SPE-LC-MS/MS method was successfully developed and 
validated in influent and effluent samples. Coefficients of correlation for each 
analyte were >0.9301 confirming the linearity of the method. The method had a 
LOQ of 400 µg/L, 1.0 µg/L, 6 µg/L, repeatability of 2.5% CV, 14.8% CV and 
11.9% CV was determined for famotidine, tamsulosin and solifenacin 
respectively in influent. The method had a LOQ of 400 µg/L, 0.8 µg/L, 6 µg/L 
repeatability of 2.0% CV, 11.0% CV and 10.9% CV was established for 
famotidine, tamsulosin and solifenacin respectively in effluent. SPE recovery 
was >90% for the three APIs in both matrices. The developed method was 
applied to the six month monitoring programme. 
 
2. All three APIs were detected frequently in both influent and effluent 
from the onsite wastewater treatment plant at Astellas Ireland 
Pharmaceutical Limited in Mullhudart Co. Dublin. Famotidine (average 2.6 
mg/L in effluent) and solifenacin (average 0.079 mg/L in effluent) were detected 
at higher concentrations than is typically found for other pharmaceuticals in 
municipal and hospital wastewater ((Lacey et al., 2008; Suarez et al., 2009). 
Tamsulosin was typically detected at only trace concentrations in the low µg/L 
range. The concentrations of the three APIs fluctuated considerably depending 
on production regimes, changes in production methods and the production 
processes. Samples were collected in plastic bottles and were transferred to 
glass bottles immediately on return to the laboratory. This may have resulted in 
a slightly lower concentration recorded for the more hydrophobic APIs. All three 
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APIs were detected in both influent and effluent samples at different times 
during the study. Famotidine and tamsulosin were present in almost every 
sample taken (85-100%).  Solifenacin was out of production during the first two 
months of the six month sampling programme and was detected in 65% of both 
influent and effluent samples.   
 
Famotidine was detected at higher concentrations than expected at an average 
concentration of 1.6 mg/L in influent and 2.6 mg/L in effluent. Solifenacin was 
also detected at concentrations much higher than those typically detected in 
surface and municipal wastewaters at a max effluent concentration of 79 µg/L. 
Tamsulosin was typically detected at only trace concentrations in the low µg/L 
range. Tamsulosin is produced in a small multipurpose facility for the 
manufacturing of small amounts of valuable pharmaceuticals. The relatively 
large loss of famotidine and solifenacin represents a monetary loss for the 
pharmaceutical company. As stated previously the maximum famotidine influent 
concentration of 5.8 mg/L corresponds to 1.65 kg of lost product per batch. The 
concentrations of the three APIs fluctuated considerably depending on 
production regimes, changes in production methods and the production 
processes. This highlights the requirement for the six-month monitoring 
programme. Other monitoring programme lengths were considered including 
monitoring daily over a production cycle and monitoring over a longer period up 
to a year.  26 weekly samples were considered sufficient to see trends over the 
approximately two week production cycles. It also covered a shut-down period to 
show minimum concentrations of the APIs released to the environment.  
 
The on-site wastewater treatment facility was broadly ineffective for the removal 
of the three APIs. Effluent concentrations of famotidine exceeded influent 77% 
of the time because wash water from the famotidine production process was 
used to make a feed for the activated sludge lagoons and that contained high 
concentrations of dissolved famotidine (20 kg in 1700 L).  Famotidine remained 
in the effluent at an average of 2.6 mg/L. Tamsulosin remained at trace 
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concentrations throughout the monitoring period. The average concentration of 
tamsulosin in the influent was only marginally higher than the effluent at 0.005 
mg/L in comparison to 0.004 mg/L. There is evidence of up to 40% removal for 
solifenacin, which is more non-polar and is less metabolically resistance. 
 
Literature documenting releases of pharmaceuticals from industrial sources are 
rare. Available reports are generally from emerging economies with less 
stringent environmental laws such as Korea or India. Such reports may be 
looking at massive production facilities producing hundreds of tonnes of 
pharmaceuticals for sale worldwide. It could therefore be argued that they may 
be looking at more extreme cases of pollution and are not representative of the 
industry as a whole. More studies are needed focusing on varying type and size 
of production facilities in different geographical locations. As discussed in 
Chapter 4 concentrations of commonly monitored APIs are generally 1-2 but can 
be as much as 4 orders of magnitude higher than hospital or municipal sources, 
depending on the size of the production facility.  This study focused on a 
medium sized production facility in a developed country. The concentrations of 
famotidine detected were at least three orders of magnitude higher than typically 
detected in municipal effluent. Concentrations of APIs in the wastewater were 
reflective of the amount of API being produced as shown in Table 5.1. 
 
Table 5.1: Approximate production and influent concentrations during 
monitoring period from November 2009 to December 2010. 
 
API 
Production 
(tonnes) 
Influent concentration 
( mg/L) 
Famotidine 9-10 1.6 
Tamsulosin 0.18 0.005 
Solifenacin 2 0.04 
 
Not only are the concentrations released by a source of API contamination of 
the environment important in relation to environmental fate but also the source 
type. The pharmaceuticals released from municipal plants may have undergone 
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metabolism in the body before being excreted, but pharmaceuticals released 
from industrial sources are in the original, unmetabolised form. This is important 
in understanding the environmental form to be evaluated, designing fate and 
effects testing strategies, interpreting results, predicting environmental fate and 
carrying out environmental risk assessments (Kümmerer, 2004).  
 
3. Photo-Fenton’s oxidation successfully removed all three APIs from 
water. Higher Fe(II) concentrations were required for the removal of famotidine 
(0.18 mM Fe(II)/5 mM H2O2) than tamsulosin and solifenacin (0.09 mM Fe(II)/5 
mM H2O2). This may be due to iron chelating or antioxidant properties of 
famotidine.  The intermediate study showed complete removal of all 
intermediates generated by photo-Fenton‘s oxidation. Pharmokinetically active 
intermediates were identified. To compare the efficiency of the Fenton‘s 
oxidation of the three APIs, the ratios of the API concentration to the 
concentration of the reactants were compared with different reported examples 
(Ay and Kargi, 2010; Mèndez-Arriaga, 2010; Xu et. al., 2009; Shemer et al., 
2006). The order of magnitude between optimum API and Fe(II) ratios was 
typically the same. H2O2 had an average of 1.2 orders of magnitude higher than 
the API and Fe(II) concentrations. Time-based kinetic modelling are commonly 
used as the rate constant and half-life can be used to compare the efficiency of 
processes (even between different types of process such as TiO2 photocatalysis 
and ozonation). Fenton‘s and photo-Fenton‘s degradation followed pseudo-first 
order degradation for all three APIs at the concentrations used. Rate constants 
and half-lives for the optimised photo-Fenton‘s conditions are shown in Table 
5.3. 
 
Table 5.2:Summary of rate constant kapp and half-life t1/2 for photo-Fenton’s 
oxidation. 
 
API kapp (min
-1
) t1/2 (min) 
Famotidine (0.18 mM Fe(II)/5 mM H2O2) 6.993x10
-2
 9.9 
Tamsulosin (0.09 mM Fe(II)/5 mM H2O2) 0.5103 1.4 
Solifenacin (0.06 mM Fe(II)/5 mM H2O2) 0.262 2.6 
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5.2 Main implications of study 
There are 2 main implications of this project: 
 
1. The effect of the concentrations detected in the pharmaceutical 
wastewater on current understanding of the sources of 
pharmaceuticals in the environment The concentrations of 
pharmaceuticals released from the Astellas facility are broadly similar to 
concentrations detected at industrial facilities in Korea and India (SIm et al., 
2011; Larsson et al., 2007). The levels detected are higher than typical 
surface waters and municipal waste waters. This may indicate that 
pharmaceutical releases represent higher concentrations than generally 
acknowledged. Studies of concentrations of pharmaceuticals released from 
industrial facilities in Europe and America are few or not publically available. 
This project may prompt further study to assess the impact of releases from 
pharmaceutical facilities and the role overall loading of pharmaceuticals 
released from industrial facilities play on the environment. 
 
2. The application of photo-Fenton’s oxidation to the treatment of 
pharmaceutical wastewater This project showed the effective removal of all 
three APIs produced at one industrial facility using photo-Fenton‘s oxidation. 
While numerous studies are available monitoring the breakdown of 
pharmaceuticals as a result of photo-Fenton‘s oxidation using UV lamps 
there is less work done on the breakdown of pharmaceuticals using halogen 
lamps to mimic solar light. The use of the halogen lamp showed little 
improvement over dark Fenton. Fenton‘s reagent is an effective method for 
the removal of micro-pollutants from aqueous solutions.  
 
5.3 Further research 
 
Further investigation of actual releases of pharmaceuticals by industrial facilities 
is required. It is generally accepted that the most significant entry route of 
pharmaceuticals into the environment is through municipal wastewater treatment 
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effluents. However the results of this study and others (Larsson et al., 2007; Sim 
et. al., 2011) indicate that larger concentrations than released by municipal 
facilities may be released locally by production facilities. Monitoring of 
production facilities in particular those producing pharmaceuticals that are 
thought to be of greater environmental concern such as EDCs and antibiotics as 
well as fermentation, R&D facilities and facilities that recover APIs from natural 
resources is required. The large concentrations of APIs released cause not only 
potential environmental problems but also represent a loss of valuable product 
to the pharmaceutical company. This suggests scope for further research in the 
area of efficient and cost effective product recovery from waste streams. 
 
The wastewater treatment facility at the manufacturing plant was unsuccessful 
for the removal of the three APIs from the wastewater. As indicated in the 
literature review, operating activated sludge plants at higher HRT may provide 
more success in the removal of APIs from wastewater. Methods for the adaption 
of existing treatment facilities for the enhanced removal of APIs from 
wastewaters such as pre-treating of wastes with AOPs is an active area of 
research.  
 
The three APIs investigated in this work are not known to have high 
environmental toxicity. Synergistic effects of cocktails of low concentrations of 
pharmaceuticals in the environment are largely unknown and represent a 
significant knowledge gap. In this particular scenario it is important to note that 
the wastewater is being released to the municipal sewer and so will be diluted 
and treated again before being released to the environment. It may be useful to 
examine the concentrations of specific APIs detected in municipal facilities if 
there is a pharmaceutical facility in its catchment area. It has been suggested by 
Enick and Moore (2007) that up to 50% of pharmaceutical wastewater is 
released to the environment totally untreated. The release of such wastewaters 
worldwide is largely unregulated. Further research is required on strategies for 
the reduction in releases of untreated wastewater and wastewater high in API 
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concentration. On-going research to characterise pharmaceuticals according to 
risk based on toxic effects (Cooper et al., 2008) may result in future restrictions 
on pharmaceuticals releases directly into the environment (Larsson and Fick, 
2009). 
 
The photo-Fenton‘s experiments conducted represent proof of concept type 
experiments showing photo-Fenton‘s is effective for the treatment of the three 
APIs. Kinetic evaluations allow the treatment efficiency to be compared with 
different treatment methods. There is a large scope for further investigation in 
this area. Further opportunities directly related to this project include monitoring 
the degradation of the three APIs in one mixture and with real wastewater. Other 
options include monitoring mineralisation and toxicity over the degradation 
process and the possibility of up-scaling. Different reactors types using dark-
Fenton‘s, UV or solar light may be investigated at small scale, up scaling to pilot 
and full scale. Feasibility studies would be necessary to determine the economic 
viability of up-scaling. 
 
Investigation of the effects of different reactants showed that very high 
concentrations of hydrogen peroxide are required for removal of the APIs. Use 
of other reactants (Fe(II) and H2O2) alone showed no removal. The use of the 
halogen light used as a substitute for sunlight made little difference to the 
removal efficiency; UV light would be expected to be more successful but is 
more expensive than sunlight. However it may reduce the concentrations of 
reactants required and thus the overall cost of removal after treatment. 
Experiments directly related to this project could be carried out to determine the 
percentage greater removal UV lamps would have over halogen lamps. Cost 
benefit analysis would be required to determine the cost efficiency of using 
higher concentrations of reactants in comparison to higher energy costs of UV 
lamps. 
 
To allow for a more comprehensive comparison between Fenton‘s and other 
treatment methods, other methods for the removal of these particular APIs 
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should be investigated. The main disadvantages to the use of the Fenton‘s 
reaction are the requirement of a method for the removal of iron following 
treatment and the sensitivity of the Fenton‘s process to pH. For Fenton‘s 
oxidation pH must be kept low because when the pH is increased chemical 
coagulation occurs. This can be used to aid removal of the iron following 
treatment. However, there is scope for further investigations into the 
immobilisation of Fe(II) onto beads or other surfaces. This may improve the pH 
range over which Fenton‘s reaction could be performed and eliminate the 
disadvantage of removing the iron following treatment. 
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Appendix A: Monthly summaries of results 
 
Period API WW Hits % Freq 
Min 
 ( mg/L) 
Max  
( mg/L) 
Median  
( mg/L) 
Average  
( mg/L) 
November 
(4 weekly 
samples) 
Famotidine 
Influent 4 100 1.500 3.100 2.575 2.413 
Effluent 4 100 1.600 2.800 2.400 2.288 
Tamsulosin 
Influent 4 100 0.002 0.004 0.003 0.003 
Effluent 4 100 0.003 0.007 0.004 0.004 
Solifenacin 
Influent 2 50 <LOQ 0.013 0.007 0.007 
Effluent 4 100 0.009 0.017 0.013 0.013 
December 
(5 weekly 
samples) 
Famotidine 
Influent 5 100 0.500 5.800 1.600 2.556 
Effluent 5 100 1.500 7.300 3.350 4.304 
Tamsulosin 
Influent 5 100 <LOQ 0.005 0.003 0.002 
Effluent 5 100 0.002 0.004 0.003 0.003 
Solifenacin 
Influent 1 20 <LOD 0.007 0.000 0.002 
Effluent 1 20 <LOD 0.007 0.000 0.002 
January 
(4 weekly 
samples) 
Famotidine 
Influent 3 75 <LOD 2.400 0.418 0.809 
Effluent 4 100 1.200 5.000 3.390 3.245 
Tamsulosin 
Influent 3 75 <LOD 0.019 0.002 0.006 
Effluent 4 100 0.003 0.004 0.003 0.003 
Solifenacin 
Influent 2 50 <LOD 0.027 0.001 0.007 
Effluent 0 0 <LOD <LOD 0.001 0.001 
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February 
(4 weekly 
samples) 
Famotidine 
Influent 3 75 <LOD 1.700 1.253 1.048 
Effluent 4 100 1.150 1.650 1.370 1.385 
Tamsulosin 
Influent 4 100 0.003 0.019 0.007 0.009 
Effluent 4 100 0.004 0.005 0.004 0.004 
Solifenacin 
Influent 4 100 0.032 0.106 0.056 0.062 
Effluent 4 100 0.007 0.019 0.011 0.012 
March  
(5 weekly 
samples) 
Famotidine 
Influent 3 60 <LOD 0.700 0.485 0.387 
Effluent 5 100 0.700 3.900 2.155 2.213 
Tamsulosin 
Influent 5 100 0.002 0.018 0.006 0.007 
Effluent 5 100 0.002 0.032 0.005 0.009 
Solifenacin 
Influent 5 100 0.009 0.056 0.046 0.038 
Effluent 4 80 <LOD 0.079 0.039 0.047 
April 
(4 weekly 
samples) 
Famotidine 
Influent 3 75 <LOD 3.100 0.430 0.363 
Effluent 4 100 1.350 2.800 1.598 1.599 
Tamsulosin 
Influent 2 50 <LOD 0.004 0.001 0.000 
Effluent 4 100 0.0004 0.007 0.002 0.002 
Solifenacin 
Influent 3 75 <LOD 0.174 0.032 0.059 
Effluent 4 100 0.033 0.075 0.036 0.041 
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Appendix B: Fenton oxidation literature examples  
 
Pharmaceutical Process pH APIs Fe(II) mM H2O2 mM k kapp %Removal Ref. 
Melatonin UV 7.0 20 mg/L - - 1 0.0030 28 Xu et al., 2009 
Melatonin UV 10.0 20 mg/L - - 1 0.0048 32 Xu et al., 2009 
Metronidazole UV 3.5 6 mg/L - - 1 3.84x10
-4
 12 Shemer et al., 2006 
Amoxicillin UV 5 104 mg/L - - - - 2.9 Elmolla and Chaudhuri, 2009 
Ampicillin UV 5 105 mg/L - - - - 3.8 Elmolla and Chaudhuri, 2009 
Cloxacillin UV 5 103 mg/L - - - - 4.9 Elmolla and Chaudhuri, 2009 
Melatonin UV/H2O2 4.0 20 mg/L - 10 1 0.018 70 Xu et al., 2009 
Melatonin UV/H2O2 3.0 20 mg/L - 10 1 0.017 69 Xu et al., 2009 
Metronidazole UV/H2O2 3.5 6 mg/L - 25 mg/L 1 0.00618 58 Shemer et al., 2006 
Metronidazole UV/H2O2  3.5 6 mg/L - 50 mg/L 1 0.00777 64 Shemer et al., 2006 
Amoxicillin UV/H2O2 3.5 105 mg/L - 500 mg/L - - 100 Ay and Kargi, 2010 
Ibuprofen UV/H2O2 6.25 0.87 mM - 0.32 - - 40 Mèndez-Arriaga, 2010 
Melatonin Fenton 3.0 20 mg/L 0.1 10 1 0.082 100 Xu et al., 2009 
Melatonin Fenton 3.0 20 mg/L 0.1 5 1 0.028 83 Xu et al., 2009 
Melatonin Fenton 3.0 20 mg/L 0.1 15 1 0.070 99 Xu et al., 2009 
Melatonin Fenton 3.0 20 mg/L 0.05 10 1 0.055 98 Xu et al., 2009 
Melatonin Fenton 3.0 20 mg/L 0.2 10 1 0.062 98 Xu et al., 2009 
Metronidazole Fenton 3.5 6 mg/L 0.00588 0.0294 2 9.48x10
-4
 73 Shemer et al., 2006 
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Metronidazole Fenton 3.5 6 mg/L 0.01176 0.0294 2 0.0011 73 Shemer et al., 2006 
Ibuprofen Fenton 3 0.87 mM 1.2 0.32 - - 80 Mèndez-Arriaga, 2010 
Melatonin Photo- Fenton 3.0 20 mg/L 0.1 10 1 0.25 100 Xu et al., 2009 
Melatonin Photo- Fenton 3.0 20 mg/L 0.05 10 1 0.18 100 Xu et al., 2009 
Metronidazole Photo- Fenton 3.5 6 mg/L 0.00294 0.0294 2 6.71x10
-4
 53 Shemer et al., 2006 
Metronidazole Photo- Fenton 3.5 6 mg/L 0.00588 0.0294 2 0.00248 73 Shemer et al., 2006 
Metronidazole Photo- Fenton 3.5 6 mg/L 0.01176 0.0294 2 0.00383 73 Shemer et al., 2006 
Amoxicillin Photo- Fenton 3.5 10 mg/L 25 mg/L 500 mg/L - - 100 Ay and Kargi, 2010 
Amoxicillin Photo- Fenton 3.5 200 mg/L 25 mg/L 500 mg/L - - 90 Ay and Kargi, 2010 
Amoxicillin Photo- Fenton 3.5 10 mg/L 0 mg/L 255 mg/L - - 90 Ay and Kargi, 2010 
Amoxicillin Photo- Fenton 3.5 10 mg/L 50 mg/L 255 mg/L - - 85 Ay and Kargi, 2010 
Amoxicillin Photo- Fenton 3.5 105 mg/L 50 mg/L 500 mg/L - - 100 Ay and Kargi, 2010 
Amoxicillin Photo- Fenton 3.5 105 mg/L 25 mg/L 255 mg/L - - 100 Ay and Kargi, 2010 
Ibuprofen Photo- Fenton 3 0.87 mM 1.2 mg/L 0.32 mg/L - - 100 Mèndez-Arriaga, 2010 
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Appendix C: Famotidine impurities 
 
N
S
CH2SCH2CH2C
NC
NH2
NH2
O
NHSO2NH2
Molecular weight 338
Impurity A1
N
S
CH2SCH2CH2COOH
NC
NH2
NH2
Molecular weight 260
Impurity A2
N
S
CH2SCH2CH2CONH2
NC
NH2
NH2
Molecular weight 259
Impurity A3 N
S
CH2SCH2CH2C
NC
NH2
NH2
O
OCH3
Molecular weight 274
Impurity A4
N
S
N
C
NH2
NH2
N
S
N
C
NH2
NH2
Molecular weight 353
Impurity A6
N
S
CH2SCH2CH2C
NC
NH2
NH2
NH2
NH
Molecular weight 258
Main impurity A7
N
S
CH2SCH2CH2
N
C
NH2
NH2
HN
N
SO2
N
CH2CH2SCH2
N
S
N
C
NH2
H2N
Molecular weight 561
Impurity A8
S
S
Molecular weight 374
Impurity A5
N
H2N
S
N
H2N
S
N
S
NH2
O
O
NH2
O
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Appendix D: Main tamsulosin metabolites 
 
 
 
 
S
O
NH
O
HO
O
NH2
O
mw 380 M-1
S
O
NH
O
O
O
NH2
O
OH
mw 424.5 M-2
S
O
NH
O
O
O
NH2
O
OH
mw 424.5 M-3
S
HO
NH
O
O
O
NH2
O
mw 394.5 M-4
HOOCCH2O
O
mw 196.1 AM-1
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Appendix E: Main solifenacin metabolites  
 
 
N O
O
N+
O-
378MW 
(N-OXIDE METABOLITE)
N O
O
N
OH
378MW 
(4R-HYDROXY METABOLITE)
N O
O
N+
OH
O-
MW394
(4R-HYDROXY-N-OXIDE
 METABOLITE)
MW539
(SOLIFENACIN N-GLUCURONIDE)  
